Top 500 Medicines Pharma

SPECIAL REPORT JULY 2008
Top 500
Prescription
medicines
What you will find in this special report
PharmaLive and Med Ad News editors have ranked the
best-selling prescription medicines by 2007 worldwide
sales in this annual special report.
As part of this detailed report, the editors researched
and compiled the 2007, 2006, and 2005 worldwide
sales information of the prescription medicines that
pharmaceutical, biotechnology, and specialty companies
manufacture and sell.
What you will find in this special report (continued)

The information in this report is supplied by the companies. This document provides information on 500
product sales entries representing about 100 companies. Some products that generate enough sales
to make the top 500 list are not represented in these charts due to the unavailability of published sales
data. For instance, certain companies publish sales information for only billion-dollar brands, or for only
their top 10 or 20 drugs, etc. Certain companies do not publish any product sales data.
The data are sorted and presented in three formats: by the highest product 2007 global sales, by the
companies that report sales for these products, and by the primary disease/medical use that each
product treats.
Some medicines are represented more than once in the Company chart because their sales are reported
separately by more than one company due to joint promotion, joint marketing, or other types of alliances
and deals. In the Sales and Primary Disease/Medical Use charts, the products with more than one
company are represented as one combined sales entry.
The charts provide the following information:
2007 sales rank for each medicine
2007, 2006 and 2005 worldwide sales for each medicine
Companies that report sales for each medicine
At least one primary disease/medical use that each medicine treats
First approval date (or launch date if the original approval date is not applicable) of each medicine,
and in some instances the region of occurrence is provided.
The top 500 prescription medicine entries of 2007 generated total sales of about $397 billion, compared
with $369 billion for the same 500 drug entries during 2006 and $333 billion for 2005. The top-selling
prescription medicine remains Lipitor (lipitor.com). Launched during the first quarter of 1997, the HMGCoA reductase inhibitor garnered 2007 sales of $12.68 billion for marketer Pfizer Inc. (pfizer.com). Tokyos
Astellas Pharma Inc. (astellas.com) reported Lipitor sales of 97.7 billion ($977 million) for the fiscal
year ended March 31, 2008. These combined sales of $13.65 billion compare with $13.83 billion for the
previous annual term. The No. 2 best-selling medicine worldwide in annual sales last year was Plavix/
Iscover. Sales reached $8.08 billion in 2007, compared to $6.31 billion for 2006 when the product ranked
third overall. An antiplatelet agent indicated for a variety of atherothrombotic conditions, Plavix (plavix.
com) was launched in 1998 in the United States. The medicine is marketed in more than 80 countries, in
some regions under the trade name Iscover. Bristol-Myers Squibb Co. (bms.com) recorded Plavix sales
of $4.76 billion for 2007. Sanofi-Aventis (sanofi-aventis.com) reported Plavix/Iscover sales of E2.42 billion
($3.32 billion) for last year.
Coming in at the No. 3 medicine sales rank was Advair/Seretide, at $6.99 billion for 2007.
GlaxoSmithKline (gsk.com) reported Advair/Seretide sales of $6.63 billion in 2006 when the drug was the
worlds No. 2 prescription seller. For treating asthma and chronic obstructive pulmonary disease, Advair
(advair.com) was approved in the United States in 2000 and Seretide was cleared for EU marketing in
1998. Climbing from the No. 11 sales rank (for 2005) to No. 7 (in 2006) to No. 4 last year was Enbrel.
The tumor necrosis factor inhibitor generated $5.46 billion in 2007, up from $4.49 billion during the
previous term. Initially cleared for marketing in 1998, Enbrel (enbrel.com) is approved for a variety of
arthritic conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. For 2007,
Enbrel sales were reported at $3.23 billion for Amgen (amgen.com) and $2.05 billion for Wyeth (wyeth.
com). For the fiscal year ended March 31, 2008, Takeda (takeda.com) reported Enbrel sales of 18.8
billion ($188 million). Ranking No. 14 in 2005 and No. 8 in 2006, Remicade was the No. 5 global seller
last year at about $5.26 billion compared with $4.46 billion in the previous annum. Last years Remicade
sales were reported to be $3.33 billion for Johnson & Johnson (jnj.com), $1.65 billion for ScheringPlough Corp. (sgp.com), and 28.6 billion ($286 million) for Mitsubishi Tanabe Pharma Corp. (mt-pharma.
co.jp). Initially FDA approved in 1998, Remicade is a treatment for inflammatory diseases.

TABLE OF CONTENTS
TOP 500 PRESCRIPTION MEDICINES BY SALES
pages 5-27
TOP 500 PRESCRIPTION MEDICINES BY COMPANY
pages 29-47
TOP 500 PRESCRIPTION MEDICINES BY PRIMARY
DISEASE/MEDICAL USE
pages 49-69
TOP 500
PRESCRIPTION
MEDICINES
BY SALES

Rank
2007
1
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Lipitor
13,652
13,833
13,102
Pfizer 12,675
Pfizer 12,886
Pfizer 12,187
Astellas 977
Astellas 947
Astellas 915
8,079
6,313
6,601
BMS 4,755
BMS 3,257
BMS 3,823
Sanofi-Aventis
3,324
Sanofi-Aventis
3,056
Sanofi-Aventis
2,778
Plavix/Iscover
Primary disease/
medical use
First approval date

(or launch date)
Pfizer and
Astellas Pharma
Cholesterol
Dec. 17, 1996
Bristol-Myers Squibb
and Sanofi-Aventis
Atherothrombosis
Nov. 17, 1997/1998
2007 company
Advair/Seretide
6,998
6,626
6,006
GlaxoSmithKline
Asthma
Aug. 24, 2000/

Sept. 7, 1998
Enbrel
5,463
4,493
3,707
Rheumatoid arthritis
Nov. 2, 1998
Amgen 3,230
Amgen 2,879
Amgen 2,573
Wyeth 2,045
Wyeth 1,500
Wyeth 1,084
Amgen,
Wyeth,
Takeda
Pharmaceutical
Takeda 188
Takeda 114
Takeda 50
5,261
4,458
3,605
Aug. 24, 1998
J&J 3,327
J&J 3,013
J&J 2,535
Schering-Plough
1,648
Schering-Plough
1,240
Schering-Plough
942
Johnson & Johnson,

Schering-Plough,
Mitsubishi Tanabe
Pharma
Mitsubishi
Tanabe 286
Mitsubishi 205
Mitsubishi 128
Remicade
Nexium
5,216
5,182
4,633
AstraZeneca
Gastrointestinal disorders
March 2000 (Sweden)
Rituxan/MabThera
5,214
4,589
3,976
Non-Hodgkins lymphoma
Notes: Genentech
reports U.S. sales
and Chugai reports
Japan sales that
are also recorded
by parent company
Roche
Roche 4,033
(includes
Genentech
2,071 and
Chugai 154)
Roche 3,462
(includes
Genentech
1,832 and
Chugai 152)
Nov. 26, 1997/

June 2, 1998
Roche 4,597
(includes
Genentech
2,285 and
Chugai 159)
Roche,
Genentech,
Biogen Idec,
Chugai
Pharmaceutical,
Zenyaku Kogyo
Biogen Idec 617
Biogen Idec 556
Biogen Idec 514
Biogen Idec records

U.S. joint-promotion
profitt
Zenyaku Kogyo
NA
Zenyaku Kogyo
NA
Zenyaku Kogyo
NA
Diovan and Diovan

HCT/CoDiovan
5,012
4,223
3,676
Novartis
Hypertension
Dec. 23, 1996 and

March 6, 1998/
Oct. 6, 1997
Zyprexa
4,761
4,364
4,202
Eli Lilly
Schizophrenia
Sept. 27, 1996
10
Risperdal, Risperdal
Consta, Invega
4,697
4,183
3,552
Johnson & Johnson
Schizophrenia
Dec. 29, 1993,

Oct. 29, 2003,
Dec. 19, 2006
11
Actos
4,333
3,812
2,931
Type 2 diabetes
July 15, 1999
Takeda 3,962
Takeda 3,363
Takeda 2,438
Takeda
Pharmaceutical and
Eli Lilly
Eli Lilly 371
Eli Lilly 449
Eli Lilly 493
12
Singulair
4,266
3,579
2,976
Merck & Co.
Asthma
Feb. 20, 1998
13
Protonix/
Pantozol/Pantoloc
(pantoprazole)
4,221
4,017
3,779
Feb. 2, 2000/1994/1997
Nycomed 2,310
(Pantoprazole,
including
Pantozol)
Altana 2,126
(Pantoprazole,
including
Pantozol)
Altana 1,866
(Pantoprazole,
including
Pantozol)
Nycomed and
Wyeth
Wyeth 1,795
(Protonix)
Wyeth 1,685
(Protonix)
Solvay 96
(Pantoloc)
Solvay 228
(Pantoloc)
4,219
3,584
2,913
Schizophrenia
Sept. 26, 1997
AstraZeneca
4,027
AstraZeneca
3,416
AstraZeneca
2,761
AstraZeneca and
Astellas Pharma
Astellas 192
Astellas 168
Astellas 152
Notes: Nycomed
acquired Altana
Pharma and
Pantoprazole
Dec. 29, 2006.
Solvay lost Pantoloc
marketing rights
in Canada during
2006.
14
Seroquel
Wyeth 1,911
(Protonix)
Solvay 0
(Pantoloc)

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
15
Herceptin
4,044
3,273
1,788
Note: Genentech
reports U.S. sales
and Chugai reports
Japan sales that
are also recorded
by parent company
Roche
Roche 4,044
(includes
Genentech
1,287 and
Chugai 138)
Roche 3,273
(includes
Genentech
1,234 and
Chugai 124)
Roche 1,788
(includes
Genentech 747
and Chugai 96)
Prevacid/Takepron
(lansoprazole)
3,962
4,280
4,254
Tap 2,275
(Prevacid)
Tap 2,600
(Prevacid)
Tap 2,501
(Prevacid)
Takeda 1,487
(Lansoprazole,
including 648 for
Takepron)
Takeda 1,507
(Lansoprazole,
including 579 for
Takepron)
Takeda 1,599
(Lansoprazole,
including 550 for
Takepron)
Abbott 200
(Lansoprazole)
Abbott 173
(Lansoprazole)
Abbott 154
(Lansoprazole)
16
Primary disease/
medical use
First approval date

(or launch date)
Roche,
Genentech,
Chugai
Pharmaceutical
Breast cancer
Sept. 25, 1998
Tap Pharmaceutical
Products,
Takeda
Pharmaceutical,
Abbott Laboratories
May 10,1995/1991
2007 company
17
Effexor line
3,794
3,722
3,459
Wyeth
Depression
Dec. 28, 1993
18
Aranesp
3,614
4,121
3,273
Amgen
Anemia
June 11, 2001
19
Lovenox/Clexane
3,581
3,339
2,938
Sanofi-Aventis
Deep-vein thrombosis
March 29, 1993/

September 1997
20
Atacand/Blopress
(candesartan)
3,518
3,172
2,883
Hypertension
Takeda 2,231
(Blopress/
candesartan)
Takeda 2,062
(Blopress/
candesartan)
Takeda 1,909
(Blopress/
candesartan)
Takeda
Pharmaceutical and
AstraZeneca
June 4, 1998/
Oct. 6, 1997
AstraZeneca
1,287 (Atacand)
AstraZeneca
1,110 (Atacand)
AstraZeneca 974
(Atacand)
Avastin
3,422
2,469
1,388
Colorectal cancer
Note: Genentech
reports U.S. sales
and Chugai reports
Japan sales that
are also recorded
by parent company
Roche.
Roche 3,422
(includes
Genentech
2,296 and
Chugai 30)
Roche 2,469
(includes
Genentech
1,746; Chugai
0 = June 2007
Japan launch
Roche 1,388
(includes
Genentech
1,133)
Roche,
Genentech,
Chugai
Pharmaceutical
Feb. 26, 2004

(U.S. approval)
22
Cozaar and Hyzaar
3,350
3,163
3,037
Merck & Co.
Hypertension
April 14, 1995, and

April 28, 1995
23
Copaxone
3,327
2,880
2,413
Multiple sclerosis
Dec. 20, 1996
Teva 1,713
Teva 1,414
Teva 1,176
Teva Pharmaceutical
Industries and
Sanofi-Aventis
Sanofi-Aventis
1,614
Sanofi-Aventis
1,466
Sanofi-Aventis
1,237
3,311
2,887
2,311
Eisai and Pfizer
Alzheimers disease
Nov. 25, 1996
Eisai 2,910
Eisai 2,529
Eisai 1,965
Pfizer 401
Pfizer 358
Pfizer 346
3,116
2,982
2,714
Aug. 19, 1999/1997
Eisai 1,759
Eisai 1,743
Eisai 1,545
Eisai and
Johnson & Johnson
J&J 1,357
J&J 1,239
J&J 1,169
21
24
25
Aricept
AcipHex/Pariet
26
Humira
3,064
2,044
1,400
Abbott Laboratories
Dec. 31, 2002
27
Gleevec/Glivec
3,050
2,554
2,170
Novartis
Leukemia
May 10, 2001/

June 26, 2001
28
Fosamax
3,049
3,134
3,191
Merck & Co.
Osteoporosis
Sept. 29, 1995
29
Lexapro/Cipralex
3,044
2,751
2,355
Major depressive disorder
Aug. 14, 2002/2002
Forest 2,292
(Lexapro)
Forest 2,106
(Lexapro)
Forest 1,873
(Lexapro)
Forest Laboratories
and
H. Lundbeck
Lundbeck 752
(Cipralex)
Lundbeck 645
(Cipralex)
Lundbeck 482
(Cipralex)
30
Norvasc
3,001
4,866
4,706
Pfizer
Hypertension
July 31, 1992
31
Neulasta
3,000
2,710
2,288
Amgen
Neutropenia
Jan. 31, 2002

Rank
2007
32
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Crestor
2,900
2,053
1,269
AstraZeneca
2,796
AstraZeneca
2,028
AstraZeneca
1,268
Primary disease/
medical use
First approval date

(or launch date)
AstraZeneca and
Shionogi
Cholesterol
Nov. 7, 2002
2007 company
Shionogi 104
Shionogi 25
Shionogi 1
33
Procrit/Eprex
2,885
3,180
3,324
Johnson & Johnson
Anemia
Dec. 31, 1990/

May 4, 1995
34
Levaquin/Cravit
(levofloxacin) and
Floxin, Floxin Otic
2,862
J&J 1,646
2,703
2,639
Johnson & Johnson,
Bacterial infections
Levaquin: Dec. 20, 1996
(Levaquin,
Floxin, Floxin
Otic)
J&J 1,530
(Levaquin,
Floxin, Floxin
Otic)
J&J 1,492
(Levaquin,
Floxin, Floxin
Otic)
Daiichi Sankyo,
Cravit: 1993
Santen
Pharmaceutical
Floxin: Dec. 28, 1990
Daiichi Sankyo
1,087 (Cravit/
levofloxacin)
Daiichi Sankyo
1,041 (Cravit/
levofloxacin)
Daiichi Sankyo
1,015 (Cravit/
levofloxacin)
Santen 129
(Cravit)
Santen 132
(Cravit)
Santen 132
(Cravit)
Floxin Otic: Dec. 16, 1997
35
Lantus
2,785
2,284
1,665
Sanofi-Aventis
Type 2 diabetes and

type 1 diabetes
April 20, 2000
36
Vytorin
2,779
1,955
1,028
Merck/
Schering-Plough
Pharmaceuticals
Cholesterol
July 23, 2004
37
Avapro/Aprovel and
Avalide/CoAprovel
2,685
2,489
2,205
Hypertension
Avapro: Sept. 30, 1997
Sanofi-Aventis
1,481 (Aprovel
and CoAprovel)
Sanofi-Aventis
1,392 (Aprovel
and CoAprovel)
Sanofi-Aventis
1,223 (Aprovel
and CoAprovel)
Sanofi-Aventis
and
Bristol-Myers
Squibb 1,204
(Avapro/Aprovel
and Avalide/
CoAprovel)
Bristol-Myers
Squibb 1,097
(Avapro/Aprovel
and Avalide/
CoAprovel)
Bristol-Myers
Squibb 982
(Avapro/Aprovel
and Avalide/
CoAprovel)
Aprovel: Aug. 27, 1997

Avalide: Sept. 30, 1997
CoAprovel:
Oct. 15, 1998
38
Taxotere
2,569
2,402
2,206
Sanofi-Aventis
Cancer
Oct. 27, 1995
39
Abilify
2,490
(estimate)
1,923
(estimate)
1,368
(estimate)
Schizophrenia
Nov. 15, 2002
Bristol-Myers
Squibb 1,660
Bristol-Myers
Squibb 1,282
Bristol-Myers
Squibb 912
and
Otsuka
Pharmaceutical
Otsuka 830
(estimate)
Otsuka 641
(estimate)
Otsuka 456
(estimate)
*2007 U.S. sales

for BMS and
Otsuka total
2,160.
*2006 U.S. sales

for BMS and
Otsuka total
1,623.
*2005 U.S. sales

for BMS and
Otsuka total
1,159.
Note: 2007-2005
total figures are
estimates; 20072005 U.S. sales are
actual numbers.
40
Epogen
2,489
2,511
2,455
Amgen
Anemia
June 1, 1989
41
Spiriva
2,457
1,893
1,304
Boehringer Ingelheim
Chronic obstructive
pulmonary disease
April 2002
42
Topamax
2,453
2,027
1,680
Johnson & Johnson
Seizures
Dec. 24, 1996
43
Prevnar
2,439
1,961
1,508
Wyeth
Pneumococcal disease
Feb. 17, 2000
44
Zetia
2,407
1,929
1,397
Merck/
Schering-Plough
Pharmaceuticals
Cholesterol
Oct. 25, 2002
45
Celebrex/Celecox
2,327
2,039
(Pfizer)
1,730
(Pfizer)
Pfizer and
Astellas Pharma
Osteoarthritis and
rheumatoid arthritis
Celebrex: February
1999 (U.S. launch)
Pfizer 2,290
Astellas 37
(June 2007
Japan launch)
Celecox: June 11, 2007

(Japan launch)

Rank
2007
46
Medicine
Zyrtec/Cirrus and
Zyrtec-D
Note:
GlaxoSmithKline
jointly markets
Zyrtec in Japan.
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2,317+
2,458+
2,259+
Pfizer 1,541
(Zyrtec and
Zyrtec-D)
Pfizer 1,569
(Zyrtec and
Zyrtec-D)
Pfizer 1,362
(Zyrtec and
Zyrtec-D)
UCB 668
(Zyrtec/Cirrus
and Zyrtec-D)
UCB 769
(Zyrtec/Cirrus
and Zyrtec-D)
UCB 771
(Zyrtec/Cirrus
and Zyrtec-D)
Daiichi Sankyo
108 (Zyrtec)
Daiichi Sankyo
120 (Zyrtec)
Daiichi Sankyo
126 (Zyrtec)
GlaxoSmithKline
NA
(Zyrtec)
GlaxoSmithKline
NA
(Zyrtec)
GlaxoSmithKline
NA
(Zyrtec)
Primary disease/
medical use
First approval date

(or launch date)
Pfizer,
UCB,
Daiichi Sankyo
Allergic rhinitis
Dec. 8, 1995/NA and

Aug. 10, 2001
2007 company
47
Lamictal
2,194
1,992
1,698
GlaxoSmithKline
Seizures
Dec. 27, 1994
48
Micardis
2,166
1,829
1,366
Hypertension
Nov. 10, 1998
Boehringer 1,540
Boehringer 1,326
Boehringer 993
and
Astellas Pharma
Astellas 626
Astellas 503
Astellas 373
2,104
1,622
1,038
Hypertension
Daiichi 1,892
(Benicar/
Olmetec and
Benicar HCT
(olmesartan))
Daiichi 1,447
(Benicar/
Olmetec and
Benicar HCT
(olmesartan))
Daiichi 924
(Benicar/
Olmetec and
Benicar HCT
(olmesartan))
Daiichi Sankyo
and
Forest Laboratories
April 25, 2002/2002 and

June 5, 2003
Forest 212
(Benicar and
Benicar HCT)
Forest 175
(Benicar and
Benicar HCT)
Forest 114
(Benicar and
Benicar HCT)
49
Benicar/Olmetec
and Benicar HCT
(olmesartan)
Note: Forest
records U.S. joint
promotion profit.
50
Cymbalta
2,103
1,316
680
Eli Lilly
Depressive disorder
Aug. 3, 2004
51
Eloxatin/Eloxatine
2,085
2,321
2,144
Sanofi-Aventis
Colorectal cancer
Aug. 9, 2002/
September 1996
52
Prograf
2,030
1,754
1,459
Astellas Pharma
Transplant rejection
April 2, 1993
53
Lupron/Leuplin
(leuprolide)
1,885
2,167
2,142
Prostate cancer
Takeda 1,240
(Leuprorelin,
including 664 for
Leuplin)
Takeda 1,275
(Leuprorelin,
including 643 for
Leuplin)
Takeda 1,224
(Leuprorelin,
including 632 for
Leuplin)
Takeda
Pharmaceutical and
Tap Pharmaceutical
Products
Jan. 26, 1989/

July 5, 2002
Tap 645 (Lupron)
Tap 662 (Lupron)
Tap 699 (Lupron)
Abbott NA
(Leuprolide)
Abbott 230
(Leuprolide)
Abbott 219
(Leuprolide)
54
Avonex
1,868
1,707
1,543
Biogen Idec
Multiple sclerosis
May 17, 1996
54
Valtrex
1,868
1,690
1,390
GlaxoSmithKline
Herpes
June 23, 1995
56
Lyrica
1,829
1,156
291
Pfizer
Neuropathic pain
July 6, 2004
57
TriCor/Lipanthyl
1,812
1,614
1,181
Cholesterol
Feb. 9, 1998/June 1999
Abbott 1,218
(TriCor)
Abbott 1,048
(TriCor)
Abbott 927
(TriCor)
Abbott Laboratories
and Solvay
Solvay 594
(TriCor/
Lipanthyl)
Solvay 566
(TriCor/
Lipanthyl)
Solvay 254
(TriCor/
Lipanthyl)
58
Viagra
1,764
1,657
1,645
Pfizer
Erectile dysfunction
March 27, 1998
59
Avandia
1,754
2,798
2,308
GlaxoSmithKline
Type 2 diabetes
May 25, 1999
60
Actonel
1,750
(actual)
1,663
(estimate)
1,582
(estimate)
Osteoporosis
March 27, 1998
P&G 1,229
(estimate)
P&G 1,106
(estimate)
P&G 1,043
(estimate)
Procter & Gamble,

Sanofi-Aventis,
Eisai
Sanofi-Aventis
439
Sanofi-Aventis
481
Sanofi-Aventis
499
Eisai 82
Eisai 75
Eisai 40
Notes: 2007 total is

actual worldwide
figure; P&G figures
are estimates.
Eisai markets
Actonel in Japan.

Rank
2007
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
1,745
1,856
1,877
Roche 1,745
(includes
Chugai 468)
Roche 1,856
(includes
Chugai 542)
Roche 1,877
(includes
Chugai 614)
Tamiflu
1,738
2,189
1,298
Note: Chugai
reports Japan
sales that are also
recorded by parent
company Roche.
Roche 1,738
(includes
Chugai 331)
Roche 2,189
(includes
Chugai 325)
Roche 1,298
(includes
Chugai 301)
63
Arimidex
1,730
1,508
64
Ambien/Stilnox
1,714
2,778
65
CellCept
1,677
Roche 1,677
61
Medicine
NeoRecormon/
Epogin
Note: Chugai
reports Japan
sales that are also
recorded by parent
company Roche.
62
Primary disease/
medical use
First approval date

(or launch date)
Roche and
Chugai
Pharmaceutical
Anemia
July 16, 1997/April 1990
Roche and
Chugai
Pharmaceutical
Influenza
Oct. 27, 1999
1,181
AstraZeneca
Breast cancer
Dec. 27, 1995
2,083
Sanofi-Aventis
Insomnia
Dec. 16, 1992/

June 9, 1987
1,535
1,421
Roche 1,535
(includes
Chugai 30)
Roche 1,421
Roche and
Chugai
Pharmaceutical
May 3, 1995
(U.S. approval)
1,670
1,452
(Serono)
1,270
(Serono)
Merck KGaA
Multiple sclerosis
February 1998
Chugai NA
66
Rebif
Note: Serono was
acquired by Merck
KGaA Jan. 5, 2007.
2007 company
Chugai 0
67
Xalatan and
Xalacom
1,604
1,453
1,372
Pfizer
Intraocular pressure
June 5, 1996, and

second-quarter 2001
68
Gemzar
1,592
1,408
1,335
Eli Lilly
Cancer
May 15, 1996
69
Truvada
1,589
1,194
568
Gilead Sciences
HIV infection
Aug. 2, 2004
70
Depakote
1,575
1,308
1,096
Abbott Laboratories
Seizures
March 10, 1983
70
Symbicort
1,575
1,184
1,006
AstraZeneca
Asthma
August 2000
72
Gardasil
1,481
235
Merck & Co.
Cervical cancer
June 8, 2006
73
Humalog
1,475
1,300
1,198
Eli Lilly
Diabetes
April 30, 1996
74
Pulmicort
1,454
1,292
1,162
AstraZeneca
Asthma
June 24, 1997
75
Toprol-XL/Seloken
1,438
1,795
1,735
AstraZeneca
Hypertension
Jan. 10, 1992/1996
76
Yasmin, Yaz,
Yasminelle
1,429
1,089
803
(Schering AG)
Bayer
Prevention of pregnancy
Yasmin: March 2000

(Netherlands approval)
Note: 2006 figure is

pro forma for Bayer
after Schering AG
products
acquisition as of
June 23, 2006.
77
Yaz: March 2006

(U.S. approval)
Yasminelle: August 2005
Betaseron/Betaferon
1,409
1,402
1,214
Notes: Bayer 2006

figure is pro forma
after Schering AG
products acquisition
as of June 23, 2006.
Bayer 1,409
Bayer 1,359
Schering 1,072
Novartis NA
Chiron 43
(estimate thru
April 2006)
Chiron 142
Bayer and Novartis
Multiple sclerosis
July 23, 1993/

Nov. 30, 1995
Chiron was acquired

by Novartis in April
2006.
78
Keppra
1,407
1,043
768
UCB
Seizures
Nov. 30, 1999
79
Flomax
1,399
1,264
989
Benign prostatic
hypertrophy
Oct. 8, 1997
80
Imitrex/Imigran
1,370
1,422
1,394
GlaxoSmithKline
Migraine
Dec. 28, 1992/1990
81
Pegasys
1,364
1,223
1,169
Hepatitis C
June 21, 2002
Note: Chugai
reports Japan
sales that are also
recorded by parent
company Roche.
Roche 1,364
(includes
Chugai 54)
Roche 1,223
(includes
Chugai 50)
Roche 1,169
(includes
Chugai 68)
Roche and
Chugai
Pharmaceutical

Rank
2007
82
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Erbitux
1,336
1,114
712
Bristol-Myers
Squibb 692
Bristol-Myers
Squibb 652
Bristol-Myers
Squibb 413
Primary disease/
medical use
First approval date

(or launch date)
and Merck KGaA
Colorectal cancer
Feb. 12, 2004
2007 company
Merck KGaA 644
Merck KGaA 462
Merck KGaA 299
83
Casodex
1,335
1,206
1,123
AstraZeneca
Prostate cancer
Oct. 4, 1995
84
Kaletra
1,325
1,135
1,005
Abbott Laboratories
HIV infection
March 9, 2001
85
Zometa
1,297
1,283
1,224
Novartis
Hypercalcemia
Aug. 21, 2000
86
Neupogen
1,277
1,213
1,216
Amgen
Neutropenia
Feb. 20, 1991
87
Evista
1,265
1,178
1,115
Osteoporosis
Dec. 9, 1997
Eli Lilly 1,091
Eli Lilly 1,045
Eli Lilly 1,036
Chugai 137
Chugai 115
Chugai 79
Eli Lilly,
Chugai
Pharmaceutical,
Daiichi Sankyo
Daiichi 37
Daiichi 18
Daiichi 0
88
Flovent/Flixotide
1,242
1,318
1,276
GlaxoSmithKline
Asthma
March 27, 1996/

March 13, 1995
89
Atripla (efavirenz)
1,238
281
HIV infection
July 12, 2006
Gilead 903
(Atripla)
Gilead 206
(Atripla)
Gilead Sciences and

Bristol-Myers
Squibb 335
(efavirenz)
Bristol-Myers
Squibb 75
(efavirenz)
90
Harnal
1,224
1,270
1,378
Astellas Pharma
Benign prostatic
hypertrophy
July 1992
91
Lucentis
1,219
417
Roche 826
(includes
Genentech 815)
Roche 398
(includes
Genentech 380)
Wet age-related macular

degeneration
June 30, 2006
Note: Genentech
reports U.S. sales that
are also recorded
by parent company
Roche
Roche,
Genentech,
Novartis
Novartis 393
Novartis 19
92
Botox
1,212
982
831
Allergan
Cervical dystonia
Dec. 29, 1989
93
Pravachol
and Mevalotin
(pravastatin)
1,192
2,132
3,688
Cholesterol
Oct. 31, 1991, and 1988
BMS 443
(Pravachol)
BMS 1,197
(Pravachol)
BMS 2,256
(Pravachol)
and Daiichi Sankyo
Daiichi 749
(Mevalotin/
pravastatin)
Daiichi 935
(Mevalotin/
pravastatin)
Daiichi 1,432
(Mevalotin/
pravastatin)
94
Detrol and Detrol LA
1,190
1,100
988
Pfizer
Overactive bladder
March 25, 1998, and

Dec. 22, 2000
95
Coreg
1,174
1,558
1,146
GlaxoSmithKline
Hypertension
Sept. 14, 1995
96
Duragesic/Fentanyl
Transdermal
1,164
1,295
1,585
Johnson & Johnson
Pain
Duragesic: Aug. 7, 1990
97
Synagis
1,161
(estimate)
1,438
1,414
AstraZeneca
Respiratory syncytial virus
June 19, 1998
AstraZeneca 0
AstraZeneca 0
MedImmune
1,065
MedImmune
1,063
Abbott 373
Abbott 231
Dainippon
Sumitomo 0
Dainippon
Sumitomo 120
Notes: MedImmune
was acquired by
AstraZeneca in
June 2007.
Abbott completed
the U.S. joint
promotion of
Synagis in
December 2006;
Abbott recorded
revenue.
AstraZeneca 618
MedImmune
543 (First-half
2007 estimate)
Abbott 0
Dainippon
Sumitomo 0
10

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
Cialis
1,144
971
747
Eli Lilly
Nov. 14, 2002
Note: Eli Lilly

acquired all of
the outstanding
common stock
of Icos, the
companys partner
in the Lilly Icos
joint venture for the
manufacture and
sales of Cialis, as
of Jan. 29, 2007.
Eli Lilly 1,144
Lilly Icos 755
Lilly Icos 577
Lilly Icos 0
Eli Lilly 216
Eli Lilly 170
99
Prilosec/Losec
1,143
1,371
1,652
AstraZeneca
Sept. 14, 1989/1987
100
Zosyn/Tazocin
1,137
972
892
Wyeth
Oct. 22, 1993/

Dec. 18, 1995
101
Cerezyme
1,130
1,007
932
Genzyme
Gauchers disease
April 5, 1991
102
Reyataz
1,124
931
696
HIV infection
Jan. 6, 2003
103
Kogenate
1,121
1,079
909 (Bayer)
Bayer
Hemophilia
Feb. 25, 1993
104
Wellbutrin XL
1,120
2,046
1,648
Depression
Aug. 28, 2003
GlaxoSmithKline
908
GlaxoSmithKline
1,596
GlaxoSmithKline
1,294
GlaxoSmithKline and
Biovail
98
Biovail 212
Biovail 450
Biovail 354
105
Paxil/Seroxat
1,106
1,240
1,230
GlaxoSmithKline
Depression
Dec. 29, 1992/

October 1998
106
Zoladex
1,104
1,008
1,004
AstraZeneca
Prostate cancer
Dec. 29, 1989
107
Nasonex
1,092
944
737
Schering-Plough
Allergic rhinitis
Oct. 1, 1997
108
Infanrix and Pediarix
1,086
1,022
862
GlaxoSmithKline
Diphtheria, tetanus, and

pertussis
January 1996 and

Dec. 13, 2002
109
NovoSeven
1,078
1,036
931
Novo Nordisk
Bleeding due to
hemophilia
Feb. 23, 1996
110
Boniva/Bonviva
1,061
597
108
Osteoporosis
Roche 739
Roche 407
Roche 72
Roche and
GlaxoSmithKline
March 24, 2005/

February 2004
GlaxoSmithKline
322
GlaxoSmithKline
190
GlaxoSmithKline
36
111
Augmentin
1,060
1,140
1,332
GlaxoSmithKline
Aug. 6, 1984
112
GlaxoSmithKline
hepatitis vaccines
(primarily Engerix-B,
Havrix, Twinrix)
1,058
958
888
GlaxoSmithKline
Hepatitis
Aug. 28, 1989,

Feb. 22, 1995,
September 1996
113
Premarin, Prempro,
Premphase
1,055
1,051
909
Wyeth
Menopausal symptoms
1942, Nov. 17, 1995,

Nov. 17, 1995
114
Tarceva
1,054
833
408
Non-small cell lung cancer
Nov. 18, 2004
Note: Genentech
reports U.S. sales
and Chugai reports
Japan sales that
are also recorded
by parent company
Roche.
Roche 885
(includes
Genentech 417
and Chugai 3)
Roche 678
(includes
Genentech 402
and Chugai 0)
Roche 323
(includes
Genentech 275
and Chugai 0)
Roche,
Genentech,
Chugai
Pharmaceutical,
OSI Pharmaceuticals
OSI 169
OSI 155
OSI 85
115
Adderall XR
1,031
864
731
Shire Pharmaceuticals
Group
Attention-deficit
hyperactivity disorder
Oct. 11, 2001
116
Concerta
1,028
930
774
Johnson & Johnson
Attention-deficit
Aug. 1, 2000
117
Sandostatin
1,027
915
896
Novartis
Acromegaly
Oct. 21, 1988
118
Delix and Tritace
1,016
1,340
1,383
Sanofi-Aventis
Hypertension
July 7, 2000, and

July 6, 2000
119
Avelox/Avalox
1,013
871
745
Bayer 610
Bayer 543
Bayer 499
Bayer,
Schering-Plough,
Shionogi
Dec. 10, 1999/

June 21, 1999
Schering-Plough
384
Schering-Plough
304
Schering-Plough
228
Shionogi 19
Shionogi 24
Shionogi 18
11

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
120
Humulin
985
925
1,005
Eli Lilly
Diabetes
Oct. 28, 1982
121
Tracleer
983
749
528
Actelion
Pulmonary arterial
hypertension
Nov. 20, 2001
122
Camptosar
969
903
910
Pfizer
Colorectal cancer
June 14, 1996
123
Allegra/Telfast
968
943
1,844
Sanofi-Aventis
Allergic rhinitis
July 25, 1996/

Dec. 3, 1996
124
Byetta
967
649
150
Type 2 diabetes
April 28, 2005
Amylin 636
Amylin 430
Amylin 75
Amylin
Pharmaceuticals
and
Eli Lilly
Roche and
Chugai
Pharmaceutical
Cancer
1998
Novartis,
Roche,
Chugai
Pharmaceutical
Breast cancer
July 25, 1997
Eli Lilly 331
Eli Lilly 219
Eli Lilly 75
Xeloda
959
809
663
Note: Chugai reports

Japan sales that
are also recorded
by parent company
Roche.
Roche 959
(includes
Chugai 23)
Roche 809
(includes
Chugai 21)
Roche 663
(includes
Chugai 23)
Femara
945
722
536

Japan sales that
are also recorded
by parent company
Roche.
Novartis 937
Novartis 719
Novartis
Roche 9
(via Chugai 9)
Roche 3
(via Chugai 3)
Roche/Chugai 0
127
Neoral and
Sandimmun
944
918
953
Novartis
July 14, 1995, and

Nov. 14, 1983
127
Zyvox
944
782
618
Pfizer
April 18, 2000
129
Ortho hormonal
contraceptives
925
1,016
1,136
Johnson & Johnson
Contraception
NA
130
PegIntron
911
837
751
Schering-Plough
Hepatitis C
May 25, 2000
131
Combivir
910
1,056
1,166
GlaxoSmithKline
HIV infection
Sept. 26, 1997
132
Combivent
887
920
769
Chronic obstructive
pulmonary disease
Oct. 24, 1996
133
Mirapex/Sifrol
883
735
595
Parkinsons disease
July 1, 1997/
Oct. 14, 1997
133
Chantix/Champix
883
101
Pfizer
Smoking cessation
May 10, 2006/

Sept. 29, 2006
135
Zocor
877
2,803
4,382
Merck & Co.
Cholesterol
Dec. 23, 1991
136
Temodar
861
703
588
Schering-Plough
Brain tumors
Aug. 11, 1999
137
Varivax
855
328
NA
Merck & Co.
Chickenpox
March 17, 1995
138
Geodon/Zeldox
854
758
589
Pfizer
Schizophrenia
Feb. 5, 2001/May 2002
138
Alimta
854
612
463
Eli Lilly
Feb. 4, 2004
140
Provigil
852
735
513
Cephalon
Sleepiness
Dec. 24, 1998
141
Genotropin
843
795
808
Pfizer
Growth failure
Aug. 24, 1995
142
Adalat
842
901
904
Bayer
Hypertension
Nov. 27, 1985
143
Namenda
830
660
508
Forest Laboratories
Alzheimers disease
Oct. 16, 2003
144
Clarinex/Aerius
799
722
646
Schering-Plough
Allergic rhinitis
Dec. 21, 2001/

Jan. 15, 2001
145
Trusopt and Cosopt
787
697
617
Merck & Co.
Dec. 9, 1994, and

April 7, 1998
146
Revlimid
774
321
Celgene
Multiple myeloma,
myelodysplastic syndrome
Dec. 27, 2005
147
Merrem
773
604
505
AstraZeneca
June 21, 1996
148
Primaxin
764
705
740
Merck & Co.
Nov. 26, 1985
149
Ultane/Sevorane
759
799
874
Abbott Laboratories
Anesthesia
June 7, 1995/1994
150
Lotrel
748
1,352
1,075
Novartis
Hypertension
June 16, 1999
151
Voltaren group
747
690
689
Novartis
Pain
July 28, 1998
152
Biaxin
724
816
1,065
Abbott Laboratories
Oct. 31, 1991
153
Forteo
709
594
389
Eli Lilly
Osteoporosis
Nov. 26, 2002
125
126
12

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
154
Lidoderm
706
567
419
155
Vesicare
701
426
174
Astellas 601
Astellas 362
Astellas 148
GlaxoSmithKline
100
GlaxoSmithKline
64
GlaxoSmithKline
26
695
585
477
Novartis 420
(Comtan/
Stalevo group)
Novartis 330
(Comtan/
Stalevo group)
Novartis 278
(Comtan/
Stalevo group)
Orion 275
(Stalevo 174 and
Comtan/
Comtess 101)
Orion 255
(Stalevo 153 and
Comtan/
Comtess 102)
Orion 199
(Stalevo 102 and
Comtan/
Comtess 97)
156
Comtan/Comtress
and Stalevo
Primary disease/
medical use
First approval date

(or launch date)
Endo
Pharmaceuticals
Holdings
Pain
March 19, 1999
Astellas Pharma and

GlaxoSmithKline
Overactive bladder
July 9, 2004
Novartis and Orion
Parkinsons disease
Oct. 19, 1999/

Sept. 16, 1998 and
June 11, 2003
2007 company
157
Trileptal
692
721
615
Novartis
Seizures
November 1999
157
Requip
692
536
312
GlaxoSmithKline
Parkinsons disease
Sept. 19, 1997
159
Januvia
668
43
Merck & Co.
Type 2 diabetes
Oct. 16, 2006
160
Lescol group
665
725
767
Novartis
Cholesterol
Dec. 31, 1993
161
Niaspan
658
(Abbott)
498
(estimate)
435
(Kos)
Abbott Laboratories
Cholesterol
July 28, 1997
Renagel
652
559
457
Hyperphosphatemia
Oct. 30, 1998
Note: Chugai
reports Japan
sales that are also
recorded by parent
company Roche.
Genzyme 603
Genzyme 515
Genzyme 418
Roche 49
(via Chugai 49)
Roche 44
(via Chugai 44)
Roche 39
(via Chugai 39)
Genzyme,
Roche,
Chugai
Pharmaceutical
163
Epzicom/Kivexa
648
482
236
GlaxoSmithKline
HIV infection
Aug. 2, 2004/
December 2004
164
Altace
646
653
554
King Pharmaceuticals
Cardiovascular events
Jan. 28, 1991
165
Norditropin
645
608
511
Novo Nordisk
Growth hormone
deficiency
1997
166
GlaxoSmithKline
influenza vaccines
(primarily Fluarix
and FluLaval/
Fluviral)
640
340
NA
GlaxoSmithKline
Influenza
Aug. 31, 2005, and

Oct. 5, 2006/
Sept. 10, 2004
167
Amlodin
636
592
568
Dainippon Sumitomo
Hypertension, angina
pectoris
NA
168
Exelon
632
525
467
Novartis
Alzheimers disease
May 12, 1998
168
Vfend
632
515
397
Pfizer
Fungal infections
March 21, 2002
170
Sustiva
621
715
680
HIV infection
Sept. 17, 1998
171
Viread
613
689
779
Gilead Sciences
HIV infection
Oct. 26, 2001
171
Xolair
613
550
345
Asthma
June 20, 2003
Note: Genentech
reports U.S. sales
that are also
recorded by parent
company Roche.
Roche 473
(includes
Genentech 472)
Roche 448
(includes
Genentech 425)
Roche 340
(includes
Genentech 320)
Roche,
Genentech,
Novartis
Novartis 140
Novartis 102
Novartis 5
173
Gaster
609
622
688
Astellas Pharma
1985
174
Lunesta
601
565
327
Sepracor
Insomnia
Dec. 15, 2004
175
Lamisil group
595
978
1,133
Novartis
Fungal infections
Dec. 30, 1992
Notes: Abbott
acquired Kos
Pharmaceuticals
along with Niaspan
in December 2006.
Kos 2006 figure is
a full-year estimate
based on Niaspan
nine-month 2006
sales.
162
13

Rank
2007
175
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Gonal-f
595
533
(Serono)
Note: Serono was

acquired by Merck
KGaA Jan. 5, 2007.
2007 company
Primary disease/
medical use
First approval date

(or launch date)
547
(Serono)
Merck KGaA
Infertility
Oct. 20, 1995
177
Avandamet
584
408
350
GlaxoSmithKline
Type 2 diabetes
Oct. 10, 2002
178
Sutent
581
219
Pfizer
Cancer
Jan. 26, 2006
179
Avodart
570
432
258
GlaxoSmithKline
Benign prostatic
hyperplasia
Nov. 20, 2001
179
Follistim/Puregon
570
(estimate)
527
(Akzo Nobel)
487
(Akzo Nobel)
Akzo Nobel and

Schering-Plough
Infertility
Sept. 29, 1997/

May 3, 1996
Notes:
Schering-Plough
acquired Akzo
Nobels Organon
BioSciences along
with Follistim/
Puregon
Nov. 19, 2007.
Akzo Nobel 513

(estimate)
Schering-Plough
57
Akzo Nobel 2007

sales are estimated
from Jan. 1, 2007,
thru Nov. 18, 2007.
Schering-Ploughs
sales are an actual
figure for the remainder of 2007.
181
Strattera
569
579
552
Eli Lilly
Attention-deficit
Nov. 26, 2002
182
Caduet
568
370
185
Pfizer
Cholesterol and
hypertension
Jan. 30, 2004
183
Levitra
553
517
436
March 6, 2003
Bayer 431
Bayer 356
Bayer and
GlaxoSmithKline
Bayer 455
GlaxoSmithKline
98
GlaxoSmithKline
86
GlaxoSmithKline
80
184
Serevent
538
582
660
GlaxoSmithKline
Asthma
Feb. 4, 1994
185
Amaryl
537
618
928
Sanofi-Aventis
Type 2 diabetes
Nov. 30, 1995
185
Cancidas
537
530
570
Merck & Co.
Fungal infections
Jan. 26, 2001
187
Synthroid
533
534
554
Abbott Laboratories
Hypothyroidism
1955
188
Zoloft
531
2,110
3,256
Pfizer
Depression
Dec. 30, 1991
189
Basen
528
557
636
Takeda
Pharmaceutical
Hyperglycemia
1994
190
Xenical
527
578
529
Roche
Obesity
July 29, 1998
191
RotaTeq
525
163
Merck & Co.
Rotavirus gastroenteritis
Feb. 3, 2006
191
Cipro/Ciprobay
525
814
866
Bayer
Oct. 22, 1987/1987
Bayer 525
Bayer 703
Bayer 720
Schering-Plough
NA
Schering-Plough
111
Schering-Plough
146
193
Relenza
524
182
NA
GlaxoSmithKline
Influenza
June 1999
194
Concor (bisoprolol)
520
497
478
Merck KGaA
Hypertension
July 31, 1992
195
Cardura
506
538
586
Pfizer
Hypertension
Nov. 2, 1990
196
Vasotec and
Vaseretic
495
547
623
Merck & Co.
Hypertension
Dec. 24, 1985, and

Dec. 24, 1985
196
Mirena
495
413
333
(Schering AG)
Bayer
Contraception
Dec. 6, 2000
487
543
411
Sepracor
Bronchospasm
March 25, 1999

pro forma for Bayer
after Schering AG
198
Xopenex Inhalation
Solution
14

Rank
2007
199
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Claritin
481
428
451
Schering-Plough
391
Schering-Plough
356
Schering-Plough
371
Primary disease/
medical use
First approval date

(or launch date)
Schering-Plough and
Shionogi
Allergic rhinitis
April 12, 1993
2007 company
Shionogi 90
Shionogi 72
Shionogi 80
200
Maxalt
467
406
348
Merck & Co.
Migraine
June 30, 2002
201
Trizivir
466
536
606
GlaxoSmithKline
HIV infection
Nov. 14, 2000
202
Sensipar
463
321
157
Amgen
Hypercalcemia
March 8, 2004
203
Tysabri
462
64
16
Multiple sclerosis
Nov. 23, 2004
Biogen Idec 230
Biogen Idec 36
Biogen Idec 5
Biogen Idec and

Elan
Elan 232
Elan 28
Elan 11
204
Xatral
457
484
450
Sanofi-Aventis
Benign prostatic
hypertrophy
January 2000
205
Valcyte and
Cymevene
452
407
328
Roche
Cytomegalovirus retinitis
March 29, 2001, and NA
206
Thalomid
447
433
388
Celgene
Erythema nodosum
leprosum
July 16, 1998
207
Humatrope
441
416
414
Eli Lilly
Growth failure
March 9, 1991
208
Skelaxin
440
415
345
Musculoskeletal conditions
NA
209
Zithromax and Zmax
438
638
2,025
Pfizer
Nov. 4, 1991, and

June 10, 2005
210
Zomig
434
398
352
AstraZeneca
Migraine
July 8, 1997
211
Depakine
433
413
436
Sanofi-Aventis
Epilepsy
NA
211
BeneFix
433
358
343
Wyeth
Hemophilia
Feb. 11, 1997
213
Neurontin
431
496
639
Pfizer
Seizures
Dec. 29, 1993
214
Mobic
428
901
2,501
Boehringer 794
Abbott 1,232
Osteoarthritis and
Feb. 27, 1996
Boehringer 326
and
Daiichi Sankyo
Daiichi 102
Daiichi 107
Boehringer 1,163
Daiichi Sankyo
106
215
Fabrazyme
424
359
305
Genzyme
Fabrys disease
August 2001
215
Nutropin and
Nutropin AQ
424
432
405
Growth failure
Roche 392
(includes
Genentech 371)
Roche 412
(includes
Genentech 378)
Roche 397
(includes
Genentech 370)
Roche,
Genentech,
Ipsen
Nutropin: Nov. 17, 1993

(U.S. approval)
Ipsen 32
(Nutropin AQ
only)
Ipsen 20
(Nutropin AQ
only)
Ipsen 8
(Nutropin AQ
only)
Note: Genentech
are also recorded
by parent company
Roche.
Nutropin AQ: Dec. 29,

1995 (U.S. approval)
217
Taxol
422
563
747
Cancers
Dec. 29, 1992
217
Androgel
422
377
328
Solvay
Hypogonadism
June 14, 2000

(U.S. approval)
219
Diflucan
415
435
498
Pfizer
Fungal infections
Jan. 29, 1990
220
Magnevist
413
443
450
(Schering)
Bayer
Magnetic resonance
imaging
June 2, 1988

pro forma for Bayer
after Schering AG
220
Tegretol
413
391
393
Novartis
Seizures
March 12, 1972
222
Proscar
411
619
741
Merck & Co.
Benign prostatic
hypertrophy
June 19, 1992
223
Glucobay
409
422
404
Bayer
Type 2 diabetes
NA
224
Propecia
405
352
292
Merck & Co.
Hair loss
Dec. 19, 1997
225
Nasacort
403
388
381
Sanofi-Aventis
Allergic rhinitis
May 21, 2000
225
Pletal
403
360
NA
Otsuka
Pharmaceutical
Cardiac ischemic
complications
1988 (Japan approval)
15

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Pulmozyme
403
363
328
Note: Genentech
are also recorded
by parent company
Roche.
Roche 403
(includes
Genentech 223)
Roche 363
(includes
Genentech 199)
Roche 328
(includes
Genentech 186)
228
Aromasin
401
320
229
Flonase/Flixonase
398
622
230
Prandin and
NovoNorm
395
231
Zofran
231
233
225
233
Primary disease/
medical use
First approval date

(or launch date)
Roche and
Genentech
Cystic fibrosis
Dec. 30, 1993
247
Pfizer
Breast cancer
Oct. 21, 1999
1,312
GlaxoSmithKline
Allergic rhinitis
Oct. 9, 1994/
Sept. 15, 1995
365
306
Novo Nordisk
Type 2 diabetes
Prandin: Dec. 22, 1997

(U.S. approval)
NovoNorm:
Aug. 17, 1998
(EU approval)
392
1,694
1,674
GlaxoSmithKline
Nausea and vomiting
Dec. 31, 1992
Lumigan franchise
392
328
268
Allergan
March 16, 2001
Abraxane
387
193
134
Breast cancer
Abraxis 325
Abraxis 175
Abraxis 134
Abraxis and
AstraZeneca
February 2005
(U.S. launch)
AstraZeneca 62
AstraZeneca 18
AstraZeneca 0
387
(estimate)
292
(Akzo Nobel)
174
(Akzo Nobel)
Akzo Nobel and

Schering-Plough
Contraception
June 12, 2001
NuvaRing
Notes:
Schering-Plough
acquired Akzo
Nobels Organon
BioSciences along
with NuvaRing
Nov. 19, 2007.
2007 company
Akzo Nobel 342

(estimate)
Schering-Plough
45
Akzo Nobel 2007

sales are estimated
from Jan. 1, 2007,
thru Nov. 18, 2007.
Schering-Ploughs
sales are an actual
235
Aggrenox
381
308
236
Stroke
Nov. 22, 1999
235
Ritalin and Focalin
381
337
212
Novartis and Celgene
Novartis 375
Novartis 330
Novartis 208
Attention-deficit
Dec. 5, 1955, and

Nov. 13, 2001
Celgene 6
Celgene 7
Celgene 4
237
Adenoscan
376
371
353
Astellas Pharma
Myocardial perfusion
scintigraphy
May 19, 1999
238
Opalmon
373
338
326
Ono Pharmaceutical
Thromboangiitis obliterans
1988
239
Nexavar
370
178
NA
Bayer 370
Bayer 178
Bayer NA
Bayer and
Onyx
Pharmaceuticals
Advanced kidney cancer

and liver cancer
Dec. 21, 2005

(U.S. launch)
Onyx NA
Onyx NA
Onyx NA
369
286
198
Dry eye
Dec. 23, 2002
Allergan 345
Allergan 270
Allergan 191
Allergan and
Inspire
Pharmaceuticals
Inspire 24
Inspire 16
Inspire 7
240
Restasis
241
Fraxiparine
368
408
422
GlaxoSmithKline
NA
242
Rapamune
365
337
300
Wyeth
Renal transplant rejection
Sept. 15, 1999
242
Glucophage/
metformin franchise
365
493
(estimate)
579
Merck KGaA and

Type 2 diabetes
Dec. 29, 1994
Merck KGaA 365

(Glucophage/
metformin
products)
BMS NA
(Glucophage
franchise)
Merck KGaA 398

(Glucophage/
metformin
products)
BMS 95
(estimate for
Glucophage
franchise)
Merck KGaA 407

(Glucophage/
metformin
products)
BMS 172
(Glucophage
franchise)
16

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
244
Foradil
362
331
332
Novartis
Asthma
Nov. 17, 1999
245
Zovirax
361
352
358
Herpes
March 30, 1986
GlaxoSmithKline
214
GlaxoSmithKline
240
GlaxoSmithKline
262
GlaxoSmithKline and
Biovail
Biovail 147
Biovail 112
Biovail 96
246
Viramune
359
378
395
HIV infection
June 22, 2000
246
rhBMP-2
359
308
236
Wyeth
Tibia fractures
Sept. 17, 2002
248
Exjade
357
143
Novartis
Iron overload
Nov. 2, 2005
(U.S. approval)
249
Espo and NESP
356
344
368
Kirin Brewery
Anemia
Espo: 1990
(Japan launch)
NESP: 2007
(Japan launch)
250
Rhinocort
354
360
387
AstraZeneca
Allergic rhinitis
Feb. 14, 1994
250
Kytril
354
415
417
Nausea and vomiting
January 1992

Japan sales that
are also recorded
by parent company
Roche.
Roche 354
(includes
Chugai 116)
Roche 415
(includes
Chugai 110)
Roche 417
(includes
Chugai 104)
Roche and
Chugai
Pharmaceutical
252
Mucosta
353
339
NA
Otsuka
Pharmaceutical
Gastritis and ulcers
1990 (Japan launch)
253
Alphagan P,
Alphagan,
Combigan
341
296
277
Allergan
March 16, 2001,

Sept. 6, 1996,
fourth-quarter 2003
254
AmBisome
339
311
310
Fungal infections
Aug. 11, 1997
Gilead 263
Gilead 223
Gilead 221
Gilead Sciences and

Astellas Pharma
Roche and
Chugai
Pharmaceutical
Neutropenia
Oct. 4, 1991
Astellas 76
Astellas 88
Astellas 89
Neutrogin
338
316
303

Japan sales that
are also recorded
by parent company
Roche.
Roche 338
(includes
Chugai 335)
Roche 316
(includes
Chugai 309)
Roche 303
(includes
Chugai 276)
256
Zeffix
336
324
290
GlaxoSmithKline
Hepatitis B
Dec. 8, 1998
256
Loxonin
336
309
290
Daiichi Sankyo
Inflammation
Feb. 17, 1978
256
Zantac
336
464
(GSK)
495
GlaxoSmithKline
June 9, 1983
255
GSK 488
Daiichi Sankyo 7
259
ReFacto
335
306
268
Wyeth
Hemophilia
April 14, 2003
260
Rocephin
333
347
773
Dec. 21, 1984

Japan sales that
are also recorded
by parent company
Roche.
Roche 333
(includes
Chugai 49)
Roche 347
(includes
Chugai 47)
Roche 773
(includes
Chugai 46)
Roche and
Chugai
Pharmaceutical
17

Rank
2007
261
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Integrilin
332
329
439
Notes:
Schering-Plough
is marketer in U.S.
and other non-EU
areas.
Schering-Plough
332
Schering-Plough
329
Schering-Plough
315
Millennium NA
Millennium NA
Millennium 124
GlaxoSmithKline
NA
GlaxoSmithKline
NA
GlaxoSmithKline
NA
Millennium
reported
co-promotion
revenue from Jan.
1, 2005, through
Sept. 1, 2005;
thereafter royalty
and strategic
alliance revenue
were recorded.
Primary disease/
medical use
First approval date

(or launch date)
Schering-Plough,
Millennium
Pharmaceuticals,
GlaxoSmithKline
Acute coronary syndrome
June 1998 (U.S. launch)
2007 company
GlaxoSmithKline is
EU marketer.
262
Arcoxia
329
265
218
Merck & Co.
Osteoarthritis and
April 15, 2002
263
Xanax and
Xanax XR
325
316
409
Pfizer
Anxiety disorder and

panic disorder
Nov. 27, 1985, and

Jan. 17, 2003
264
Ultravist
322
304
340
(Schering AG)
Bayer
Imaging/various
May 11, 1999
Notes: Bayer 2006

figure is pro forma
after Schering AG
264
Decapeptyl
322
304
289
Ipsen
Advanced metastatic
prostate cancer
1986 (France launch)
266
Activase, TNKase,
Cathflo Activase
318
302
258
Myocardial infarction
Roche 318
(includes
Genentech 268)
Roche 302
(includes
Genentech 243)
Roche 258
(includes
Genentech 218)
Roche and
Genentech
Feb. 17, 1996,

June 2, 2000, and
Sept. 4, 2001
Note: Genentech
reports U.S. sales
that are recorded
by parent company
Roche.
267
Relpax
315
286
233
Pfizer
Migraine
June 14, 2001
268
Epivir
312
404
522
GlaxoSmithKline
HIV infection
Nov. 17, 1995
268
Omnipaque
312
315
347
Daiichi Sankyo
Contrast enhancement
Dec. 26, 1985

(U.S. approval)
270
Venofer
311
309
226
Daiichi Sankyo
Iron deficiency anemia
Nov. 7, 2000
271
Crixivan and Stocrin
310
327
348
Merck & Co.
HIV infection
March 13, 1996,

and 1999
272
Tenormin
308
320
352
AstraZeneca
Hypertension
Aug. 19, 1981
273
Ebixa
304
250
203
H. Lundbeck
Alzheimers disease
May 23, 2002
273
Remeron
304
(estimate)
347
(Akzo Nobel)
388
(Akzo Nobel)
Akzo Nobel and

Schering-Plough
Depression
June 15, 2000
Notes:
Schering-Plough
acquired Akzo
Nobels Organon
BioSciences along
with Remeron
Nov. 19, 2007.
Akzo Nobel 271

(estimate)
Schering-Plough
33
Akzo Nobel 2007

sales are estimated
from Jan. 1, 2007,
thru Nov. 18, 2007.
Schering-Ploughs
sales are an actual
275
Hepsera
303
231
187
Gilead Sciences
Hepatitis B
Sept. 20, 2002
276
Zestril
295
307
332
AstraZeneca
Hypertension
Dec. 30, 1987
18

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
277
Iopamiron
289
303
Notes: Bayer 2006

figure is pro forma
after Schering AG
2007 company
Primary disease/
medical use
First approval date

(or launch date)
332
(Schering)
Bayer
Imaging/uroangiography
NA
278
Flomox
286
306
341
Shionogi
June 1997
279
Cubicin
285
190
113
Cubist
Pharmaceuticals
Sept. 12, 2003
280
Agenerase and
Lexiva
282
262
224
GlaxoSmithKline
HIV infection
April 15, 1999, and

Oct. 20, 2003
281
Miacalcin/
Miacalcic
281
339
365
Novartis
Osteoporosis
July 3,1986/NA
282
Vaqta,
Recombivax HB,
Comvax
280
249
195
Merck & Co.
Hepatitis
Vaqta: May 1996

(U.S. launch)
Recombivax HB:
Aug. 27, 1999
(U.S. approval)
Comvax: January 1997
(U.S. launch)
283
Radicut
279
286
325
Mitsubishi Tanabe
Pharma
Cerebral infarction
June 2001
(Japan launch)
284
Rebetol
277
311
331
Schering-Plough
Hepatitis C
June 4, 2002
285
Baraclude
275
83
12
Hepatitis B
March 29, 2005
286
Tobi/Tobramycin
273
(Novartis)
245
233
(Chiron)
Novartis
Cystic fibrosis infection
Tobi: Dec. 22, 1997

(U.S. approval)
Note: Chiron and

Tobi were acquired
by Novartis in April
2006.
Novartis 177
Chiron 68
(estimate)
287
Onon
271
268
265
Ono Pharmaceutical
Bronchial asthma and

allergic rhinitis
Oct. 1, 1999
287
Plendil
271
275
360
AstraZeneca
Hypertension
July 27, 1995
287
Creon
271
262
222
Solvay
Pancreatic exocrine
insufficiency
NA
290
Fuzeon
267
249
208
Roche
HIV infection
March 27, 2003

(U.S. launch)
290
Thrombin-JMI
267
247
221
Bleeding during surgery
Feb. 24, 1995
292
Velcade
265
221
192
Multiple myeloma
Note: Millennium
figures are net
product sales and
exclude strategic
alliance revenue
and royalties
associated with
non-U.S. marketer,
J&Js Ortho
Biotech.
Millennium 265
Millennium 221
Millennium 192
May 13, 2003

(U.S. approval)
J&J NA
J&J NA
J&J NA
Millennium
Pharmaceuticals
and
Johnson & Johnson
293
ProQuad
264
235
NA
Merck & Co.
Measles, mumps, rubella
Sept. 6, 2005
294
Diprivan
263+
304+
Oct. 2, 1989
AstraZeneca 263
AstraZeneca 304
AstraZeneca and
Abraxis
Anesthesia
Note: Abraxis
acquired U.S. rights
to Diprivan from
AstraZeneca in
June 2006.
369
(AstraZeneca)
Abraxis NA
Abraxis NA
DuoNeb
260
(estimate)
369
(Merck KGaA)
344
(Merck KGaA)
Merck KGaA and

Mylan
Bronchospasm
March 21, 2001
206
181
Schering-Plough
Cancers
June 21, 1996
295
Note: Merck
KGaAs Dey LP
along with DuoNeb
were acquired Oct.
2, 2007, by Mylan;
DuoNeb product
exclusivity was lost
in July 2007.
296
Caelyx
Merck KGaA 218

(estimate)
Mylan 42
(estimate)
257
19

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
297
Zanidip/Lercadip/
lercanidipine
256
235
194
Recordati
Hypertension
NA
298
Clarith
255
273
275
Taisho
Pharmaceutical
NA
298
Angiomax
255
201
150
The Medicines Co.
Percutaneous coronary
interventions
January 2001
(U.S. launch)
300
Coniel
254
263
281
Kyowa Hakko Kogyo
Hypertension
NA
301
Urso franchise
248
221
223
Primary biliary cirrhosis
Mitsubishi
Tanabe 171
Mitsubishi
Pharma 159
Mitsubishi
Pharma 176
Mitsubishi Tanabe
Pharma and
Axcan Pharma
July 1962 (Japan)

May 1998 (U.S. launch)
Axcan 77
Axcan 62
Axcan 47
302
Synvisc
242
234
219
Genzyme
Osteoarthritis
Aug. 13, 1997
303
Actiq
240
578
412
Cephalon
Cancer pain
Nov. 4, 1998
303
Diane
240
240
236
(Schering AG)
Bayer
Contraception
NA
Notes: Bayer 2006

figure is pro forma
after Schering AG
305
Iressa
238
237
273
AstraZeneca
Nonsmall cell lung cancer
May 5, 2003
305
Hycamtin
238
226
198
GlaxoSmithKline
Cancers
May 29, 2000
307
Zostavax
236
39
Merck & Co.
Shingles
May 25, 2006
308
Omnicef
235
637
495
Abbott Laboratories
Dec. 4, 1997
309
Intron A
233
237
287
Schering-Plough
Hepatitis
June 5, 1990
309
Allelock
233
210
199
Kyowa Hakko Kogyo
Allergic rhinitis
Dec. 22, 2000
311
Orencia
231
89
Dec. 23, 2005
312
Xyzal
230
196
173
UCB
Allergic rhinitis
Aug. 28, 2001
313
M-M-R II
228
NA
NA
Merck & Co.
Measles, mumps, and

rubella
NA
314
WelChol
227
187
148
Daiichi Sankyo
Cholesterol
May 27, 2004
315
Saizen
224
209
(Serono)
206
(Serono)
Merck KGaA
Growth failure
Oct. 8, 1996
Note: Merck KGaA

acquired Serono
along with Saizen
Jan. 5, 2007.
316
Subutex/Subuxone
220
203
197
Schering-Plough
Opiate addiction
Oct. 8, 2002
(U.S. approvals)
317
Ziagen
218
234
272
GlaxoSmithKline
HIV infection
Dec. 17, 1998
318
Aloxi
216
(estimate)
251
249
MGI Pharma
Nausea and vomiting
July 25, 2003
319
Visudyne
215
354
484
Novartis
Age-related macular
degeneration
April 12, 2000
319
Myslee
215
194
171
Astellas Pharma
Insomnia
Dec. 13, 2000
321
Faslodex
214
186
140
AstraZeneca
Breast cancer
April 25, 2002
322
Raptiva
213
160
113
Psoriasis
Notes: Total
2007, 2006 and
2005 figures
were reported by
Raptiva developer
Xoma.
Roche 107 (via

Genentech 107)
Roche 90 (via
Genentech 90)
Roche 79 (via
Genentech 79)
Genentech and
Merck KGaA
November 2003
(U.S. launch)
Merck KGaA
106
Serono 70
Serono 34
211
193
182
Daiichi Sankyo
Congestive heart failure
NA
Genentech reports
U.S. sales that are
recorded by parent
company Roche.
Merck KGaA
acquired Serono
Jan. 5, 2007.
323
Artist
20

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
324
Serc
206
200
167
Solvay
Menieres Syndrome
NA
325
Emend
204
131
87
Merck & Co.
Nausea and vomiting
March 26, 2003
325
Vancocin
204
167
126
ViroPharma
April 15, 1986

(U.S. approval)
327
Coumadin
201
220
212
NA
327
Myozyme
201
59
Genzyme
Pompe disease
NA
327
Remodulin
201
153
110
United Therapeutics
Pulmonary arterial
hypertension
May 21, 2002

(U.S. launch)
327
Livial
201
(estimate)
207
(Akzo Nobel)
211
(Akzo Nobel)
Akzo Nobel and

Schering-Plough
Menopausal symptoms
March 1997
Notes:
Schering-Plough
acquired Akzo
Nobels Organon
BioSciences along
with Livial
Nov. 19, 2007.
Akzo Nobel 177

(estimate)
Schering-Plough
24
Akzo Nobel 2007

sales are estimated
from Jan. 1, 2007,
thru Nov. 18, 2007.
Schering-Ploughs
sales are an actual
331
Arixtra
200
116
48
GlaxoSmithKline
Dec. 7, 2001
332
Cefzon
198
255
293
Astellas Pharma
1991
332
Cardizem LA
198
(estimate)
162
(estimate)
132
Abbott Laboratories
and Biovail
Hypertension
Feb. 6, 2003
Abbott 129
(estimate)
Kos 105
(estimate)
Biovail 69
Abbott NA
Note: Abbott
acquired Kos
Pharmaceuticals in
December 2006
Kos 70
Biovail 62
Biovail 57
334
Amitiza
196
(Takeda)
57
(Takeda)
Takeda
Pharmaceutical
and Sucampo
Pharmaceuticals
Constipation
April 25, 2006

(U.S. launch)
335
Gasmotin
195
185
163
Dainippon Sumitomo
1998
335
Hyalein
195
179
169
Santen
Pharmaceutical
Corneal disease
June 1995
(Japan launch)
337
Invanz
190
139
94
Merck & Co.
Nov. 9, 2001
337
Timoptic/Timoptol
and Timoptic-XE/
Timoptol XE
190
198
211
Merck & Co. 120

(Timoptic and
Timoptic XE)
Merck & Co. 127

(Timoptic and
Timoptic XE)
Merck & Co. 138

(Timoptic and
Timoptic XE)
Merck & Co. and

Santen
Pharmaceutical
Intraocular pressure and

glaucoma
Santen 70
(Timoptol and
Timoptol XE)
Santen 71
(Timoptol and
Timoptol XE)
Santen 73
(Timoptol and
Timoptol XE)
Timoptic: Aug. 17, 1978

(U.S. approval)
Timoptic-XE: Nov. 4,
Timoptol: September
1981 (Japan launch)
Timoptol XE: November
1999 (Japan launch)
339
Euthyrox products
186
176
156
Merck KGaA
Hypothyroidism
NA
340
Anplag
183
167
177
Mitsubishi Tanabe
Pharma
Chronic arterial occlusion
October 1993 (launch)
341
Rotarix
182
88
NA
GlaxoSmithKline
Rotavirus infection
Feb. 27, 2006
341
Elaprase
182
24
Group
Hunter syndrome
July 24, 2006

(U.S. approval)
341
Bonalon
182
138
119
Teijin
Osteoporosis
August 2001
(Japan launch)
344
Enablex/Emselex
179
114
46
Novartis
Overactive bladder
Enablex: Dec. 22, 2004

(U.S. appoval)
Emselex: Oct. 27, 2004
(EU approval)
345
Mycamine/
Funguard
178
165
152
Astellas Pharma
Fungal infections
March 16, 2005/

December 2002
346
Dysport
176
155
127
Ipsen
Cervical dystonia
1991 (U.K. launch)
21

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
346
Elidel
176
179
268
Novartis
Atopic dermatitis
Dec. 13, 2001
346
Herbesser
176
180
188
Mitsubishi Tanabe
Pharma
Hypertension
February 1974
346
Pentasa
176
138
136
Group
Ulcerative colitis
May 11, 1997
346
Calcichew
176
174
145
NA
Nycomed 128
Nycomed 106
Nycomed and
Group
Osteoporosis
Nycomed 122
Shire 54
Shire 46
Shire 39
351
Thymoglobulin/
Lymphoglobuline
175
150
128
Genzyme
Dec. 30, 1998/NA
352
Kinedak
174
173
212
Ono Pharmaceutical
Peripheral neuropathy
NA
352
Influvac
174
162
137
Solvay
Influenza
2003 (launch)
354
Teveten franchise
172
(estimate)
154
(estimate)
153
Solvay and Abbott

Laboratories
Hypertension
Dec. 22, 1997

(U.S. approval)
Solvay 145
Solvay 130
Abbott 27
(estimate)
Kos 24
(estimate)
Notes: Abbott
acquired Kos
Pharmaceuticals in
December 2006.
Biovail
transferred
product rights for
Teveten to Kos in
May 2005.
Solvay 125
Kos 22
Biovail 6
Abbott NA
355
Vectibix
170
39
Amgen
Colorectal cancer
Sept. 27, 2006
356
Kadian
168
138
102
Alpharma
Pain
July 3, 1996
357
Benet
165
162
157
Takeda
Pharmaceutical
Osteoporosis
May 2002
(Japan launch)
358
Protopic
164
147
144
Astellas Pharma
Dermatitis
June 16, 1999
358
Tanakan
164
178
166
Ipsen
Neurological and vascular

disorders
360
Sprycel
158
25
Leukemia
June 28, 2006
361
Tussionex
156
144
148
UCB
Cough
Dec. 31, 1987
362
Sigmart
153
154
165
Chugai
Pharmaceutical
Angina pectoris
1984
363
Ceredist
152
145
137
Mitsubishi Tanabe
Pharma
Spinal cerebellar
degeneration
September 2000
(Japan launch)
364
Azilect
151
57
1+
Teva 44
Teva NA
Teva Pharmaceutical
Industries and
H. Lundbeck
Parkinsons disease
Teva 120
March 2005
(Israel launch)
Lundbeck 31
Lundbeck 13
Lundbeck 1
150
204
184
Depression
GSK 150
GSK 204
GSK 184
GlaxoSmithKline and
Biovail
Dec. 30, 1985, and

Oct. 4, 1996
Biovail NA
Biovail NA
Biovail NA
150
123
70
Prostate cancer
Astellas 92
Astellas 59
Astellas 26
Astellas Pharma,
MediGene, QLT
May 2004
(Germany launch)
MediGene 30
MediGene 42
MediGene 27
QLT 28
QLT 22
QLT 17
365
365
Wellbutrin IR and SR
Eligard
365
Trasylol
150
210
315
Bayer
Perioperative blood loss
Dec. 29, 1993
368
Loestrin 24 FE
149
44
Warner Chilcott
Feb. 17, 2006

(U.S. approval)
369
Meropen
148
143
141
Dainippon Sumitomo
NA
370
Prorenal
145
138
126
Dainippon Sumitomo
Peripheral circulation
1988
371
Tanatril
144
145
147
Mitsubishi Tanabe
Pharma
Hypertension
December 1993
371
Replagal
144
118
41
Group
Fabrys disease
Aug. 3, 2001
371
Marinol
144
145
115
Solvay
Nausea and vomiting
1987 (U.S. launch)
22

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
374
Somatuline
142
126
112
Ipsen
Acromegaly
375
Durotep
139
141
135
Kyowa Hakko Kogyo
Cancer pain
October 2001
375
Elcitonin
139
138
152
Asahi Kasei
Osteoporosis
NA
377
Nootropil
138
136
141
UCB
Cognitive disorders
NA
377
Tygacil
138
72
10
Wyeth
June 15, 2005
379
Fentora
135
29
Cephalon
Cancer pain
Sept. 25, 2006
380
Boostrix
132
120
NA
GlaxoSmithKline

pertussis
May 3, 2005
381
Gran
130
134
138
Kirin Brewery
Leukopenia
1991 (Japan launch)
382
Venoglobulin-IH
129
132
141
Mitsubishi Tanabe
Pharma
Immunological conditions
January 1992
383
Taclonex
127
60
Warner Chilcott
Psoriasis vulgaris
April 3, 2006
(U.S. launch)
383
Avinza
127
137
113
March 20, 2002
King 109
King 0
King 0
and Ligand
Pharmaceuticals
Pain
Note: King
acquired all rights
to Avinza in the
United States, its
territories and
Canada from
Ligand Feb. 26,
2007.
Ligand 18
Ligand 137
Ligand 113
385
Actovegin
126
108
88
Nycomed
Metabolic stimulation
NA
385
Rozerem
126
103
30
Takeda
Pharmaceutical
Insomnia
Sept. 26, 2005

(U.S. launch)
387
Isovorin
125
140
128
Takeda
Pharmaceutical
Tumors
October 1999
(Japan launch)
387
Onealfa
125
118
120
Teijin
Osteoporosis
NA
389
Kremezin
124
122
130
Daiichi Sankyo
Renal failure
December 1991
389
Aldurazyme
124
96
76
BioMarin/Genzyme
(joint venture)
Mucopolysaccharidosis
April 30, 2003
391
Maxipime
123
160
140
Elan
Jan. 18, 1996
391
Alfarol
123
125
135
Chugai
Pharmaceutical
Osteoporosis
1981
391
Seltouch
123
127
137
Takeda
Pharmaceutical
Pain
September 1993
(Japan launch)
394
Flumarin
122
133
156
Shionogi
NA
394
Percocet
122
103
111
Endo
Pharmaceuticals
Holdings
Pain
June 25, 1999
394
Smecta
122
110
93
Ipsen
Diarrhea and pain
397
Sunrythm
121
117
119
Daiichi Sankyo
Arrhythmia
NA
398
Frandol
120
123
127
Astellas Pharma
Angina pectoris
NA
399
Vancomycin
117
117
111
Shionogi
NA
399
Imunace
117
117
111
Shionogi
Cancers
NA
399
Dacogen
117
(estimate)
36
MGI Pharma
Myelodysplastic syndrome
May 26, 2006

(U.S. launch)
402
Depas
116
113
126
Mitsubishi Tanabe
Pharma
Anxiety
March 1984 (launch)
402
Doryx
116
102
96
Warner Chilcott
July 22, 1985

(U.S. approval)
404
Palux
114
112
120
Taisho
Pharmaceutical
Ulcers
1999
405
Ebastel
111
114
113
Dainippon Sumitomo
Allergies
NA
405
Mucosolvan
111
115
117
Teijin
Expectorant
NA
407
Luvox
110
111
103
Astellas Pharma
Depression
April 8, 2003
407
Onon Dry Syrup
110
114
94
Ono Pharmaceutical
Pediatric bronchial
asthma
Oct. 1, 1999
409
Metadate CD/
Equasym XL
108
93
70
UCB
Attention-deficit
April 3, 2001/
February 2005
23

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
410
Opana and
Opana ER
107
Endo
Pharmaceuticals
Holdings
Pain
July 24, 2006

(U.S. launches)
411
Depakene
105
102
102
Kyowa Hakko Kogyo
Seizures
NA
412
Liple
104
102
113
Mitsubishi Tanabe
Pharma
November 1988
(launch)
413
Maintate
103
99
102
Mitsubishi Tanabe
Pharma
Hypertension
NA
413
Exforge
103
10
Novartis
Hypertension
Jan. 18, 2007

(EU approval date)
415
Calblock
102
88
64
Daiichi Sankyo
Hypertension
2003
415
Fosrenol
102
45
54
Group
Phosphorus level reduction
Oct. 26, 2004
415
Tykerb
102
GlaxoSmithKline
Breast cancer
March 13, 2007
418
Avandaryl
100
84
GlaxoSmithKline
Type 2 diabetes
Nov. 23, 2005
418
Levoxyl
100
112
140
Hypothyroidism
May 25, 2001
418
Rinderon
100
101
102
Shionogi
Ocular surface disorders
NA
421
HANP
98
92
86
Daiichi Sankyo
Acute heart failure
NA
422
Sermion
95
102
114
Mitsubishi Tanabe
Pharma
Cerebral circulation
June 1988
(Japan launch)
422
Urief
95
37
Dysuria
May 2006
Daiichi 54
Daiichi 23
Daiichi Sankyo and

Kissei Pharmaceutical
Kissei 41
Kissei 14
95
(estimate)
87
(MedImmune)
95
(MedImmune)
AstraZeneca and
MedImmune
Renal toxicity reduction
Dec. 8, 1995
422
Ethyol
Note: MedImmune
2007 figure is a
first-half estimate;
MedImmune was
acquired along
with Ethyol by
AstraZeneca in
June 2007.
MedImmune 52
(estimate)
AstraZeneca 43
425
Flivas
94
93
91
Asahi Kasei
Benign prostatic
hyperplasia
NA
425
Suvenyl
94
78
69
Chugai
Pharmaceutical
March 2000
425
Bezatol
94
98
106
Hyperlipidemia
April 1991
428
Zoton
93
131
376
Wyeth
1994
429
Colazal
92
103
110
Salix Pharmaceuticals
Ulcerative colitis
July 18, 2000
429
Plan B
92
NA
NA
Barr Pharmaceuticals
Contraception
July 28, 1999
Notes: 2007 includes

Rx and OTC sales
as the two segments
were not broken
down by Barr.
Barr changed from
a June 30 fiscal year
for 2006 and 2005 to
a Dec. 31 year end
for 2007.
431
Prexige
91
47
Novartis
Osteoarthritic pain
2005 (Australia, Brazil,

New Zealand,
U.K. launches)
432
Venilon
89
94
93
Teijin
Severe infectious diseases
February 1980
(Japan launch)
432
Noxafil
89
19
NA
Schering-Plough
Fungal infections
Sept. 15, 2006

(U.S. approval)
434
Zelnorm/Zelmac
88
561
417
Novartis
Irritable bowel syndrome
March 19, 2002/

Oct. 30, 2001
434
TachoSil
88
84
64
Nycomed
Tissue management
NA
434
Glovenin
88
86
85
Takeda
Pharmaceutical
Blood disorders
November 1991
(Japan launch)
24

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
434
Talion
88
70
64
438
Aggrastat
87+
90+
Notes: Medicure
acquired Aggrastat
U.S. rights from MGI
Aug. 8, 2006.
Merck 87
Merck 86
99
(estimate)
Medicure NA
MGI 4
Medicure NA
MGI acquired Aggrastat U.S. rights from

Guilford Pharmaceuticals in October
2005.
438
Ultram ER
Primary disease/
medical use
First approval date

(or launch date)
Mitsubishi Tanabe
Pharma
Allergic rhinitis
Merck & Co. and

Medicure
Biovail and
Johnson & Johnson
Pain
Feb. 21, 2006 (U.S. launch)
2007 company
Merck 88
Guilford 9
(estimate)
MGI Pharma 2
Medicure 0
87+
54+
Biovail 87
Biovail 54
J&J NA
J&J NA
438
Meptin
87
37
NA
Otsuka
Pharmaceutical
Bronchial muscle
relaxation
1980 (Japan launch)
438
Farmorubicin and
Adriacin
87
86
95
Kyowa Hakko Kogyo
Cancers
NA
442
Oxis
86
88
91
AstraZeneca
Asthma
March 4, 2001
442
Azactam
86
78
58
Elan
Dec. 31, 1986
442
Naglazyme
86
47
BioMarin
Pharmaceutical
May 31, 2005
442
Janumet
86
Merck & Co.
Type 2 diabetes
March 30, 2007

(U.S. approval)
446
Pansporin
84
109
127
Takeda
Pharmaceutical
February 1981
(Japan launch)
446
Intal
84
94
96
Asthma
May 29, 1986
Astellas 70
Astellas 79
Astellas 84
Astellas Pharma and

King 14
King 15
King 12
448
Nolvadex
83
89
114
AstraZeneca
Breast cancer
Dec. 30, 1977
449
Tazorac, Zorac,
Avage
80
91
87
Allergan
Acne, facial wrinkles
June 13, 1997,

Dec. 12, 1996,
Sept. 30, 2002
449
Campral
80
79
70
Alcoholism
Merck KGaA 49
Merck KGaA 49
Merck KGaA 47
Merck KGaA and

Forest Laboratories
U.S. approval:
July 29, 2004
U.S. launch:
January 2005
Forest 31
Forest 30
Forest 23
451
Sonata
79
86
83
Insomnia
Aug. 13, 1999
452
Dasen
77
81
85
Takeda
Pharmaceutical
Inflammation
November 1968
(Japan launch)
452
Rheumatrex
77
69
67
Takeda
Pharmaceutical
August 1999
(Japan launch)
452
Vyvanse
77
Group
Attention deficit
July 27, 2007

(U.S. launch)
455
Accolate
76
81
72
AstraZeneca
Asthma
Sept. 24, 1996
455
Mearubik
76
59
Mitsubishi Tanabe
Pharma
Measels and Rubella

immunization
December 2005
(launch)
457
Serostim
75
72
(Serono)
70
(Serono)
Merck KGaA
AIDS wasting
Aug. 23, 1996
Note: Serono along

with Serostim were
acquired by Merck
KGaA Jan. 5, 2007.
457
Atarax
75
74
67
UCB
Anxiety
NA
459
Dorner
74
78
85
Astellas Pharma
Circulatory disorders
1992
459
Oxarol
74
65
62
Chugai
Pharmaceutical
Hyperparathyroidism
September 2000
459
Alkeran
74
50
50
Celgene
Multiple myeloma,
ovarian cancer
May 27, 1974
25

Rank
2007
459
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Frova/Migard
74
58
38+
Endo 52 (Frova)
Endo 41 (Frova)
Endo 38 (Frova)
Menarini 22
(Migard)
Menarini 17
(Migard)
Menarini NA
(Migard)
Primary disease/
medical use
First approval date

(or launch date)
Endo
Pharmaceuticals
Holdings and
Menarini
Migraine
Migard: January 2002

(EU approval)
2007 company
Frova: June 2002

(U.S. launch)
459
Nisis and Nisisco
74
70
57
Ipsen
Arterial hypertension
NA
464
Estrace Cream
73
66
54
Warner Chilcott
Menopausal symptoms
Jan. 31, 1984

(U.S. approval)
465
Carbatrol
72
68
72
Group
Seizures
Sept. 30, 1997
465
Efudex/Efudix
72
78
60
Valeant
Pharmaceuticals
Multiple actinic keratoses

and superficial basal cell
carcinoma
Efudex: July 29, 1970

(U.S. approval)
467
Neupro
71
14
UCB
Parkinsons disease
Feb. 20, 2006

(Europe approval)
467
Forlax
71
63
59
Ipsen
Constipation
469
Dogmatyl
70
73
78
Astellas Pharma
Ulcers
NA
469
Paragard
70
NA
NA
Contraception
Nov. 15, 1984
Note: Barr changed

from a June 30 fiscal
year for 2006 and
2005 to a Dec. 31
year end for 2007.
471
Xagrid
69
53
47
Group
Thrombocythemia
November 2004
(EU approval)
472
Ranexa
67
18
CV Therapeutics
Chronic angina
March 24, 2006

(U.S. launch)
473
OxyContin
66+
52+
43+
Cancer pain
Purdue NA
Purdue NA
Purdue NA
Purdue Pharma
and Shionogi
Dec. 12, 1995

(U.S. approval)
July 7, 2003
(Japan launch)
Shionogi 66
Shionogi 52
Shionogi 43
473
Perdipine and
Perdipine LA
66
75
89
Astellas Pharma
Hypertension
1981 and NA
473
Cefamezin
66
66
75
Astellas Pharma
NA
473
Symlin
66
44
12
Amylin
Pharmaceuticals
Diabetes
March 16, 2005
473
Soliris
66
Alexion
Pharmaceuticals
Paroxysmal nocturnal
hemoglobinuria
April 2007 (U.S. launch)
473
Atmadisc
66
65
(Schwarz)
61
(Schwarz)
UCB
Asthma
Aug. 24, 2000
Ventavis
65+
24+
Actelion and Bayer
Notes: 2006 figure

is an estimate
based on
nine-month
2006 sales of
CoTherix, which
was acquired by
Actelion in March
2007.
Actelion 65
65+
(estimate)
Pulmonary arterial
hypertension
Sept. 22, 2003

(EU approval)
Note: Schwarz
Pharma was
acquired by UCB in
December 2006.
479
CoTherix NA
CoTherix 65
(estimate)
Bayer NA
Bayer NA
CoTherix 24
Schering NA
Bayer acquired
Schering AG June
23, 2006.
479
Canasa
65
53
29
Axcan Pharma
Jan. 5, 2001
481
Firstcin
64
69
75
Takeda
Pharmaceutical
August 1995
(Japan launch)
481
Xifaxan
64
52
30
Travelers diarrhea
May 25, 2004
481
Cefspan
64
57
60
Astellas Pharma
NA
481
Daytrana
64
25
Group
Attention deficit
June 29, 2006

(U.S. launch)
26

Rank
2007
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Primary disease/
medical use
First approval date

(or launch date)
481
Femhrt
64
59
61
Warner Chilcott
Menopausal symptoms
Oct. 15, 1999

(U.S. approval)
486
Targocid
63
64
70
Astellas Pharma
July 1998
486
Toledomin
63
60
62
Asahi Kasei
Depression
NA
486
Aptivus
63
73
NA
HIV infection
June 22, 2005
489
Pentcillin
62
61
66
Taisho
Pharmaceutical
NA
489
Bredinin
62
60
61
Asahi Kasei
Kidney transplantation
NA
489
Topotecin
62
54
48
Daiichi Sankyo
Colorectal cancer
NA
489
Omeprazon
62
59
70
Mitsubishi Tanabe
Pharma
Ulcers
April 1991 (launch)
489
Novastan
62
54
38
Mitsubishi Tanabe
Pharma
Peripheral arterial
occlusive disease
NA
494
Nauzelin
60
65
66
Kyowa Hakko Kogyo
NA
494
Sumiferon
60
64
60
Dainippon Sumitomo
Hepatitis B and C
1987
494
Theo-Dur
60
77
127
Mitsubishi Tanabe
Pharma
Asthma
April 1984 (launch)
497
Bicilin
59
43
54
May 19, 1957
497
Cabaser
59
99
103
Parkinsons disease
September 1999
497
Antara
59
17
Oscient
Pharmaceuticals
Hypercholesterolemia and
hypertriglyceridemia
Nov. 30, 2004

(U.S. approval)
500
Gastrom
58
61
64
Mitsubishi Tanabe
Pharma
Ulcers
December 1993
(launch)
500
Neuart
58
59
62
Mitsubishi Tanabe
Pharma
Disseminated intravascular
coagulation
June 1987 (launch)
NOTES/LEGEND:
*First approval date or launch date = anywhere worldwide; in some instances, the first approval or launch date and region of occurrence are provided.
*NA = not applicable.
*+ = sales are assumed to be higher than the represented total.
*This chart presents 500 medicines in sales order as reported by the companies. Certain products are represented by more than one company due to joint-marketing or
joint-promotion accords. The combined product sales from such company alliances are presented in this chart at the top of each medicine sales entry, followed by the
breakdown in company-reported sales.
*Some product entries have their (chemical) listed depending on where and under which name the drug is marketed, or how the company reports the drugs sales.
*All foreign product sales are reported in U.S. dollars using Federal Reserve or company-provided exchange rates.
*Estimate = sales were not provided by company or found by Med Ad News editors, who made an estimate based on previous-year figures and/or other information
provided. This report does exclude certain products that probably would have been ranked in the top 500 list for 2007, but were omitted since no 2007 information could
be found to make an estimate. In most of these instances, there are products with declining annual sales figures due to patent expirations.
*All Japanese-company 2007 product sales are for the fiscal year ended March 31, 2008 (2006 = year ended March 31, 2007; 2005 = year ended March 31, 2006), except
for Chugai Pharmaceutical and Kirin Brewery, which report annual sales on a Dec. 31 calendar-year basis.
*Forest Laboratories 2007 product sales are for the fiscal year ended March 31, 2008 (2006 = year ended March 31, 2007; 2005 = year ended March 31, 2006).
*Barr Pharmaceuticals for 2007 reported on a Dec. 31 calendar-year basis; previously, the company provided figures for years ended June 30).
*Axcan Pharma 2007 figures are for the fiscal year ended Sept. 30, 2007 (2006 = year ended Sept. 30, 2006; 2005 = year ended Sept. 30, 2005).
27
TOP 500
PRESCRIPTION
MEDICINES
BY COMPANY

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Abbott Laboratories
Humira
3,064
2,044
1,400
Dec. 31, 2002
Note: Abbott acquired Kos

Pharmaceuticals (along with
Niaspan and certain rights to
Cardizem and Teveten) Dec.
13, 2006.
Depakote
1,575
1,308
1,096
Seizures
March 10, 1983
Kaletra
1,325
1,135
1,005
HIV infection
March 9, 2001
TriCor
1,218
1,048
927
Cholesterol
Feb. 9, 1998
Ultane/Sevorane
759
799
874
Anesthesia
June 7, 1995/1994
Biaxin
724
816
1,065
Oct. 31, 1991
Niaspan
658
Cholesterol
July 28, 1997
Synthroid
533
534
554
Hypothyroidism
1955
Omnicef
235
637
495
Dec. 4, 1997
Lansoprazole
200
173
154
NA
Cardizem LA
129
(estimate)
NA
Hypertension
Feb. 6, 2003
Teveten franchise
27
(estimate)
NA
Hypertension
Dec. 22, 1997

(U.S. approval)
Leuprolide
NA
230
219
Prostate cancer
NA
Synagis
373
(U.S. joint
promotion
revenue)
231
(U.S. joint
promotion
revenue)
June 19, 1998

(U.S. approval)
Mobic
1,232
Osteoarthritis and
Feb. 27, 1996
Abraxane
325
175
134
Breast cancer
February 2005
(U.S. launch)
Diprivan
NA
NA
Anesthesia
Oct. 2, 1989
Tracleer
983
749
528
Pulmonary arterial
hypertension
Nov. 20, 2001
Ventavis
65
Pulmonary arterial
hypertension
Sept. 22, 2003

(EU approval)
Follistim/Puregon
513
(estimate)
527
487
Infertility
Sept. 29, 1997/May 3, 1996
NuvaRing
342
(estimate)
292
174
Contraception
June 12, 2001
Remeron
271
(estimate)
347
388
Depression
June 15, 2000
Livial
177
(estimate)
207
211
Menopausal symptoms
March 1997
Alexion Pharmaceuticals
Soliris
66
hemoglobinuria
Allergan
Botox
1,212
982
831
Cervical dystonia
Dec. 29, 1989
Lumigan franchise
392
328
268
March 16, 2001
Restasis
345
270
191
Dry eye
Dec. 23, 2002
Alphagan P, Alphagan,
Combigan
341
296
277
March 16, 2001, Sept. 6,

1996, fourth-quarter 2003
Tazorac, Zorac, Avage
80
91
87
June 13, 1997, Dec. 12,

1996, Sept. 30, 2002
Alpharma
Kadian
168
138
102
Pain
July 3, 1996
Altana Pharma
Pantoprazole
(including Pantozol)
2,126
1,866
Pantozol: 1994
Note: Abbott completed

the U.S. joint-promotion
deal of Synagis
with MedImmune in
December 2006)
Abraxis
Note: Abraxis acquired

U.S. rights to Diprivan
from AstraZeneca in
June 2006.
Actelion
Note: CoTherix and U.S.

rights to Ventavis were
acquired by Actelion in
March 2007.
Akzo Nobel
Note: Akzo Nobel 2007
product sales are estimates
from Jan. 1, 2007, thru Nov.
18, 2007; Schering-Plough
acquired Akzo Nobels
Organon BioSciences as of
Nov. 19, 2007.
Note: Nycomed acquired

Altana Pharma along with
Pantoprazole products
Dec. 29, 2006.
29

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Amgen
Aranesp
3,614
4,121
3,273
Anemia
June 11, 2001
Enbrel
3,230
2,879
2,573
Nov. 2, 1998
Neulasta
3,000
2,710
2,288
Neutropenia
Jan. 31, 2002
Epogen
2,489
2,511
2,455
Anemia
June 1, 1989
Neupogen
1,277
1,213
1,216
Neutropenia
Feb. 20, 1991
Sensipar
463
321
157
Hypercalcemia
March 8, 2004
Vectibix
170
39
Colorectal cancer
Sept. 27, 2006
Byetta
636
430
75
Type 2 diabetes
April 28, 2005
Symlin
66
44
12
Diabetes
March 16, 2005
Elcitonin
139
138
152
Osteoporosis
NA
Flivas
94
93
91
Benign prostatic hyperplasia
NA
Toledomin
63
60
62
Depression
NA
Bredinin
62
60
61
NA
Prograf
2,030
1,754
1,459
April 2, 1993
Harnal
1,224
1,270
1,378
Benign prostatic hypertrophy
July 1992
Lipitor
977
947
915
Cholesterol
Dec. 17, 1996
Micardis
626
503
373
Hypertension
Nov. 10, 1998
Gaster
609
622
688
1985
Vesicare
601
362
148
Overactive bladder
July 9, 2004
Adenoscan
376
371
353
scintigraphy
May 19, 1999
Myslee
215
194
171
Insomnia
Dec. 13, 2000
Cefzon
198
255
293
1991
Seroquel
192
168
152
Schizophrenia
Sept. 26, 1997
Mycamine/Funguard
178
165
152
Fungal infections
March 16, 2005/

December 2002
Protopic
164
147
144
Dermatitis
June 16, 1999
Frandol
120
123
127
Angina pectoris
NA
Luvox
110
111
103
Depression
April 8, 2003
Eligard
92
59
26
Prostate cancer
May 2004
(Germany launch)
AmBisome
76
88
89
Fungal infections
Aug. 11, 1997
Dorner
74
78
85
1992
Intal
70
79
84
Asthma
May 29, 1986
Dogmatyl
70
73
78
Ulcers
NA
Perdipine and
Perdipine LA
66
75
89
Hypertension
1981 and NA
Cefamezin
66
66
75
NA
Cefspan
64
57
60
NA
Targocid
63
64
70
July 1998
Celecox
37
Osteoarthritis and
June 11, 2007

(Japan launch)
AstraZeneca
Nexium
5,216
5,182
4,633
March 2000 (Sweden)
Note: AstraZeneca
acquired MedImmune,
including Synagis and
Ethyol, in June 2007.
Seroquel
4,027
3,416
2,761
Schizophrenia
Sept. 26, 1997
Crestor
2,796
2,028
1,268
Cholesterol
Nov. 7, 2002
Arimidex
1,730
1,508
1,181
Breast cancer
Dec. 27, 1995
Symbicort
1,575
1,184
1,006
Asthma
August 2000
Pulmicort
1,454
1,292
1,162
Asthma
June 24, 1997
Toprol-XL/Seloken
1,438
1,795
1,735
Hypertension
Jan. 10, 1992/1996
Casodex
1,335
1,206
1,123
Prostate cancer
Oct. 4, 1995
Atacand
1,287
1,110
974
Hypertension
June 4, 1998
Prilosec/Losec
1,143
1,371
1,652
Sept. 14, 1989/1987
Zoladex
1,104
1,008
1,004
Prostate cancer
Dec. 29, 1989
Amylin Pharmaceuticals
Asahi Kasei
Astellas Pharma
30

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
AstraZeneca
(continued)
Merrem
773
604
505
June 21, 1996
Synagis
618
June 19, 1998

(U.S. approval)
Zomig
434
398
352
Migraine
July 8, 1997
Rhinocort
354
360
387
Allergic rhinitis
Feb. 14, 1994
Tenormin
308
320
352
Hypertension
Aug. 19, 1981
Zestril
295
307
332
Hypertension
Dec. 30, 1987
Plendil
271
275
360
Hypertension
July 27, 1995
Diprivan
263
304
369
Anesthesia
Oct. 2, 1989
Iressa
238
237
273
Nonsmall cell lung cancer
May 5, 2003
Faslodex
214
186
140
Breast cancer
April 25, 2002
Oxis
86
88
91
Asthma
March 4, 2001
Nolvadex
83
89
114
Breast cancer
Dec. 30, 1977
Accolate
76
81
72
Asthma
Sept. 24, 1996
Abraxane
62
18
Breast cancer
February 2005
(U.S. launch)
Ethyol
43
Dec. 8, 1995
Urso franchise
77
62
47
Canasa
65
53
29
Jan. 5, 2001
Plan B
92
NA
NA
Contraception
July 28, 1999
Note: Barr changed from a

June 30 fiscal year for 2006
and 2005 to a Dec. 31 year
end for 2007.
Note: Plan B 2007

figure include Rx and
OTC sales as the two
segments were not
broken down by Barr.
Paragard
70
NA
NA
Contraception
Nov. 15, 1984
Yasmin, Yaz, Yasminelle
1,429
1,089
Yasmin: March 2000

Yaz: March 2006
(U.S. approval)
Betaseron/Betaferon
1,409
1,359
Multiple sclerosis
July 23, 1993/Nov. 30, 1995
Kogenate
1,121
1,079
909
Hemophilia
Feb. 25, 1993
Adalat
842
901
904
Hypertension
Nov. 27, 1985
Avelox/Avalox
610
543
499
Dec. 10, 1999/

June 21, 1999
Cipro/Ciprobay
525
703
720
Oct. 22, 1987/1987
Mirena
495
413
Contraception
Dec. 6, 2000
Levitra
455
431
356
March 6, 2003
Magnevist
413
443
Magnetic resonance
imaging
June 2, 1988
Glucobay
409
422
404
Type 2 diabetes
NA
Nexavar
370
178
NA

and liver cancer
Dec. 21, 2005 (U.S. launch)
Ultravist
322
304
Imaging/various
May 11, 1999
Iopamiron
289
303
NA
Diane
240
240
Contraception
NA
Trasylol
150
210
315
Dec. 29, 1993
Ventavis
NA
NA
NA
Pulmonary arterial
hypertension
Sept. 22, 2003

(EU approval)
Avonex
1,868
1,707
1,543
Multiple sclerosis
May 17, 1996
Rituxan
617
556
514
Nov. 26, 1997
Tysabri
230
36
Multiple sclerosis
Nov. 23, 2004
Naglazyme
86
47
May 31, 2005
Note: AstraZeneca
acquired MedImmune,
including Synagis and
Ethyol, in June 2007.
Axcan Pharma
Bayer
Note: 2006 figures are
pro forma for Yasmin line,
Betaseron/Betaferon,
Mirena, Magnevist, Ultravist,
Iopamiron and Diane after
Schering AG products
acquisition by Bayer as of
June 23, 2006.
Biogen Idec
Note: Figures = U.S. joint

promotion profit.
BioMarin Pharmaceutical
31

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
BioMarin/Genzyme
(joint venture)
Aldurazyme
124
96
76
April 30, 2003
Biovail
Wellbutrin XL
212
450
354
Depression
Aug. 28, 2003
Zovirax
147
112
96
Herpes
March 30, 1986
Ultram ER
87
54
Pain
Cardizem LA
69
57
62
Hypertension
Feb. 6, 2003
NA
NA
NA
Depression
Dec. 30, 1985, and

Oct. 4, 1996
Teveten
Hypertension
Dec. 22, 1997

(U.S. approval)
Spiriva
2,457
1,893
1,304
Chronic obstructive
pulmonary disease
April 2002
Micardis
1,540
1,326
993
Hypertension
Nov. 10, 1998
Flomax
1,399
1,264
989
Oct. 8, 1997
Combivent
887
920
769
Chronic obstructive
pulmonary disease
Oct. 24, 1996
Mirapex/Sifrol
883
735
595
Parkinsons disease
July 1, 1997/Oct. 14, 1997
Aggrenox
381
308
236
Stroke
Nov. 22, 1999
Viramune
359
378
395
HIV infection
June 22, 2000
Mobic
326
794
1,163
Osteoarthritis and
Feb. 27, 1996
Flomox
286
306
341
June 1997
Aptivus
63
73
NA
HIV infection
June 22, 2005
Plavix
4,755
3,257
3,823
Atherothrombosis
Nov. 17, 1997
Abilify
1,660
1,282
912
Schizophrenia
Nov. 15, 2002
Avapro/Aprovel and
Avalide/CoAprovel
1,204
1,097
982
Hypertension
Sept. 30, 1997/

Aug. 27, 1997 and
Sept. 30, 1997/
Oct. 15, 1998
Reyataz
1,124
931
696
HIV infection
Jan. 6, 2003
Erbitux
692
652
413
Colorectal cancer
Feb. 12, 2004
Sustiva
621
715
680
HIV infection
Sept. 17, 1998
Pravachol
443
1,197
2,256
Cholesterol
Oct. 31, 1991
Taxol
422
563
747
Cancers
Dec. 29, 1992
Efavirenz
335
75
HIV infection
NA
Baraclude
275
83
12
Hepatitis B
March 29, 2005
Orencia
231
89
Dec. 23, 2005
Coumadin
201
220
212
Thrombosis
NA
Sprycel
158
25
Leukemia
June 28, 2006
Glucophage franchise
NA
95
(estimate)
172
Type 2 diabetes
Dec. 29, 1994
Revlimid
774
321
Multiple myeloma,
myelodysplastic syndrome
Dec. 27, 2005
Thalomid
447
433
388
Erythema nodosum
leprosum
July 16, 1998
Alkeran
74
50
50
Multiple myeloma, ovarian

cancer
May 27, 1974
Ritalin and Focalin
Attention-deficit hyperactivity
disorder
Dec. 5, 1955, and

Nov. 13, 2001
Provigil
852
735
513
Sleepiness
Dec. 24, 1998
Actiq
240
578
412
Cancer pain
Nov. 4, 1998
Note: Biovail
transferred product
rights for Teveten to Kos
Pharmaceuticals in May
2005.
Note: Efavirenz is
marketed as Atripla by
Gilead Sciences.
Celgene
Cephalon
32

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Cephalon
(continued)
Fentora
135
29
Cancer pain
Sept. 25, 2006
Chiron
Tobi
233
Note: Chiron was acquired

by Novartis in April 2006.
68
(estimate)
Dec. 22, 1997

(U.S. approval)
Betaseron
43
(estimate)
142
Multiple sclerosis
July 23, 1993
Chugai Pharmaceutical
Epogin
468
542
614
Anemia
July 16, 1997/April 1990
Neutrogin
335
309
276
Neutropenia
Oct. 4, 1991
Tamiflu
331
325
301
Influenza
Oct. 27, 1999
Rituxan
159
154
152
Nov. 26, 1997
Sigmart
153
154
165
Angina pectoris
1984
Herceptin
138
124
96
Breast cancer
Sept. 25, 1998
Evista
137
115
79
Osteoporosis
Dec. 9, 1997
Alfarol
123
125
135
Osteoporosis
1981
Kytril
116
110
104
Nausea and vomiting
January 1992
Suvenyl
94
78
69
March 2000
Oxarol
74
65
62
Hyperparathyroidism
September 2000
Pegasys
54
50
68
Hepatitis C
June 21, 2002
Renagel
49
44
39
Hyperphosphatemia
Oct. 30, 1998
Rocephin
49
47
46
1986 (Japan)
Avastin
30
Colorectal cancer
June 2007
(Japan launch)
Xeloda
23
21
23
Cancer
1998
Femara
Breast cancer
July 25, 1997
Tarceva
Nov. 18, 2004
CellCept
NA
30
May 3, 1995
CoTherix
Ventavis
NA
24
Note: CoTherix and U.S.

rights to Ventavis were
acquired by Actelion in
March 2007.
Note: 2006 figure is a

full-year estimate based
on nine-month 2006
sales.
65
(estimate)
Pulmonary arterial
hypertension
Sept. 22, 2003

(EU approval)
Cubist Pharmaceuticals
Cubicin
285
190
113
Sept. 12, 2003
CV Therapeutics
Ranexa
67
18
Chronic angina
March 24, 2006

(U.S. launch)
Daiichi Sankyo
Benicar/Olmetec and
Benicar HCT (olmesartan)
1,892
1,447
924
Hypertension
April 25, 2002/2002 and

June 5, 2003
Cravit (levofloxacin)
1,087
1,041
1,015
1993 (Japan launch)
Mevalotin (pravastatin)
749
935
1,432
Cholesterol
1988 (Japan launch)
Loxonin
336
309
290
Inflammation
Feb. 17, 1978
Omnipaque
312
315
347
Contrast media for X-Ray

and CT examinations
Dec. 26, 1985 (U.S.

approval)
Venofer
311
309
226
Nov. 7, 2000
WelChol
227
187
148
Cholesterol
May 27, 2004
Artist
211
193
182
Congestive heart failure
NA
Kremezin
124
122
130
Renal failure
December 1991
Sunrythm
121
117
119
Arrhythmia
NA
Zyrtec
108
120
126
Allergic rhinitis
NA (Japan)
Calblock
102
88
64
Hypertension
2003
Mobic
102
107
106
Osteoarthritis and
Feb. 27, 1996
HANP
98
92
86
Acute heart failure
NA
Topotecin
62
54
48
Colorectal cancer
NA
Urief
54
23
Dysuria
May 2006
Evista
37
18
Osteoporosis
Dec. 9, 1997
Zantac
June 9, 1983
33

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Dainippon Sumitomo
Amlodin
636
592
568
Hypertension, angina
pectoris
NA
Gasmotin
195
185
163
1998
Meropen
148
143
141
NA
Prorenal
145
138
126
1988
Ebastel
111
114
113
Allergies
NA
Sumiferon
60
64
60
Hepatitis B and C
1987
Synagis
120
NA (Japan)
Aricept
2,910
2,529
1,965
Alzheimers disease
Nov. 25, 1996
AcipHex/Pariet
1,759
1,743
1,545
Aug. 19, 1999/1997
Actonel
82
75
40
Osteoporosis
March 27, 1998
Tysabri
232
28
11
Multiple sclerosis
Nov. 23, 2004
Maxipime
123
160
140
Jan. 18, 1996
Azactam
86
78
58
Dec. 31, 1986
Lidoderm
706
567
419
Pain
March 19, 1999
Percocet
122
103
111
Pain
June 25, 1999
Opana and Opana ER
107
Pain
July 24, 2006

(U.S. launches)
Frova
52
41
38
Migraine
Lexapro
2,292
2,106
1,873
Aug. 14, 2002/2002
Namenda
830
660
508
Alzheimers disease
Oct. 16, 2003
Benicar and Benicar HCT
212
175
114
Hypertension
April 25, 2002 and

June 5, 2003
Campral
31
30
23
Alcoholism
U.S. approval:
July 29, 2004
U.S. launch: January 2005
Avastin
2,296
1,746
1,133
Colorectal cancer
Feb. 26, 2004

(U.S. approval)
Rituxan
2,285
2,071
1,832
Nov. 26, 1997
Herceptin
1,287
1,234
747
Breast cancer
Sept. 25, 1998
Lucentis
815
380

degeneration
June 30, 2006
Xolair
472
425
320
Asthma
June 20, 2003
Tarceva
417
402
275
Nov. 18, 2004
Nutropin products
371
378
370
Growth failure
Nov. 17, 1993

(U.S. approval)
Activase, TNKase,
Cathflo Activase
268
243
218
Feb. 17, 1996, June 2, 2000,

Sept. 4, 2001
Pulmozyme
223
199
186
Cystic fibrosis
Dec. 30, 1993
Raptiva
107
90
79
Psoriasis
November 2003
(U.S. launch)
Cerezyme
1,130
1,007
932
Gauchers disease
April 5, 1991
Renagel
603
515
418
Hyperphosphatemia
Oct. 30, 1998
Fabrazyme
424
359
305
Fabrys disease
August 2001
Synvisc
242
234
219
Osteoarthritis
Aug. 13, 1997
Myozyme
201
59
Pompe disease
NA
Thymoglobulin/
Lymphoglobuline
175
150
128
Dec. 30, 1998/NA
Truvada
1,589
1,194
568
HIV infection
Aug. 2, 2004
Atripla
903
206
HIV infection
July 12, 2006
Viread
613
689
779
HIV infection
Oct. 26, 2001
Hepsera
303
231
187
Hepatitis B
Sept. 20, 2002
AmBisome
263
223
221
Fungal infections
Aug. 11, 1997
Eisai
Elan
Endo Pharmaceuticals
Holdings
Forest Laboratories
Note: Figures = (U.S.

joint-promotion profit)
Genentech
Genzyme
Gilead Sciences
34

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
GlaxoSmithKline
Advair/Seretide
6,998
6,626
6,006
Asthma
Aug. 24, 2000/Sept. 7, 1998
Lamictal
2,194
1,992
1,698
Seizures
Dec. 27, 1994
Valtrex
1,868
1,690
1,390
Herpes
June 23, 1995
Avandia
1,754
2,798
2,308
Type 2 diabetes
May 25, 1999
Imitrex/Imigran
1,370
1,422
1,394
Migraine
Dec. 28, 1992/1990
Flovent/Flixotide
1,242
1,318
1,276
Asthma
March 27, 1996/

March 13, 1995
Coreg
1,174
1,558
1,146
Hypertension
Sept. 14, 1995
Paxil/Seroxat
1,106
1,240
1,230
Depression
Dec. 29, 1992/

October 1998
1,086
1,022
862

pertussis
January 1996 and

Dec. 13, 2002
Augmentin
1,060
1,140
1,332
Aug. 6, 1984
Hepatitis vaccines
(primarily Engerix-B,
Havrix, Twinrix)
1,058
958
888
Hepatitis
Aug. 28, 1989,

Feb. 22, 1995,
September 1996
Combivir
910
1,056
1,166
HIV infection
Sept. 26, 1997
Wellbutrin XL
908
1,596
1,294
Depression
Aug. 28, 2003
Requip
692
536
312
Parkinsons disease
Sept. 19, 1997
Epzicom/Kivexa
648
482
236
HIV infection
Aug. 2, 2004/
December 2004
Influenza vaccines
(primarily Fluarix and
FluLaval/Fluviral)
640
340
NA
Influenza
Aug. 31, 2005, and

Oct. 5, 2006/Sept. 10, 2004
Avandamet
584
408
350
Type 2 diabetes
Oct. 10, 2002
Avodart
570
432
258
Benign prostatic hyperplasia
Nov. 20, 2001
Serevent
538
582
660
Asthma
Feb. 4, 1994
Relenza
524
182
NA
Influenza
June 1999
Trizivir
466
536
606
HIV infection
Nov. 14, 2000
Flonase/Flixonase
398
622
1,312
Allergic rhinitis
Oct. 9, 1994/Sept. 15, 1995
Zofran
392
1,694
1,674
Nausea and vomiting
Dec. 31, 1992
Fraxiparine
368
408
422
NA
Zeffix
336
300
264
Hepatitis B
Dec. 8, 1998
Zantac
336
464
488
June 9, 1983
Boniva/Bonviva
322
190
36
Osteoporosis
March 24, 2005/

February 2004
Epivir
312
404
522
HIV infection
Nov. 17, 1995
Agenerase and Lexiva
282
262
224
HIV infection
April 15, 1999, and

Oct. 20, 2003
Hycamtin
238
226
198
Ovarian cancer
May 29, 2000
Ziagen
218
234
272
HIV infection
Dec. 17, 1998
Zovirax
214
240
262
Herpes
March 30, 1986
Arixtra
200
116
48
Dec. 7, 2001
Rotarix
182
88
NA
Rotavirus infection
Feb. 27, 2006
150
204
184
Depression
Dec. 30, 1985, and

Oct. 4, 1996
Boostrix
132
120
NA

pertussis
May 3, 2005
Tykerb
102
Breast cancer
March 13, 2007
Avandaryl
100
78
Type 2 diabetes
Nov. 23, 2005
Vesicare
100
64
26
Overactive bladder
July 9, 2004
Levitra
98
86
80
March 6, 2003
Zyrtec
NA
(GSK is Japan
joint marketer)
NA
(GSK is Japan
joint marketer)
NA
(GSK is Japan
joint marketer)
Allergic rhinitis
NA (Japan)
Integrilin
NA
(EU marketer)
NA
(EU marketer)
NA
(EU marketer)
35

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Guilford Pharmaceuticals
Aggrastat
9
(estimate)
Inspire Pharmaceuticals
Restasis
24
16
Dry eye
Dec. 23, 2002
Ipsen
Decapeptyl
322
304
289
Advanced metastatic
prostate cancer
Dysport
176
155
127
Cervical dystonia
1991 (U.K. launch)
Tanakan
164
178
166

disorders
Somatuline
142
126
112
Acromegaly
Smecta
122
110
93
Diarrhea and pain
Nisis and Nisisco
74
70
57
Arterial hypertension
NA
Forlax
71
63
59
Constipation
Nutropin AQ
32
20
Growth failure
Dec. 29, 1995

(U.S. approval)
Risperdal, Risperdal
Consta, Invega
4,697
4,183
3,552
Schizophrenia
Dec. 29, 1993,

Oct. 29, 2003, Dec. 19, 2006
Remicade
3,327
3,013
2,535
Aug. 24, 1998
Procrit/Eprex
2,885
3,180
3,324
Anemia
Dec. 31, 1990/May 4, 1995
Topamax
2,453
2,027
1,680
Seizures
Dec. 24, 1996
Levaquin and Floxin,

Floxin Otic
1,646
1,530
1,492
Dec. 20, 1996 and

Dec. 28, 1990,
Dec. 16, 1997
AcipHex/Pariet
1,357
1,239
1,169
Aug. 19, 1999/1997
Duragesic/Fentanyl
Transdermal
1,164
1,295
1,585
Pain
Duragesic: Aug. 7, 1990

(U.S. approval)
Concerta
1,028
930
774
disorder
Aug. 1, 2000
Ortho hormonal
contraceptives
925
1,016
1,136
Contraception
NA
Velcade
NA
NA
NA
Multiple myeloma
April 2004 (EU approval)
Ultram ER
NA
NA
NA
Pain
Altace
646
653
554
Cardiovascular events
Jan. 28, 1991
Skelaxin
440
415
345
NA
Thrombin-JMI
267
247
221
Feb. 24, 1995
Avinza
109
Pain
March 20, 2002
Levoxyl
100
112
140
Hypothyroidism
May 25, 2001
Sonata
79
86
83
Insomnia
Aug. 13, 1999
Bicilin
59
43
54
May 19, 1957
Intal
14
15
12
Asthma
May 29, 1986
Espo and NESP
356
344
368
Anemia
Espo: 1990
(Japan launch)
Note: MGI Pharma acquired

Aggrastat U.S. rights from
Guilford in October 2005.
Johnson & Johnson
Note: J&Js Ortho

Biotech is Velcade
non-U.S. marketer.
Note: King acquired

all rights to Avinza
in the United States,
its territories and
Canada from Ligand
Pharmaceuticals
Feb. 26, 2007.
Kirin Brewery
NESP: 2007
(Japan launch)
Gran
130
134
138
Leukopenia
1991 (Japan launch)
Bezatol
94
98
106
Hyperlipidemia
April 1991
Cabaser
59
99
103
Parkinsons disease
September 1999
Urief
41
14
Dysuria
May 2006
36

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Kos Pharmaceuticals
Niaspan
435
Cholesterol
July 28, 1997
Notes: Abbott acquired Kos

Pharmaceuticals (along with
Niaspan and certain rights to
Cardizem and Teveten)
Dec. 13, 2006.
498
(estimate)
Cardizem LA
105
(estimate)
70
Hypertension
Feb. 6, 2003
Teveten franchise
24
(estimate)
22
Hypertension
Dec. 22, 1997

(U.S. approval)
Coniel
254
263
281
Hypertension
NA
Allelock
233
210
199
Allergic rhinitis
Dec. 22, 2000
Durotep
139
141
135
Cancer pain
October 2001
Depakene
105
102
102
Seizures
NA
Farmorubicin and
Adriacin
87
86
95
Cancers
NA
Nauzelin
60
65
66
NA
Avinza
18
137
113
Pain
March 20, 2002
Zyprexa
4,761
4,364
4,202
Schizophrenia
Sept. 27, 1996
Cymbalta
2,103
1,316
680
Depressive disorder
Aug. 3, 2004
Gemzar
1,592
1,408
1,335
Cancer
May 15, 1996
Humalog
1,475
1,300
1,198
Diabetes
April 30, 1996
Cialis
1,144
216
170
Nov. 14, 2002
Evista
1,091
1,045
1,036
Osteoporosis
Dec. 9, 1997
Humulin
985
925
1,005
Diabetes
Oct. 28, 1982
Alimta
854
612
463
Feb. 4, 2004
Forteo
709
594
389
Osteoporosis
Nov. 26, 2002
Strattera
569
579
552
disorder
Nov. 26, 2002
Humatrope
441
416
414
Growth failure
March 9, 1991
Actos
371
449
493
Type 2 diabetes
July 15, 1999
Byetta
331
219
40
Type 2 diabetes
April 28, 2005
Cialis
755
577
Nov. 14, 2002
Cipralex
752
645
482
2002
Ebixa
304
250
203
Alzheimers disease
May 23, 2002
Azilect
31
13
Parkinsons disease
March 2005
(Israel launch)
Medicines Co., The
Angiomax
255
201
150
interventions
January 2001
(U.S. launch)
Medicure
Aggrastat
NA
NA
2006 product figures =

full-year estimates based on
Kos nine-month 2006 actual
sales.
Kyowa Hakko Kogyo
Ligand Pharmaceuticals
Note: King
Pharmaceuicals
acquired all rights to
Avinza in the United
States, its territories and
Canada from Ligand
Feb. 26, 2007.
Lilly, Eli
Lilly Icos
Note: Eli Lilly acquired all
outstanding common stock
of Icos, the companys
partner in the Lilly Icos joint
venture for the manufacture
and sales of Cialis, as of Jan.
29, 2007.
Lundbeck, H.
Note: Medicure
acquired Aggrastat U.S.
rights from MGI Pharma
Aug. 8, 2006.
37

2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Synagis
543
(estimate)
1,065
1,063
June 19, 1998

(U.S. approval)
Ethyol
52
(estimate)
87
95
Dec. 8, 1995
Menarini
Migard
22
17
NA
Migraine
January 2002
(EU approval)
Merck & Co.
Singulair
4,266
3,579
2,976
Asthma
Feb. 20, 1998
Cozaar and Hyzaar
3,350
3,163
3,037
Hypertension
April 14, 1995, and

April 28, 1995
Fosamax
3,049
3,134
3,191
Osteoporosis
Sept. 29, 1995
Gardasil
1,481
235
Cervical cancer
June 8, 2006
Zocor
877
2,803
4,382
Cholesterol
Dec. 23, 1991
Varivax
855
328
NA
Chickenpox
March 17, 1995
Trusopt and Cosopt
787
697
617
Dec. 9, 1994, and

April 7, 1998
Primaxin
764
705
740
Nov. 26, 1985
Januvia
668
43
Type 2 diabetes
Oct. 16, 2006
Cancidas
537
530
570
Fungal infections
Jan. 26, 2001
RotaTeq
525
163
Feb. 3, 2006
Vasotec and Vaseretic
495
547
623
Hypertension
Dec. 24, 1985, and

Dec. 24, 1985
Maxalt
467
406
348
Migraine
June 30, 2002
Proscar
411
619
741
June 19, 1992
Propecia
405
352
292
Hair loss
Dec. 19, 1997
Arcoxia
329
265
218
Osteoarthritis and
April 15, 2002
310
327
348
HIV infection
March 13, 1996, and 1999
Vaqta, Recombivax HB,

Comvax
280
249
195
Hepatitis
Vaqta: May 1996

(U.S. launch)
Recombivax HB: Aug. 27,
(U.S. launch)
ProQuad
264
235
NA
Sept. 6, 2005
Zostavax
236
39
Shingles
May 25, 2006
M-M-R II
228
NA
NA
Measles, mumps, and

rubella
NA
Emend
204
131
87
Nausea and vomiting
March 26, 2003
Invanz
190
139
94
Nov. 9, 2001
Timoptic and Timoptic-XE
120
127
138
Aug. 17, 1978, and

Nov. 4, 1993
(U.S. approvals)
Aggrastat
87
86
88
Janumet
86
Type 2 diabetes
March 30, 2007

(U.S. approval)
Merck KGaA
Rebif
1,670
Multiple sclerosis
February 1998
Note: Merck KGaA acquired

Serono along with Rebif,
Gonal-f, Saizen, Serostim, and
certain rights to Raptiva in
January 2007.
Erbitux
644
462
299
Colorectal cancer
Feb. 12, 2004
Gonal-f
595
Infertility
Oct. 20, 1995
Concor (bisoprolol)
520
497
478
Hypertension
July 31, 1992
Glucophage/metformin
products
365
398
407
Type 2 diabetes
Dec. 29, 1994
Saizen
224
Growth failure
Oct. 8, 1996
Company
Medicine
MedImmune
Notes: MedImmune along
with Synagis and Ethyol were
acquired by AstraZeneca in
June 2007.
2007 product figures =
first-half 2007 estimates.
38

2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
218
(estimate)
369
344
Bronchospasm
March 21, 2001
Euthyrox products
186
176
156
Hypothyroidism
NA
Raptiva
106
Psoriasis
Oct. 27, 2003
Serostim
75
AIDS wasting
Aug. 23, 1996
Campral
49
49
47
Alcoholism
U.S. approval:
July 29, 2004
U.S. launch: January 2005
Aloxi
216
(estimate)
251
249
Nausea and vomiting
July 25, 2003
Dacogen
117
(estimate)
36
May 26, 2006 (U.S. launch)
Aggrastat
May 15, 2002
265
221
192
Multiple myeloma
May 13, 2003

(U.S. approval)
NA
NA
124
May 19, 2002
Company
Medicine
Merck KGaA
(continued)
DuoNeb
Note: Merck KGaA acquired

Serono along with Rebif,
Gonal-f, Saizen, Serostim, and
certain rights to Raptiva in
January 2007.
MGI Pharma
Note: Merck KGaAs Dey

LP along with DuoNeb
were acquired Oct. 2,
2007, by Mylan; DuoNeb
product exclusivity was
lost in July 2007.
Notes: Medicure
acquired Aggrastat
U.S. rights from MGI
Aug. 8, 2006.
MGI acquired Aggrastat
U.S. rights from Guilford
Pharmaceuticals in
October 2005.
Millennium
Pharmaceuticals
Velcade
Note: 2007-2005 = net
product sales only;
excludes strategic
alliance revenue and
royalties associated
with non-U.S. marketer
Ortho Biotech.
Integrilin
Note: Millennium
reported royalty and
strategic alliance
revenue for 2007 and
2006; 2005 sales =
co-promotion revenue.
MediGene
Eligard
30
42
27
Prostate cancer
May 2004
(Germany launch)
Merck/Schering-Plough
Pharmaceuticals
Vytorin
2,779
1,955
1,028
Cholesterol
July 23, 2004
Zetia
2,407
1,929
1,397
Cholesterol
Oct. 25, 2002
Mitsubishi Pharma
Radicut
286
325
Cerebral infarction
June 2001
(Japan launch)
Anplag
167
177
Urso
159
176
Hepatic, biliary, and

digestive function
improvement
July 1962 (Japan)
Venoglobulin-IH
132
141
January 1992
Depas
113
126
Anxiety
March 1984 (launch)
Liple
102
113
November 1988 (launch)
Theo-Dur
77
127
Asthma
April 1984 (launch)
Omeprazon
59
70
Ulcers
April 1991 (launch)
Neuart
59
62
coagulation
June 1987 (launch)
Novastan
54
38
Peripheral arterial occlusive

disease
NA
Note: All Mitsubishi Pharma

2007 sales entries = 0 as
Mitsubishi Pharma and
Tanabe Seiyaku merged
Oct. 1, 2007, to form Mitsubishi
Tanabe Pharma; 2007 sales
for these products are listed
with Mitsubishi Tanabe
Pharma
39

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Mitsubishi Tanabe Pharma
Remicade
286
Aug. 24, 1998
Note: All Mitsubishi Tanabe

Pharma 2006 and 2005
sales entries = 0 as Mitsubishi
Pharma and Tanabe Seiyaku
merged Oct. 1, 2007, to form
Mitsubishi Tanabe Pharma;
2006 and 2005 sales for
these products are listed with
Mitsubishi Pharma or Tanabe
Seiyaku.
Radicut
279
Cerebral infarction
June 2001
(Japan launch)
Anplag
183
Herbesser
176
Hypertension
February 1974
Urso
171
Hepatic, biliary, and

digestive function
improvement
July 1962 (Japan)
Ceredist
152
Spinal cerebellar
degeneration
September 2000
(Japan launch)
Tanatril
144
Hypertension
December 1993
Venoglobulin-IH
129
January 1992
Depas
116
Anxiety
March 1984 (launch)
Liple
104
Maintate
103
Hypertension
Sermion
95
June 1988
(Japan launch)
Talion
88
Allergic rhinitis
Mearubik
76
Measels and Rubella

immunization
December 2005 (launch)
Omeprazon
62
Ulcers
April 1991 (launch)
Novastan
62

disease
NA
Theo-Dur
60
Asthma
April 1984 (launch)
Gastrom
58
Ulcers
Neuart
58
coagulation
June 1987 (launch)
DuoNeb
42
(estimate)
Bronchospasm
March 21, 2001
Diovan and Diovan HCT/

CoDiovan
5,012
4,223
3,676
Hypertension
Dec. 23, 1996 and

March 6, 1998/Oct. 6, 1997
Gleevec/Glivec
3,050
2,554
2,170
Leukemia
May 10, 2001/

June 26, 2001
Zometa
1,297
1,283
1,224
Hypercalcemia
Aug. 21, 2000
Sandostatin
1,027
915
896
Acromegaly
Oct. 21, 1988
Neoral and Sandimmun
944
918
953
July 14, 1995, and

Nov. 14, 1983
Femara
937
719
536
Breast cancer
July 25, 1997
Lotrel
748
1,352
1,075
Hypertension
June 16, 1999
Voltaren group
747
690
689
Pain
July 28, 1998
Trileptal
692
721
615
Seizures
November 1999
Lescol group
665
725
767
Cholesterol
Dec. 31, 1993
Exelon
632
525
467
Alzheimers disease
May 12, 1998
Lamisil group
595
978
1,133
Fungal infections
Dec. 30, 1992
Comtan and Stalevo

group
420
330
278
Parkinsons disease
Oct. 19, 1999, and

June 11, 2003
Tegretol
413
391
393
Seizures
March 12, 1972
Lucentis
393
19

degeneration
June 30, 2006
Ritalin and Focalin
375
330
208
disorder
Dec. 5, 1955, and

Nov. 13, 2001
Foradil
362
331
332
Asthma
Nov. 17, 1999
Exjade
357
143
Iron overload
Nov. 2, 2005
(U.S. approval)
Miacalcin/Miacalcic
281
339
365
Osteoporosis
July 3,1986/NA
Mylan

2007, by Mylan.
Novartis
Note: Chiron along with
Tobi and certain rights to
Betaseron/Betaferon were
acquired by Novartis in April
2006.
40

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Novartis
(continued)
Tobi/Tobramycin
273
177
Dec. 22, 1997

(U.S. approval)
Visudyne
215
354
484
Age-related macular
degeneration
April 12, 2000
Enablex/Emselex
179
114
46
Overactive bladder

(U.S. appoval)
(EU approval)
Elidel
176
179
268
Atopic dermatitis
Dec. 13, 2001
Xolair
140
102
Asthma
June 20, 2003
Exforge
103
10
Hypertension
Jan. 18, 2007

(EU approval date)
Prexige
91
47
Osteoarthritic pain

New Zealand,
U.K. launches)
Zelnorm/Zelmac
88
561
417
March 19, 2002/

Oct. 30, 2001
Betaseron
NA
NA
Multiple sclerosis
July 23, 1993
NovoSeven
1,078
1,036
931
Bleeding due to hemophilia
Feb. 23, 1996
Norditropin
645
608
511
Growth hormone deficiency
1997
Prandin and NovoNorm
395
365
306
Type 2 diabetes

(U.S. approval)
NovoNorm: Aug. 17, 1998
(EU approval)
Pantoprazole
(including Pantozol)
2,310
Pantozol: 1994
Actovegin
126
108
88
NA
Calcichew
88
84
64
Osteoporosis
NA
TachoSil
88
77
59
Tissue management
NA
Opalmon
373
338
326
1988
Onon
271
268
265
Bronchial asthma and

allergic rhinitis
Oct. 1, 1999
Kinedak
174
173
212
NA
Note: Chiron along with

Tobi and certain rights to
Betaseron/Betaferon were
acquired by Novartis in April
2006.
Novo Nordisk
Nycomed
Note: Nycomed acquired
Altana Pharma and
Pantoprazole products
Dec. 29, 2006.
Ono Pharmaceutical
Onon Dry Syrup
110
114
94
Pediatric bronchial asthma
Oct. 1, 1999
Onyx Pharmaceuticals
Nexavar
NA
NA
NA

and liver cancer
Orion
Comtan/Comtress and
Stalevo
275
255
199
Parkinsons disease
Stalevo: 174
Comtan/
Comtess: 101)
Stalevo: 153
Comtan/
Comtess: 102
Stalevo: 102
Comtan/
Comtess: 97
Oct. 19, 1999/

Sept. 16, 1998 and
June 11, 2003
Oscient Pharmaceuticals
Antara
59
17
Hypercholesterolemia and
hypertriglyceridemia
Nov. 30, 2004

(U.S. approval)
OSI Pharmaceuticals
Tarceva
169
155
85
Nov. 18, 2004
Otsuka Pharmaceutical
Abilify
830
(estimate)
641
(estimate)
456
(estimate)
Schizophrenia
Nov. 15, 2002
Pletal
403
360
NA
Cardiac ischemic
complications
1988 (Japan launch)
Mucosta
353
339
NA
Gastritis and ulcers
1990 (Japan launch)
Meptin
87
37
NA
Bronchial muscle relaxation
1980 (Japan launch)
Lipitor
12,675
12,886
12,187
Cholesterol
Dec. 17, 1996
Norvasc
3,001
4,866
4,706
Hypertension
July 31, 1992
Celebrex
2,290
2,039
1,730
Osteoarthritis and
Dec. 31, 1998
Lyrica
1,829
1,156
291
Neuropathic pain
July 6, 2004
Viagra
1,764
1,657
1,645
March 27, 1998
Xalatan and Xalacom
1,604
1,453
1,372
June 5, 1996, and

second-quarter 2001
Pfizer
41

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Pfizer
(continued)
Zyrtec and Zyrtec-D
1,541
1,569
1,362
Allergic rhinitis
Dec. 8, 1995 and

Aug. 10, 2001
1,190
1,100
988
Overactive bladder
March 25, 1998, and

Dec. 22, 2000
Camptosar
969
903
910
Colorectal cancer
June 14, 1996
Zyvox
944
782
618
April 18, 2000
Chantix/Champix
883
101
Smoking cessation
May 10, 2006/

Sept. 29, 2006
Geodon/Zeldox
854
758
589
Schizophrenia
Feb. 5, 2001/May 2002
Genotropin
843
795
808
Growth failure
Aug. 24, 1995
Vfend
632
515
397
Fungal infections
March 21, 2002
Sutent
581
219
Cancer
Jan. 26, 2006
Caduet
568
370
185
Cholesterol and
hypertension
Jan. 30, 2004
Zoloft
531
2,110
3,256
Depression
Dec. 30, 1991
Cardura
506
538
586
Hypertension
Nov. 2, 1990
Zithromax and Zmax
438
638
2,025
Nov. 4, 1991, and

June 10, 2005
Neurontin
431
496
639
Seizures
Dec. 29, 1993
Diflucan
415
435
498
Fungal infections
Jan. 29, 1990
Aricept
401
358
346
Alzheimers disease
Nov. 25, 1996
Aromasin
401
320
247
Breast cancer
Oct. 21, 1999
Xanax and Xanax XR
325
316
409
Anxiety disorder and

panic disorder
Nov. 27, 1985, and

Jan. 17, 2003
Relpax
315
286
233
Migraine
June 14, 2001
Actonel
1,229
(estimate)
1,106
(estimate)
1,043
(estimate)
Osteoporosis
March 27, 1998
Procter & Gamble
Note: 2007 figure =

estimate based on
actual global sales
figure provided
Purdue Pharma
OxyContin
NA
NA
NA
Cancer pain
Dec. 12, 1995

(U.S. approval)
QLT
Eligard
28
22
17
Prostate cancer
May 2004
(Germany launch)
Recordati
Zanidip/Lercadip/
lercanidipine
256
235
194
Hypertension
NA
Roche
Rituxan/MabThera
4,597
4,033
3,462
Nov. 26, 1997/June 2, 1998
Herceptin
4,044
3,273
1,788
Breast cancer
Sept. 25, 1998
Avastin
3,422
2,469
1,388
Colorectal cancer
Feb. 26, 2004

(U.S. approval)
NeoRecormon/Epogin
1,745
1,856
1,877
Anemia
July 16, 1997/April 1990
Tamiflu
1,738
2,189
1,298
Influenza
Oct. 27, 1999
CellCept
1,677
1,535
1,421
May 3, 1995
Pegasys
1,364
1,223
1,169
Hepatitis C
June 21, 2002
Xeloda
959
809
663
Cancer
1998
Tarceva
885
678
323
Nov. 18, 2004
Lucentis
826
398

degeneration
June 30, 2006
Boniva/Bonviva
739
407
72
Osteoporosis
March 24, 2005/

February 2004
Xenical
527
578
529
Obesity
July 29, 1998
Xolair
473
448
340
Asthma
June 20, 2003
Valcyte and Cymevene
452
407
328
Pulmozyme
403
363
328
Cystic fibrosis
Dec. 30, 1993
Nutropin
392
412
397
Growth failure
Nov. 17, 1993

(U.S. approval)
Kytril
354
415
417
Nausea and vomiting
January 1992
42

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Roche
(continued)
Neutrogin
338
316
303
Neutropenia
Oct. 4, 1991
Rocephin
333
347
773
Dec. 21, 1984
Activase, TNKase,
Cathflo Activase
318
302
258
Feb. 17, 1996, June 2, 2000,

Sept. 4, 2001
Fuzeon
267
249
208
HIV infection
March 27, 2003

(U.S. launch)
Raptiva
107
(via Genentech)
90
(via Genentech)
79
(via Genentech)
Psoriasis
November 2003
(U.S. launch)
49
(via Chugai)
44
(via Chugai)
39
(via Chugai)
Hyperphosphatemia
Oct. 30, 1998
9
(via Chugai)
3
(via Chugai)
Breast cancer
July 25, 1997
Colazal
92
103
110
Ulcerative colitis
July 18, 2000
Xifaxan
64
52
30
Travelers diarrhea
May 25, 2004
Lovenox/Clexane
3,581
3,339
2,938
March 29, 1993/

September 1997
Plavix/Iscover
3,324
3,056
2,778
Thrombotic events
Nov. 17, 1997/1998
Lantus
2,785
2,284
1,665
Type 2 diabetes and

type 1 diabetes
April 20, 2000
Taxotere
2,569
2,402
2,206
Cancer
Oct. 27, 1995
Eloxatin/Eloxatine
2,085
2,321
2,144
Colorectal cancer
Aug. 9, 2002/
September 1996
Ambien/Stilnox
1,714
2,778
2,083
Insomnia
Dec. 16, 1992/June 9, 1987
Copaxone
1,614
1,466
1,237
Multiple sclerosis
Dec. 20, 1996
Avapro/Aprovel
1,481
1,392
1,223
Hypertension
Sept. 30, 1997/

Aug. 27, 1997
Delix and Tritace
1,016
1,340
1,383
Hypertension
July 7, 2000, and

July 6, 2000
Allegra/Telfast
968
943
1,844
Allergic rhinitis
July 25, 1996/Dec. 3, 1996
Amaryl
537
618
928
Type 2 diabetes
Nov. 30, 1995
Xatral
457
484
450
January 2000
Actonel
439
481
499
Osteoporosis
March 27, 1998
Depakine
433
413
436
Epilepsy
NA
Nasacort
403
388
381
Allergic rhinitis
May 21, 2000
Hyalein
195
179
169
Corneal disease
June 1995
(Japan launch)
Cravit
129
132
132
1993 (Japan launch)
Timoptol and Timoptol XE
70
71
73
Glaucoma
September 1981 and

November 1999
(Japan launches)
Betaseron/Betaferon
NA
1,072
Multiple sclerosis
July 23, 1993/Nov. 30, 1995
Note: These sales were

reported by Genentech
and not Roche, which
records Genentech U.S.
sales in its results.
Renagel
reported by Chugai
records Chugai Japan
Femara
reported by Chugai
records Chugai Japan
Sanofi-Aventis
Santen Pharmaceutical
Schering AG
Note: All Schering 2007 and
2006 sales = 0 or NA as Bayer
acquired Schering June 23,
2006; 2007 and 2006 sales
for these products are listed
with Bayer.
43

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Schering AG
(continued)
NA
803
Yasmin: March 2000

Yaz: March 2006
(U.S. approval)
Magnevist
NA
450
Magnetic resonance
imaging
June 2, 1988
Ultravist
NA
340
Imaging/various
May 11, 1999
Mirena
NA
333
Contraception
Dec. 6, 2000
Iopamiron
NA
332
NA
Diane
NA
236
Contraception
NA
Schering-Plough
Remicade
1,648
1,240
942
Aug. 24, 1998
Note: Follistim/Puregon,
NuvaRing, Livial, and
Remeron 2007 sales are
from Nov. 19 thru Dec.
31; Schering-Plough
Organon BioSciences and
aforementioned products
Nov. 19, 2007.
Nasonex
1,092
944
737
Allergic rhinitis
Oct. 1, 1997
PegIntron
911
837
751
Hepatitis C
May 25, 2000
Temodar
861
703
588
Brain tumors
Aug. 11, 1999
Clarinex/Aerius
799
722
646
Allergic rhinitis
Dec. 21, 2001/Jan. 15,

2001
Claritin
391
356
371
Allergic rhinitis
April 12, 1993
Avelox/Avalox
384
304
228
Dec. 10, 1999/June 21,

1999
Integrilin
332
329
315
May 19, 2002
Rebetol
277
311
331
Hepatitis C
June 4, 2002
Caelyx
257
206
181
Cancers
June 21, 1996
Intron A
233
237
287
Hepatitis
June 5, 1990
Subutex/Subuxone
220
203
197
Opiate addiction
Oct. 8, 2002
(U.S. approvals)
Noxafil
89
19
NA
Fungal infections
Sept. 15, 2006

(U.S. approval)
Follistim/Puregon
57
Infertility
Sept. 29, 1997/May 3, 1996
NuvaRing
45
Contraception
June 12, 2001
Remeron
33
Depression
June 15, 2000
Livial
24
Menopausal symptoms
March 1997
Cipro/Ciprobay
NA
111
146
Oct. 22, 1987/1987
Atmadisc
65
61
Asthma
Aug. 24, 2000
Lunesta
601
565
327
Insomnia
Dec. 15, 2004
Xopenex Inhalation
Solution
487
543
411
Bronchospasm
March 25, 1999
Serono
Rebif
1,452
1,270
Multiple sclerosis
February 1998
Note: All Serono 2007 sales

entries = 0 as Serono was
acquired by Merck KgaA in
January 2007; 2007 sales for
Merck KGaA.
Gonal-f
533
547
Infertility
Oct. 20, 1995
Saizen
209
206
Growth failure
Oct. 8, 1996
Serostim
72
70
AIDS wasting
Aug. 23, 1996
Raptiva
70
33
Psoriasis
November 2003
(U.S. launch)
Shionogi
Flumarin
122
133
156
NA
Imunace
117
117
111
Cancers
NA
Vancomycin
106
129
161
NA
Crestor
104
25
Cholesterol
Nov. 7, 2002
Rinderon
100
101
102
NA
Claritin
90
72
80
Allergic rhinitis
April 12, 1993
OxyContin
66
52
43
Cancer pain
July 7, 2003
(Japan launch)
Note: All Schering 2007 and

2006 sales = 0 or NA as Bayer
acquired Schering June 23,
2006; 2007 and 2006 sales for
Bayer.
Schwarz Pharma
Note: Schwarz Pharma

along with Atmadisc
were acquired by UCB
in December 2006.
Sepracor
44

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Shionogi
(continued)
Avelox/Avalox
19
24
18
Dec. 10, 1999/

June 21, 1999
Group
Adderall XR
1,031
864
731
disorder
Oct. 11, 2001
Elaprase
182
24
Hunter syndrome
July 24, 2006

(U.S. approval)
Pentasa
176
138
136
Ulcerative colitis
May 11, 1997
Replagal
144
118
41
Fabrys disease
Aug. 3, 2001
Fosrenol
102
45
54
Oct. 26, 2004
Vyvanse
77
Attention deficit hyperactivity

disorder
July 27, 2007 (U.S. launch)
Carbatrol
72
68
72
Seizures
Sept. 30, 1997
Xagrid
69
53
47
Thrombocythemia
November 2004
(EU approval)
Daytrana
64
25
Attention deficit hyperactivity

disorder
June 29, 2006

(U.S. launch)
Calcichew
54
46
39
Osteoporosis
NA
TriCor/Lipanthyl
594
566
254
Cholesterol
Feb. 9, 1998/June 1999
Androgel
422
377
328
Hypogonadism
June 14, 2000

(U.S. approval)
Creon
271
262
222
Pancreatic exocrine
insufficiency
NA
Serc
206
200
167
Menieres Syndrome
NA
Influvac
174
162
137
Influenza
2003 (launch)
Teveten franchise
145
130
125
Hypertension
Dec. 22, 1997

(U.S. approval)
Marinol
144
145
115
Nausea and vomiting
1987 (U.S. launch)
Pantoloc
96
228
1997
Constipation
April 25, 2006 (U.S. launch)
Clarith
255
273
275
NA
Palux
114
112
120
Ulcers
1999
Pentcillin
62
61
66
NA
Actos
3,962
3,363
2,438
Type 2 diabetes
July 15, 1999
Blopress (candesartan)
2,231
2,062
1,909
Hypertension
Oct. 6, 1997
Lansoprazole
(including Takepron)
1,487
(including 648 for
Takepron)
1,507
(including 579 for
Takepron)
1,599
(including 550 for
Takepron)
Takepron: 1991
Leuprorelin
(including Leuplin)
1,240 (including
664 for Leuplin)
1,275 (including
643 for Leuplin)
1,224 (including
632 for Leuplin)
Prostate cancer
Jan. 26, 1989/July 5, 2002
Basen
528
557
636
Hyperglycemia
1994
Amitiza
196
57
Constipation
Enbrel
188
114
50
Nov. 2, 1998
Benet
165
162
157
Osteoporosis
May 2002
(Japan launch)
Rozerem
126
103
30
Insomnia
Sept. 26, 2005 (U.S. launch)
Isovorin
125
140
128
Tumors
October 1999
(Japan launch)
Seltouch
123
127
137
Pain
September 1993
(Japan launch)
Glovenin
88
86
85
Blood disorders
November 1991
(Japan launch)
Pansporin
84
109
127
February 1981
(Japan launch)
Solvay
Note: Solvay lost

Pantoloc marketing
rights in Canada during
2006.
Sucampo Pharmaceuticals
Amitiza
Note: Figures =
co-promotion revenue
Taisho Pharmaceutical
Takeda Pharmaceutical
45

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
(continued)
Dasen
77
81
85
Inflammation
November 1968
(Japan launch)
Rheumatrex
77
69
67
August 1999
(Japan launch)
Firstcin
64
69
75
August 1995
(Japan launch)
Remicade
205
128
May 2002
(Japan launch)
Herbesser
180
188
Hypertension
February 1974
Ceredist
145
137
Spinal cerebellar
degeneration
September 2000
(Japan launch)
Tanatril
145
147
Hypertension
December 1993
Sermion
102
114
June 1988
(Japan launch)
Maintate
99
102
Hypertension
Talion
70
64
Allergic rhinitis
Gastrom
61
64
Ulcers
Mearubik
59
Measels and Rubella

immunization
Tap Pharmaceutical
Products
Prevacid
2,275
2,600
2,501
May 10, 1995
Lupron
645
662
699
Prostate cancer
Jan. 26, 1989
Teijin
Bonalon
182
138
119
Osteoporosis
August 2001
(Japan launch)
Onealfa
125
118
120
Osteoporosis
NA
Mucosolvan
111
115
117
Expectorant
NA
Venilon
89
94
93
Severe infectious diseases
February 1980
(Japan launch)
Copaxone
1,713
1,414
1,176
Multiple sclerosis
Dec. 20, 1996
Azilect
120
44
NA
Parkinsons disease
June 27, 2005
Keppra
1,407
1,043
768
Seizures
Nov. 30, 1999
Zyrtec/Cirrus and Zyrtec-D
668
769
771
Allergic rhinitis
Dec. 8, 1995/NA and

Aug. 10, 2001
Xyzal
230
196
173
Allergic rhinitis
Aug. 28, 2001
Tussionex
156
144
148
Cough
Dec. 31, 1987
Nootropil
138
136
141
Cognitive disorders
NA
Metadate CD/Equasym
XL
108
93
70
disorder
April 3, 2001/February
2005
Atarax
75
74
67
Anxiety
NA
Neupro
71
14
Parkinsons disease
Feb. 20, 2006

(Europe approval)
Atmadisc
66
NA
Asthma
Aug. 24, 2000
Tanabe Seiyaku
Note: All Tanabe Seiyaku 2007
sales entries = 0 as Mitsubishi
Pharma and Tanabe Seiyaku
merged Oct. 1, 2007, to form
Mitsubishi Tanabe Pharma;
2007 sales for these products
are listed with Mitsubishi
Tanabe Pharma.
Teva Pharmaceutical
Industries
UCB
Note: UCB acquired

Schwarz Pharma along
with Atmadisc in
December 2006.
United Therapeutics
Remodulin
201
153
110
Pulmonary arterial
hypertension
Valeant Pharmaceuticals
Efudex/Efudix
72
78
60
Multiple actinic keratoses

and superficial basal cell
carcinoma

(U.S. approval)
ViroPharma
Vancocin
204
167
126
April 15, 1986

(U.S. approval)
Warner Chilcott
Loestrin 24 FE
149
44
Feb. 17, 2006

(U.S. approval)
Taclonex
127
60
Psoriasis vulgaris
Doryx
116
102
96
July 22, 1985

(U.S. approval)
Estrace Cream
73
66
54
Menopausal symptoms
Jan. 31, 1984

(U.S. approval)
46

Company
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Primary disease/
medical use
First approval date

(or launch date)
Warner Chilcott
(continued)
Femhrt
64
59
61
Menopausal symptoms
Oct. 15, 1999

(U.S. approval)
Wyeth
Effexor line
3,794
3,722
3,459
Depression
Dec. 28, 1993
Prevnar
2,439
1,961
1,508
Feb. 17, 2000
Enbrel
2,045
1,500
1,084
Nov. 2, 1998
Protonix
1,911
1,795
1,685
Feb. 2, 2000
Zosyn/Tazocin
1,137
972
892
Oct. 22, 1993/

Dec. 18, 1995
Premarin, Prempro,
Premphase
1,055
1,051
909
Menopausal symptoms
1942, Nov. 17, 1995,

Nov. 17, 1995
BeneFix
433
358
343
Hemophilia
Feb. 11, 1997
Rapamune
365
337
300
Sept. 15, 1999
rhBMP-2
359
308
236
Tibia fractures
Sept. 17, 2002
ReFacto
335
306
268
Hemophilia
April 14, 2003
Tygacil
138
72
10
June 15, 2005
Zoton
93
131
376
1994
Rituxan
NA
NA
NA
Nov. 26, 1997
Zenyaku Kogyo
NOTES/LEGEND:
*This list presents the 500 medicines from the sales-order chart as reported by each company. Certain products are represented by more than one company due to joint-marketing
or joint-promotion accords. Some companies that have been acquired or merged in recent years are listed in this chart under their former name if their drug made the top 500 list for
2007. Former joint-marketing or joint-promotion companies from 2006 and 2005 (but not a 2007 marketer) are additionally included to show previous-year sales comparisons.
*Estimate = sales were not provided by company or found by Med Ad News editors, who made an estimate based on previous-year figures and/or other information provided.
This report does exclude certain products that probably would have been ranked in the top 500 list for 2007, but were omitted since no 2007 information could be found to make an
estimate. In most of these instances, there are products with declining annual sales figures due to patent expirations.
*All Japanese-company 2007 product sales are for the fiscal year ended March 31, 2008 (2006 = year ended March 31, 2007; 2005 = year ended March 31, 2006), except for Chugai
Pharmaceutical and Kirin Brewery, which report annual sales on a Dec. 31 calendar-year basis.
47
TOP 500
PRESCRIPTION
MEDICINES
BY
PRIMARY
DISEASE/
MEDICAL USE
TOP 500 PRESCRIPTION MEDICINES BY PRIMARY DISEASE/MEDICAL USE

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
First approval date

(or launch date)
Tazorac, Zorac, Avage
80
91
87
Allergan
June 13, 1997,

Dec. 12, 1996,
Sept. 30, 2002
Acromegaly
Sandostatin
1,027
915
896
Novartis
Oct. 21, 1988
Somatuline
142
126
112
Ipsen
Actinic keratoses
Efudex/Efudix
72
78
60
Valeant Pharmaceuticals

(U.S. approval)
Integrilin
332
329
439
Notes:
Schering-Plough is the
marketer in U.S. and
other non-EU areas.
Schering-Plough
332
Schering-Plough
329
Schering-Plough
315
Schering-Plough,
Millennium Pharmaceuticals,
GlaxoSmithKline
Millennium NA
Millennium NA
Millennium 124
Millennium reported
co-promotion revenue
from Jan. 1, 2005,
through Sept. 1, 2005;
therafter royalty and
strategic alliance
revenue were recorded
by the company .
GlaxoSmithKline
NA
GlaxoSmithKline
NA
GlaxoSmithKline
NA
Aggrastat
87+
90+
Merck 87
Merck 86
Merck & Co. and

Medicure
Notes: Medicure
acquired Aggrastat U.S.
rights from MGI
Aug. 8, 2006.
99
(estimate)
Medicure NA
MGI Pharma 4
Roche,
Genentech,
Novartis
June 30, 2006
GlaxoSmithKline is the
EU marketer.
Medicure NA
MGI acquired Aggrastat

U.S. rights from Guilford
Pharmaceuticals in
October 2005.
Age-related macular
degeneration
AIDS wasting
Allergies
Guilford 9
(estimate)
MGI Pharma 2
Medicure 0
Lucentis
1,219
417
Note: Genentech
are recorded by parent
company Roche.
Roche 826
(includes
Genentech 815)
Roche 398
(includes
Genentech 380)
Novartis 393
Novartis 19
Visudyne
215
354
484
Novartis
April 12, 2000
Serostim
75
72
(Serono)
70
(Serono)
Merck KGaA
Aug. 23, 1996
80
79
70
Merck KGaA 49
Merck KGaA 49
Merck KGaA 47
Merck KGaA and

Forest Laboratories
U.S. approval:
July 29, 2004
Forest 31
Forest 30
Forest 23
Zyrtec/Cirrus and Zyrtec-D
2,317
2,458
2,259
Note: GlaxoSmithKline
jointly markets Zyrtec in
Japan.
Pfizer 1,541
(Zyrtec and
Zyrtec-D)
Pfizer 1,569
(Zyrtec and
Zyrtec-D)
Pfizer 1,362
(Zyrtec and
Zyrtec-D)
UCB 668
(Zyrtec/Cirrus and
Zyrtec-D)
UCB 769
(Zyrtec/Cirrus and
Zyrtec-D)
UCB 771
(Zyrtec/Cirrus and
Zyrtec-D)
Daiichi Sankyo
108 (Zyrtec)
Daiichi Sankyo
120 (Zyrtec)
Daiichi Sankyo
126 (Zyrtec)
GlaxoSmithKline
NA (Zyrtec)
GlaxoSmithKline
NA (Zyrtec)
GlaxoSmithKline
NA (Zyrtec)
Nasonex
1,092
944
Allegra/Telfast
968
943
Clarinex/Aerius
799
722
Note: Merck KGaA

acquired Serono along
with Serostim
Jan. 5, 2007.
Alcoholism
Merck 88
Campral
U.S. launch:
January 2005
Pfizer,
UCB,
Daiichi Sankyo
Dec. 8, 1995/NA and

Aug. 10, 2001
737
Schering-Plough
Oct. 1, 1997
1,844
Sanofi-Aventis
July 25, 1996/Dec. 3, 1996
646
Schering-Plough
Dec. 21, 2001/

Jan. 15, 2001
49

Primary disease/
medical use
Allergies
(continued)
Alzheimers disease
Anemia
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Claritin
481
428
451
Schering-Plough
391
Schering-Plough
356
Schering-Plough
371
2007 company
First approval date

(or launch date)
Schering-Plough and
Shionogi
April 12, 1993
Shionogi 90
Shionogi 72
Shionogi 80
Nasacort
403
388
381
Sanofi-Aventis
May 21, 2000
Flonase/Flixonase
398
622
1,312
GlaxoSmithKline
Oct. 9, 1994/Sept. 15, 1995
Rhinocort
354
360
387
AstraZeneca
Feb. 14, 1994
Allelock
233
210
199
Kyowa Hakko Kogyo
Dec. 22, 2000
Xyzal
230
196
173
UCB
Aug. 28, 2001
Ebastel
111
114
113
Dainippon Sumitomo
NA
Talion
88
70
64
Aricept
3,311
2,887
2,311
Eisai and Pfizer
Nov. 25, 1996
Eisai 2,910
Eisai 2,529
Eisai 1,965
Pfizer 401
Pfizer 358
Pfizer 346
Namenda
830
660
508
Forest Laboratories
Oct. 16, 2003
Exelon
632
525
467
Novartis
May 12, 1998
Ebixa
304
250
203
H. Lundbeck
May 23, 2002
Aranesp
3,614
4,121
3,273
Amgen
June 11, 2001
Procrit/Eprex
2,885
3,180
3,324
Johnson & Johnson
Dec. 31, 1990/May 4, 1995
Epogen
2,489
2,511
2,455
Amgen
June 1, 1989
NeoRecormon/Epogin
1,745
1,856
1,877
July 16, 1997/April 1990

Japan sales that are
recorded by parent
company Roche.
Roche 1,745
(includes
Chugai 468)
Roche 1,856
(includes
Chugai 542)
Roche 1,877
(includes
Chugai 614)
Roche and
Espo and NESP
356
344
368
Kirin Brewery
Espo: 1990
(Japan launch)
NESP: 2007
(Japan launch)
Anesthesia
Ultane/Sevorane
759
799
874
Abbott Laboratories
June 7, 1995/1994
Diprivan
263+
304+
369
Oct. 2, 1989
Note: Abraxis acquired

U.S. rights to Diprivan
from AstraZeneca in
June 2006.
AstraZeneca 263
AstraZeneca 304
AstraZeneca 369
AstraZeneca and
Abraxis
Abraxis NA
Abraxis NA
Angina (chronic)
Ranexa
67
18
CV Therapeutics
March 24, 2006

(U.S. launch)
Angina pectoris
Sigmart
153
154
165
1984
Frandol
120
123
127
Astellas Pharma
NA
Xanax and Xanax XR
325
316
409
Pfizer
Nov. 27, 1985, and

Jan. 17, 2003
Depas
116
113
126
March 1984 (launch)
Atarax
75
74
67
UCB
NA
Arrhythmia
Sunrythm
121
117
119
Daiichi Sankyo
NA
Arterial occlusion (chronic)
Anplag
183
167
177
Liple
104
102
113
Enbrel
5,463
4,493
3,707
Nov. 2, 1998
Amgen 3,230
Amgen 2,879
Amgen 2,573
Amgen,
Wyeth,
Wyeth 2,045
Wyeth 1,500
Wyeth 1,084
Takeda 188
Takeda 114
Takeda 50
Anxiety
Arthritis
50

Primary disease/
medical use
Arthritis
(continued)
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Remicade
5,261
4,458
3,605
Note: Mitsubishi Pharma

and Tanabe Seiyaku
merged Oct. 1, 2007, to
form Mitsubishi Tanabe
Pharma.
J&J 3,327
J&J 3,013
J&J 2,535
Schering-Plough
1,648
Schering-Plough
1,240
Schering-Plough
942
Mitsubishi Tanabe
Pharma 286
Mitsubishi
Pharma 205
Mitsubishi
Pharma 128
Humira
3,064
2,044
Celebrex/Celecox
2,327
2,039
Note: Celecox was

launched in Japan by
Atellas in June 2007.
Pfizer 2,290
Pfizer 2,039
Pfizer 1,730
Mobic
428
901
2,501
Boehringer 326
Boehringer 794
Abbott 1,232
Daiichi 102
Daiichi 107
Boehringer 1,163
Arcoxia
329
265
Synvisc
242
234
Orencia
231
Suvenyl
94
Rheumatrex
2007 company
First approval date

(or launch date)
Johnson & Johnson,

Schering-Plough,
Aug. 24, 1998
1,400
Abbott Laboratories
Dec. 31, 2002
1,730
Pfizer and Astellas Pharma
Celebrex: February 1999

(U.S. launch)
Celecox: June 11, 2007
(Japan launch)
Astellas 37
Boehringer Ingelheim and
Daiichi Sankyo
Feb. 27, 1996
218
Merck & Co.
April 15, 2002
219
Genzyme
Aug. 13, 1997
89
Dec. 23, 2005
78
69
March 2000
77
69
67
August 1999
(Japan launch)
Advair/Seretide
6,998
6,626
6,006
GlaxoSmithKline
Aug. 24, 2000/Sept. 7, 1998
Singulair
4,266
3,579
2,976
Merck & Co.
Feb. 20, 1998
Symbicort
1,575
1,184
1,006
AstraZeneca
August 2000
Pulmicort
1,454
1,292
1,162
AstraZeneca
June 24, 1997
Flovent/Flixotide
1,242
1,318
1,276
GlaxoSmithKline
March 27, 1996/

March 13, 1995
Xolair
613
550
345
June 20, 2003
Note: Genentech
company Roche.
Roche 473
(includes
Genentech 472)
Roche 448
(includes
Genentech 425)
Roche 340
(includes
Genentech 320)
Roche,
Genentech,
Novartis
Novartis 140
Novartis 102
Novartis 5
Serevent
538
582
660
GlaxoSmithKline
Feb. 4, 1994
Foradil
362
331
332
Novartis
Nov. 17, 1999
Onon
271
268
265
Ono Pharmaceutical
Oct. 1, 1999
Onon Dry Syrup
110
114
94
Ono Pharmaceutical
Oct. 1, 1999
Oxis
86
88
91
AstraZeneca
March 4, 2001
Intal
84
94
96
May 29, 1986
Astellas 70
Astellas 79
Astellas 84
Astellas Pharma and

Daiichi106
Asthma
King 14
King 15
King 12
Accolate
76
81
72
AstraZeneca
Sept. 24, 1996
Atmadisc
66
65
(Schwarz)
61
(Schwarz)
UCB
Aug. 24, 2000
Theo-Dur
60
77
127
April 1984 (launch)
Plavix/Iscover
8,079
6,313
6,601
Nov. 17, 1997/1998
Bristol-Myers
Squibb 4,755
Bristol-Myers
Squibb 3,257
Bristol-Myers
Squibb 3,823
Bristol-Myers Squibb and

Sanofi-Aventis
Sanofi-Aventis
3,324
Sanofi-Aventis
3,056
Sanofi-Aventis
2,778
Note: 2006 and 2005

sales reported by
Schwarz Pharma, which
was acquired by UCB in
December 2006.
Atherothrombosis
51

Primary disease/
medical use
Attention-deficit
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Adderall XR
1,031
864
731
Group
Oct. 11, 2001
Concerta
1,028
930
774
Johnson & Johnson
Aug. 1, 2000
Strattera
569
579
552
Eli Lilly
Nov. 26, 2002
Ritalin and Focalin
381
337
212
Novartis and Celgene
Novartis 375
Novartis 330
Novartis 208
Dec. 5, 1955, and

Nov. 13, 2001
Celgene 6
Celgene 7
Celgene 4
Metadate CD/
Equasym XL
108
93
70
UCB
April 3, 2001/
February 2005
Vyvanse
77
Group
July 27, 2007 (U.S. launch)
Daytrana
64
25
Group
June 29, 2006

(U.S. launch)
Levaquin/Cravit
(levofloxacin) and
Floxin, Floxin Otic
2,862
2,703
2,639
Levaquin: Dec. 20, 1996
J&J 1,646
(Levaquin, Floxin,
Floxin Otic)
J&J 1,530
(Levaquin, Floxin,
Floxin Otic)
J&J 1,492
(Levaquin, Floxin,
Floxin Otic)
Johnson & Johnson,

Daiichi Sankyo,
Daiichi 1,087
(Cravit/
levofloxacin)
Daiichi 1,041
(Cravit/
levofloxacin)
Daiichi 1,015
(Cravit/
levofloxacin)
Santen 129
(Cravit)
Santen 132
(Cravit)
Santen 132
(Cravit)
Zosyn/Tazocin
1,137
972
892
Wyeth
Oct. 22, 1993/

Dec. 18, 1995
Augmentin
1,060
1,140
1,332
GlaxoSmithKline
Aug. 6, 1984
Avelox/Avalox
1,013
871
745
Bayer 610
Bayer 543
Bayer 499
Bayer,
Schering-Plough,
Shionogi
Dec. 10, 1999/

June 21, 1999
Schering-Plough
384
Schering-Plough
304
Schering-Plough
228
Shionogi 19
Shionogi 24
Shionogi 18
Zyvox
944
782
618
Pfizer
April 18, 2000
Merrem
773
604
505
AstraZeneca
June 21, 1996
Primaxin
764
705
740
Merck & Co.
Nov. 26, 1985
Biaxin
724
816
1,065
Abbott Laboratories
Oct. 31, 1991
Cipro/Ciprobay
525
814
866
Bayer
Oct. 22, 1987/1987
Bayer 525
Bayer 703
Bayer 720
Schering-Plough
NA
Schering-Plough
111
Schering-Plough
146
Zithromax and Zmax
438
638
2,025
Pfizer
Nov. 4, 1991, and

June 10, 2005
Rocephin
333
347
773
Dec. 21, 1984

recorded by parent
company Roche.
Roche 333
(includes
Chugai 49)
Roche 347
(includes
Chugai 47)
Roche 773
(includes
Chugai 46)
Roche and
Flomox
286
306
341
Shionogi
June 1997
Cubicin
285
190
113
Cubist Pharmaceuticals
Sept. 12, 2003
Clarith
255
273
275
NA
Omnicef
235
637
495
Abbott Laboratories
Dec. 4, 1997
Vancocin
204
167
126
ViroPharma
April 15, 1986

(U.S. approval)
Cefzon
198
255
293
Astellas Pharma
1991
Invanz
190
139
94
Merck & Co.
Nov. 9, 2001
Meropen
148
143
141
Dainippon Sumitomo
NA
Tygacil
138
72
10
Wyeth
June 15, 2005
2007 company
First approval date

(or launch date)
Cravit: 1993
Floxin: Dec. 28, 1990
Floxin Otic: Dec. 16, 1997
52

Primary disease/
medical use
(continued)
Benign prostatic
hyperplasia
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
First approval date

(or launch date)
Maxipime
123
160
140
Elan
Jan. 18, 1996
Flumarin
122
133
156
Shionogi
NA
Vancomycin
117
117
111
Shionogi
NA
Doryx
116
102
96
Warner Chilcott
July 22, 1985

(U.S. approval)
Azactam
86
78
58
Elan
Dec. 31, 1986
Pansporin
84
109
127
February 1981
(Japan launch)
Cefamezin
66
66
75
Astellas Pharma
NA
Firstcin
64
69
75
August 1995
(Japan launch)
Cefspan
64
57
60
Astellas Pharma
NA
Targocid
63
64
70
Astellas Pharma
July 1998
Pentcillin
62
61
66
NA
Bicilin
59
43
54
May 19, 1957
Flomax
1,399
1,264
989
Oct. 8, 1997
Harnal
1,224
1,270
1,378
Astellas Pharma
July 1992
Avodart
570
432
258
GlaxoSmithKline
Nov. 20, 2001
Xatral
457
484
450
Sanofi-Aventis
January 2000
Proscar
411
619
741
Merck & Co.
June 19, 1992
Flivas
94
93
91
Asahi Kasei
NA
Bleeding due to hemophilia
NovoSeven
1,078
1,036
931
Novo Nordisk
Feb. 23, 1996
Thrombin-JMI
267
247
221
Feb. 24, 1995
Blood disorders
Glovenin
88
86
85
November 1991
(Japan launch)
Brain tumors
Temodar
861
703
588
Schering-Plough
Aug. 11, 1999
Bronchial muscle relaxation
Meptin
87
37
NA
1980 (Japan launch)
Bronchospasm
Xopenex Inhalation
Solution
487
543
411
Sepracor
March 25, 1999
DuoNeb
260
(estimate)
369
(Merck KGaA)
344
(Merck KGaA)
Merck KGaA and

Mylan
March 21, 2001
Roche,
Genentech,
Sept. 25, 1998
Roche,
Genentech,
Feb. 26, 2004

2007, by Mylan; DuoNeb
product exclusivity was
lost in July 2007.
Cancer
Merck KGaA 218

(estimate)
Mylan 42
(estimate)
Herceptin
4,044
3,273
1,788
Note: Genentech
reports U.S. sales and
Chugai reports Japan
sales that are recorded
by parent company
Roche.
Roche 4,044
(includes
Genentech 1,287
and Chugai 138)
Roche 3,273
(includes
Genentech 1,234
and Chugai 124)
Roche 1,788
(includes
Genentech 747
and Chugai 96)
Avastin
3,422
2,469
1,388
Note: Genentech
by parent company
Roche.
Roche 3,422
(includes
Genentech 2,296
and Chugai 30)
Roche 2,469
(includes
Genentech 1,746;
Chugai 0 = June
2007 Japan
launch
Roche 1,388
(includes
Genentech
1,133)
Taxotere
2,569
2,402
2,206
Sanofi-Aventis
Oct. 27, 1995
Eloxatin/Eloxatine
2,085
2,321
2,144
Sanofi-Aventis
Aug. 9, 2002/
September 1996
53

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Cancer
(continued)
Lupron/Leuplin
(leuprolide)
1,885
2,167
2,142
Takeda 1,240
(Leuprorelin,
including 664 for
Leuplin)
Takeda 1,275
(Leuprorelin,
including 643 for
Leuplin)
Takeda 1,224
(Leuprorelin,
including 632 for
Leuplin)
Tap 645 (Lupron)
Tap 662 (Lupron)
Tap 699 (Lupron)
Abbott NA
(Leuprolide)
Abbott 230
(Leuprolide)
Abbott 219
(Leuprolide)
Arimidex
1,730
1,508
Gemzar
1,592
1,408
Gardasil
1,481
Erbitux
2007 company
First approval date

(or launch date)
and
Tap Pharmaceutical
Products
Jan. 26, 1989/July 5, 2002
1,181
AstraZeneca
Dec. 27, 1995
1,335
Eli Lilly
May 15, 1996
235
Merck & Co.
June 8, 2006
1,336
1,114
712
Feb. 12, 2004
Bristol-Myers
Squibb 692
Bristol-Myers
Squibb 652
Bristol-Myers
Squibb 413

Merck KGaA
Merck KGaA 644
Merck KGaA 462
Merck KGaA 299
Casodex
1,335
1,206
1,123
AstraZeneca
Oct. 4, 1995
Zoladex
1,104
1,008
1,004
AstraZeneca
Dec. 29, 1989
Tarceva
1,054
833
408
Note: Tarceva was

launched in Japan by
Chugai Dec. 18, 2007).
Roche 885
(includes
Genentech 417
and Chugai 3)
Roche 678
(includes
Genentech 402)
Roche 323
(includes
Genentech 275)
Roche,
Genentech,
Chugai Pharmaceutical,
OSI Pharmaceuticals
Nov. 18, 2004

(U.S. approval)
Dec. 18, 2007
(Japan launch)
OSI 155
OSI 85
OSI 169
Camptosar
969
903
910
Pfizer
June 14, 1996
Xeloda
959
809
663
1998

recorded by parent
company Roche.
Roche 959
(includes
Chugai 23)
Roche 809
(includes
Chugai 21)
Roche 663
(includes
Chugai 23)
Roche and
Femara
945
722
536
July 25, 1997

recorded by parent
company Roche.
Novartis 937
Novartis 719
Novartis 536
Novartis,
Roche,
Roche 9
(via Chugai 9)
Roche 3
(via Chugai 3)
Alimta
854
612
463
Eli Lilly
Feb. 4, 2004
Sutent
581
219
Pfizer
Jan. 26, 2006
Taxol
422
563
747
Dec. 29, 1992
Aromasin
401
320
247
Pfizer
Oct. 21, 1999
Abraxane
387
193
134
Abraxis and AstraZeneca
Abraxis 325
Abraxis 175
Abraxis 134
February 2005
(U.S. launch)
AstraZeneca 62
AstraZeneca 18
AstraZeneca 0
370
178
NA
Bayer 178
Bayer NA
Bayer and
Onyx Pharmaceuticals
Bayer 370
Onyx NA
Onyx NA
Onyx NA
Decapeptyl
322
304
289
Ipsen
Caelyx
257
206
181
Schering-Plough
June 21, 1996
Hycamtin
238
226
198
GlaxoSmithKline
May 29, 2000
Iressa
238
237
273
AstraZeneca
May 5, 2003
Faslodex
214
186
140
AstraZeneca
April 25, 2002
Vectibix
170
39
Amgen
Sept. 27, 2006
Nexavar
54

Primary disease/
medical use
Cancer
(continued)
Cancer pain
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Eligard
150
123
70
Astellas 92
Astellas 59
Astellas 26
MediGene 30
MediGene 42
MediGene 27
QLT 28
QLT 22
QLT 17
Imunace
117
117
Tykerb
102
Farmorubicin and
Adriacin
87
Nolvadex
Topotecin
2007 company
First approval date

(or launch date)
Astellas Pharma,
MediGene,
QLT
May 2004
(Germany launch)
111
Shionogi
NA
GlaxoSmithKline
March 13, 2007
86
95
Kyowa Hakko Kogyo
NA
83
89
114
AstraZeneca
Dec. 30, 1977
62
54
48
Daiichi Sankyo
NA
Actiq
240
578
412
Cephalon
Nov. 4, 1998
Durotep
139
141
135
Kyowa Hakko Kogyo
October 2001
Fentora
135
29
Cephalon
Sept. 25, 2006
OxyContin
66+
52+
43+
Purdue NA
Purdue NA
Purdue NA
Purdue Pharma and

Shionogi
Dec. 12, 1995

(U.S. approval)
Shionogi 66
Shionogi 52
Shionogi 43
July 7, 2003
(Japan launch)
Cardiac ischemic
complications
Pletal
403
360
NA
1988 (Japan approval)
Sermion
95
102
114
June 1988
(Japan launch)
Cerebral infarction
Radicut
279
286
325
June 2001
(Japan launch)
Cervical dystonia
Botox
1,212
982
831
Allergan
Dec. 29, 1989
Dysport
176
155
127
Ipsen
1991 (U.K. launch)
Chickenpox
Varivax
855
328
NA
Merck & Co.
March 17, 1995
Cholesterol
Lipitor
13,652
13,833
13,102
Pfizer and Astellas Pharma
Dec. 17, 1996
Pfizer 12,675
Pfizer 12,886
Pfizer 12,187
Astellas 977
Astellas 947
Astellas 915
2,900
2,053
1,269
AstraZeneca and Shionogi
Nov. 7, 2002
AstraZeneca
2,796
AstraZeneca
2,028
AstraZeneca
1,268
Crestor
Shionogi 104
Shionogi 25
Shionogi 1
Vytorin
2,779
1,955
1,028
Pharmaceuticals
July 23, 2004
Zetia
2,407
1,929
1,397
Pharmaceuticals
Oct. 25, 2002
TriCor/Lipanthyl
1,812
1,614
1,181
Feb. 9, 1998/June 1999
Abbott (TriCor)
1,218
Abbott (TriCor)
1,048
Abbott (TriCor)
927
Abbott Laboratories and

Solvay
Solvay (TriCor/
Lipanthyl) 594
Solvay (TriCor/
Lipanthyl) 566
Solvay (TriCor/
Lipanthyl) 254
1,192
2,132
3,688
Oct. 31, 1991, and 1988
Bristol-Myers
Squibb 443
(Pravachol)
Bristol-Myers
Squibb 1,197
(Pravachol)
Bristol-Myers
Squibb 2,256
(Pravachol)

Daiichi Sankyo
Daiichi Sankyo
749 (Mevalotin/
pravastatin)
Daiichi Sankyo
935 (Mevalotin/
pravastatin)
Daiichi Sankyo
1,432 (Mevalotin/
pravastatin)
Zocor
877
2,803
4,382
Merck & Co.
Dec. 23, 1991
Lescol group
665
725
767
Novartis
Dec. 31, 1993
Pravachol and Mevalotin

(pravastatin)
55

Primary disease/
medical use
2007 company
First approval date

(or launch date)
435
(Kos)
Abbott Laboratories
July 28, 1997
1,197
2,256
Oct. 31, 1991
187
148
Daiichi Sankyo
May 27, 2004
94
98
106
April 1991
Antara
59
17
Oscient Pharmaceuticals
Nov. 30, 2004

(U.S. approval)
Cholesterol and
hypertension
Caduet
568
370
185
Pfizer
Jan. 30, 2004
Chronic obstructive
pulmonary disease
Spiriva
2,457
1,893
1,304
April 2002
Combivent
887
920
769
Oct. 24, 1996
Dorner
74
78
85
Astellas Pharma
1992
Cognitive disorders
Nootropil
138
136
141
UCB
NA
Constipation
Amitiza
196
(Takeda)
57
(Takeda)
Takeda Pharmaceutical and

Sucampo Pharmaceuticals
Forlax
71
63
59
Ipsen
1,429
1,089
803
(Schering AG)
Bayer
Yasmin: March 2000

Yaz: March 2006
(U.S. approval)
Ortho hormonal
contraceptives
925
1,016
1,136
Johnson & Johnson
NA
Mirena
495
413
333
(Schering AG)
Bayer
Dec. 6, 2000
387
(estimate)
292
(Akzo Nobel)
174
(Akzo Nobel)
Akzo Nobel and

Schering-Plough
June 12, 2001
240
240
236
(Schering AG)
Bayer
NA
Loestrin 24 FE
149
44
Warner Chilcott
Feb. 17, 2006

(U.S. approval)
Plan B
92
NA
NA
July 28, 1999
Cholesterol
(continued)
Contraception
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
658
(Abbott)
498
(estimate for calendar-year 2006
based on Kos
nine-month 2006
actual sales)
Pravachol
443
WelChol
227
Bezatol
Medicine
Niaspan
Note: Abbott acquired
Kos Pharmaceuticals in
December 2006.
Note: 2006 figure is pro

forma for Bayer after
acquisition as of June
23, 2006.

acquisition as of
June 23, 2006.
NuvaRing
Notes:
Schering-Plough
Organon BioSciences
along with NuvaRing
Nov. 19, 2007.
Akzo Nobel 342

(estimate)
Schering-Plough
45
Akzo Nobel 2007 sales

are estimated from
Jan. 1, 2007, thru Nov.
18, 2007. ScheringPloughs sales are an
actual figure for the
remainder of 2007.
Diane
acquisition as of June
23, 2006.
Notes: 2007 includes Rx

and OTC sales as the
two segments were not
broken down by Barr.
Barr changed from a
June 30 fiscal year for
2006 and 2005 to a Dec.
31 year end for 2007.
56

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
First approval date

(or launch date)
Contraception
(continued)
Paragard
70
NA
NA
Nov. 15, 1984
Corneal disease
Hyalein
195
179
169
June 1995
(Japan launch)
Cough
Tussionex
156
144
148
UCB
Dec. 31, 1987
Cystic fibrosis
Pulmozyme
403
363
328
Dec. 30, 1993
Note: Genentech
company Roche.
Roche 403
(includes
Genentech 223)
Roche 363
(includes
Genentech 199)
Roche 328
(includes
Genentech 186)
Roche and
Genentech
Tobi/Tobramycin
273
245
233
(Chiron)
Novartis
Dec. 22, 1997

(U.S. approval)
Note: Barr changed

from a June 30 fiscal
year for 2006 and 2005
to a Dec. 31 year end
for 2007.
Note: Chiron and Tobi

were acquired by
Novartis in April 2006.
Novartis 177
Chiron 68
Valcyte and Cymevene
452
407
328
Roche
Lovenox/Clexane
3,581
3,339
2,938
Sanofi-Aventis
March 29, 1993/

September 1997
Fraxiparine
368
408
422
GlaxoSmithKline
NA
Coumadin
201
220
212
NA
Arixtra
200
116
48
GlaxoSmithKline
Dec. 7, 2001
Effexor line
3,794
3,722
3,459
Wyeth
Dec. 28, 1993
Lexapro/Cipralex
3,044
2,751
2,355
Aug. 14, 2002/2002
Forest 2,292
(Lexapro)
Forest 2,106
(Lexapro)
Forest 1,873
(Lexapro)
Forest Laboratories and

H. Lundbeck
H. Lundbeck 752
(Cipralex)
H. Lundbeck 645
(Cipralex)
H. Lundbeck 482
(Cipralex)
Cymbalta
2,103
1,316
680
Eli Lilly
Aug. 3, 2004
Wellbutrin XL
1,120
2,046
1,648
Aug. 28, 2003
GlaxoSmithKline
908
GlaxoSmithKline
1,596
GlaxoSmithKline
1,294
GlaxoSmithKline and
Biovail
Depression
Biovail 212
Biovail 450
Biovail 354
Paxil/Seroxat
1,106
1,240
1,230
GlaxoSmithKline
Dec. 29, 1992/

October 1998
Zoloft
531
2,110
3,256
Pfizer
Dec. 30, 1991
Remeron
304
(estimate)
347
(Akzo Nobel)
388
(Akzo Nobel)
Akzo Nobel and

Schering-Plough
June 15, 2000
150
204
184
GlaxoSmithKline and Biovail
GlaxoSmithKline
150
GlaxoSmithKline
204
GlaxoSmithKline
184
Dec. 30, 1985, and

Oct. 4, 1996
Biovail NA
Biovail NA
Biovail NA
Luvox
110
111
103
Astellas Pharma
April 8, 2003
Toledomin
63
60
62
Asahi Kasei
NA
Elidel
176
179
268
Novartis
Dec. 13, 2001
Protopic
164
147
144
Astellas Pharma
June 16, 1999
Notes:
Schering-Plough
Organon BioSciences
along with Remeron
Nov. 19, 2007.
Akzo Nobel 271

(estimate)
Schering-Plough
33

are estimated from
remainder of 2007.
Dermatitis
57

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Diabetes
Actos
4,333
3,812
2,931
Takeda 3,962
Takeda 3,363
Takeda 2,438
2007 company
First approval date

(or launch date)
and Eli Lilly
July 15, 1999
Eli Lilly 371
Eli Lilly 449
Eli Lilly 493
Lantus
2,785
2,284
1,665
Sanofi-Aventis
April 20, 2000
Avandia
1,754
2,798
2,308
GlaxoSmithKline
May 25, 1999
Humalog
1,475
1,300
1,198
Eli Lilly
April 30, 1996
Humulin
985
925
1,005
Eli Lilly
Oct. 28, 1982
Byetta
967
649
150
April 28, 2005
Amylin 636
Amylin 430
Amylin 75
and Eli Lilly
Eli Lilly 331
Eli Lilly 219
Eli Lilly 75
Januvia
668
43
Merck & Co.
Oct. 16, 2006
Avandamet
584
408
350
GlaxoSmithKline
Oct. 10, 2002
Amaryl
537
618
928
Sanofi-Aventis
Nov. 30, 1995
Glucobay
409
422
404
Bayer
NA
Prandin and NovoNorm
395
365
306
Novo Nordisk

(U.S. approval)
NovoNorm: Aug. 17, 1998
(EU approval)
Glucophage/metformin
franchise
365
493
(estimate)
579
Merck KGaA and

Dec. 29, 1994
Merck KGaA 365

(Glucophage/
metformin
products)
BMS NA
(Glucophage
franchise)
Merck KGaA 398

(Glucophage/
metformin
products)
BMS 95 (estimate)
(Glucophage
franchise)
Merck KGaA 407

(Glucophage/
metformin
products)
BMS 172
(Glucophage
franchise)
Avandaryl
100
78
GlaxoSmithKline
Nov. 23, 2005
Janumet
86
Merck & Co.
March 30, 2007

(U.S. approval)
Symlin
66
44
12
March 16, 2005
Diarrhea
Smecta
122
110
93
Ipsen

pertussis
1,086
1,022
862
GlaxoSmithKline
January 1996 and

Dec. 13, 2002
Boostrix
132
120
NA
GlaxoSmithKline
May 3, 2005
coagulation
Neuart
58
59
62
June 1987 (launch)
Dry eye
Restasis
369
286
198
Dec. 23, 2002
Allergan 345
Allergan 270
Allergan 191
Allergan and
Inspire Pharmaceuticals
Inspire 24
Inspire 16
Inspire 7
95
37
May 2006
Daiichi 54
Daiichi 23
Daiichi Sankyo and

Dysuria
Urief
Kissei 41
Kissei 14
Viagra
1,764
1,657
1,645
Pfizer
March 27, 1998
Cialis
1,144
971
747
Eli Lilly
Nov. 14, 2002
Note: Eli Lilly acquired

all outstanding
common stock of Icos
Corp., the companys
partner in the Lilly Icos
joint venture for the
manufacture and sales
of Cialis, as of
Jan. 29, 2007.
Eli Lilly 1,144
Lilly Icos 755
Lilly Icos 577
Lilly Icos 0
Eli Lilly 216
Eli Lilly 170
58

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
(continued)
Levitra
553
517
436
Bayer 455
Bayer 431
Bayer 356
GSK 98
GSK 86
GSK 80
Erythema nodosum
leprosum
Thalomid
447
433
Expectorant
Mucosolvan
111
Fabrys disease
Fabrazyme
424
Replagal
Fungal infections
2007 company
First approval date

(or launch date)
Bayer and
GlaxoSmithKline
March 6, 2003
388
Celgene
July 16, 1998
115
117
Teijin
NA
359
305
Genzyme
August 2001
144
118
41
Group
Aug. 3, 2001
Vfend
632
515
397
Pfizer
March 21, 2002
Lamisil group
595
978
1,133
Novartis
Dec. 30, 1992
Cancidas
537
530
570
Merck & Co.
Jan. 26, 2001
Diflucan
415
435
498
Pfizer
Jan. 29, 1990
AmBisome
339
311
310
Aug. 11, 1997
Gilead 263
Gilead 223
Gilead 221
Gilead Sciences and

Astellas Pharma
Astellas 76
Astellas 88
Astellas 89
Mycamine/Funguard
178
165
152
Astellas Pharma
March 16, 2005/

December 2002
Noxafil
89
19
NA
Schering-Plough
Sept. 15, 2006

(U.S. approval)
Nexium
5,216
5,182
4,633
AstraZeneca
March 2000 (Sweden)
Protonix/Pantozol/
Pantoloc (pantoprazole)
4,221
4,017
3,779
Feb. 2, 2000/1994/1997
Nycomed 2,310
(Pantoprazole)
Altana 2,126
(Pantoprazole)
Altana 1,866
(Pantoprazole)
Nycomed and
Wyeth
Wyeth 1,911
(Protonix)
Wyeth 1,795
(Protonix)
Wyeth 1,685
(Protonix)
Solvay 0
(Pantoloc)
Solvay 96
(Pantoloc)
Solvay 228
(Pantoloc)
3,962
4,280
4,254
May 10,1995/1991
Tap 2,275
(Prevacid)
Tap 2,600
(Prevacid)
Tap 2,501
(Prevacid)
Tap Pharmaceutical
Products,
Takeda Pharmaceutical,
Abbott Laboratories
Takeda 1,487
(Lansoprazole,
including 648 for
Takepron)
Takeda 1,507
(Lansoprazole,
including 579 for
Takepron)
Takeda 1,599
(Lansoprazole,
including 550 for
Takepron)
Abbott 200
(Lansoprazole)
Abbott 173
(Lansoprazole)
Abbott 154
(Lansoprazole)
3,116
2,982
2,714
Aug. 19, 1999/1997
Eisai 1,759
Eisai 1,743
Eisai 1,545
Eisai and
Johnson & Johnson
Notes: Nycomed
acquired Altana
Pharma and
Pantoprazole
Dec. 29, 2006.
Solvay lost Pantoloc
marketing rights in
Canada during 2006.
Prevacid/Takepron
(lansoprazole)
AcipHex/Pariet
J&J 1,357
J&J 1,239
J&J 1,169
Prilosec/Losec
1,143
1,371
1,652
AstraZeneca
Sept. 14, 1989/1987
Gaster
609
622
688
Astellas Pharma
1985
Mucosta
353
339
NA
1990 (Japan launch)
Zantac
336
(GSK)
464
(GSK)
495
GlaxoSmithKline
June 9, 1983
Gasmotin
195
185
163
Dainippon Sumitomo
1998
Palux
114
112
120
1999
Zoton
93
131
376
Wyeth
1994
Dogmatyl
70
73
78
Astellas Pharma
NA
Canasa
65
53
29
Axcan Pharma
Jan. 5, 2001
Omeprazon
62
59
70
April 1991 (launch)
GSK 488
Daiichi Sankyo 7
59

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
First approval date

(or launch date)
(continued)
Nauzelin
60
65
66
Kyowa Hakko Kogyo
NA
Gastrom
58
61
64
Gauchers disease
Cerezyme
1,130
1,007
932
Genzyme
April 5, 1991
Growth failure
Genotropin
843
795
808
Pfizer
Aug. 24, 1995
Humatrope
441
416
414
Eli Lilly
March 9, 1991
Nutropin and Nutropin AQ
424
432
405
Note: Genentech
are also recorded by
parent company Roche.
Roche 392
(includes
Genentech 371)
Roche 412
(includes
Genentech 378)
Roche 397
(includes
Genentech 370)
Roche,
Genentech,
Ipsen
Nutropin: Nov. 17, 1993

(U.S. approval)
Ipsen 32
(Nutropin AQ
only)
Ipsen 20
(Nutropin AQ
only)
Ipsen 8
(Nutropin AQ
only)
Saizen
224
209
(Serono)
206
(Serono)
Merck KGaA
Oct. 8, 1996
Note: Merck KGaA

with Saizen Jan. 5, 2007.
Growth hormone deficiency
Nutropin AQ: Dec. 29, 1995

(U.S. approval)
Norditropin
645
608
511
Novo Nordisk
1997
Hair loss
Propecia
405
352
292
Merck & Co.
Dec. 19, 1997
Heart failure
Artist
211
193
182
Daiichi Sankyo
NA
HANP
98
92
86
Daiichi Sankyo
NA
Kogenate
1,121
1,079
909
Bayer
Feb. 25, 1993
BeneFix
433
358
343
Wyeth
Feb. 11, 1997
ReFacto
335
306
268
Wyeth
April 14, 2003
Pegasys
1,364
1,223
1,169
June 21, 2002

recorded by parent
company Roche.
Roche 1,364
(includes
Chugai 54)
Roche 1,223
(includes
Chugai 50)
Roche 1,169
(includes
Chugai 68)
Roche and
GlaxoSmithKline hepatitis
vaccines (primarily
Engerix-B, Havrix, Twinrix)
1,058
958
888
GlaxoSmithKline
Aug. 28, 1989,

Feb. 22, 1995,
September 1996
PegIntron
911
837
751
Schering-Plough
May 25, 2000
Zeffix
336
300
264
GlaxoSmithKline
Dec. 8, 1998
Hepsera
303
231
187
Gilead Sciences
Sept. 20, 2002
Vaqta,
Recombivax HB,
Comvax
280
249
195
Merck & Co.
Vaqta: May 1996

(U.S. launch)
Recombivax HB: Aug. 27,
(U.S. launch)
Rebetol
277
311
331
Schering-Plough
June 4, 2002
Baraclude
275
83
12
March 29, 2005
Intron A
233
237
287
Schering-Plough
June 5, 1990
Sumiferon
60
64
60
Dainippon Sumitomo
1987
Valtrex
1,868
1,690
1,390
GlaxoSmithKline
June 23, 1995
Zovirax
361
352
358
March 30, 1986
GSK 214
GSK 240
GSK 262
GlaxoSmithKline and
Biovail
Hemophilia
Hepatitis
Herpes
HIV infection
Biovail 147
Biovail 112
Biovail 96
Truvada
1,589
1,194
568
Gilead Sciences
Aug. 2, 2004
Kaletra
1,325
1,135
1,005
Abbott Laboratories
March 9, 2001
Atripla (efavirenz)
1,238
281
July 12, 2006
Gilead 903
(Atripla)
Gilead 206
(Atripla)
Gilead Sciences and

Bristol-Myers
Squibb 335
(efavirenz)
Bristol-Myers
Squibb 75
(efavirenz)
1,124
931
696
Jan. 6, 2003
Reyataz
60

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
First approval date

(or launch date)
Combivir
910
1,056
1,166
GlaxoSmithKline
Sept. 26, 1997
Epzicom/Kivexa
648
482
236
GlaxoSmithKline
Aug. 2, 2004/
December 2004
Sustiva
621
715
680
Sept. 17, 1998
Viread
613
689
779
Gilead Sciences
Oct. 26, 2001
Trizivir
466
536
606
GlaxoSmithKline
Nov. 14, 2000
Viramune
359
378
395
June 22, 2000
Epivir
312
404
522
GlaxoSmithKline
Nov. 17, 1995
310
327
348
Merck & Co.
March 13, 1996, and 1999
Agenerase and Lexiva
282
262
224
GlaxoSmithKline
April 15, 1999, and

Oct. 20, 2003
Fuzeon
267
249
208
Roche
March 27, 2003

(U.S. launch)
Ziagen
218
234
272
GlaxoSmithKline
Dec. 17, 1998
Aptivus
63
73
NA
June 22, 2005
Hunter syndrome
Elaprase
182
24
Group
July 24, 2006

(U.S. approval)
Hypercalcemia
Zometa
1,297
1,283
1,224
Novartis
Aug. 21, 2000
HIV infection
(continued)
Sensipar
463
321
157
Amgen
March 8, 2004
Hyperglycemia
Basen
528
557
636
1994
Hyperparathyroidism
Oxarol
74
65
62
September 2000
Hyperphosphatemia
Renagel
652
559
457
Oct. 30, 1998

recorded by parent
company Roche.
Genzyme 603
Genzyme 515
Genzyme 418
Genzyme,
Roche,
Roche 49
(via Chugai 49)
Roche 44
(via Chugai 44)
Roche 39
(via Chugai 39)
Diovan and Diovan

HCT/CoDiovan
5,012
4,223
3,676
Novartis
Dec. 23, 1996 and

March 6, 1998/Oct. 6, 1997
Atacand/Blopress
(candesartan)
3,518
3,172
2,883
June 4, 1998/Oct. 6, 1997
Takeda 2,231
(Blopress/
candesartan)
Takeda 2,062
(Blopress/
candesartan)
Takeda 1,909
(Blopress/
candesartan)
Takeda Pharmaceutical and

AstraZeneca
AstraZeneca
1,287 (Atacand)
AstraZeneca
1,110 (Atacand)
AstraZeneca 974
(Atacand)
Cozaar and Hyzaar
3,350
3,163
3,037
Merck & Co.
April 14, 1995, and April

28, 1995
Norvasc
3,001
4,866
4,706
Pfizer
July 31, 1992
Avapro/Aprovel and
Avalide/CoAprovel
2,685
2,489
2,205
Sanofi-Aventis
1,481 (Aprovel
and CoAprovel)
Sanofi-Aventis
1,392 (Aprovel
and CoAprovel)
Sanofi-Aventis
1,223 (Aprovel
and CoAprovel)
Sanofi-Aventis and
Avapro: Sept. 30, 1997

Aprovel: Aug. 27, 1997
Avalide: Sept. 30, 1997
CoAprovel: Oct. 15, 1998
BMS 1,204
(Avapro/Aprovel
and Avalide/
CoAprovel)
BMS 1,097
(Avapro/Aprovel
and Avalide/
CoAprovel)
BMS 982
(Avapro/Aprovel
and Avalide/
CoAprovel)
2,166
1,829
1,366
Nov. 10, 1998
Boehringer 1,540
Boehringer 1,326
Boehringer 993
Boehringer Ingelheim and

Astellas Pharma
Astellas 626
Astellas 503
Astellas 373
2,104
1,622
1,038
Daiichi 1,892
(Benicar/
Olmetec and
Benicar HCT
(olmesartan))
Daiichi 1,447
(Benicar/
Olmetec and
Benicar HCT
(olmesartan))
Daiichi 924
(Benicar/
Olmetec and
Benicar HCT
(olmesartan))
Daiichi Sankyo and

Forest Laboratories
April 25, 2002/2002 and

June 5, 2003
Forest 212
(Benicar and
Benicar HCT)
Forest 175
(Benicar and
Benicar HCT)
Forest 114
(Benicar and
Benicar HCT)
1,438
1,795
1,735
AstraZeneca
Jan. 10, 1992/1996
Hypertension
Micardis
Benicar/Olmetec and
Benicar HCT (olmesartan)
Note: Forest figures =
profit.
Toprol-XL/Seloken
61

Primary disease/
medical use
Hypertension
(continued)
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
First approval date

(or launch date)
Coreg
1,174
1,558
1,146
GlaxoSmithKline
Sept. 14, 1995
Delix and Tritace
1,016
1,340
1,383
Sanofi-Aventis
July 7, 2000, and

July 6, 2000
Adalat
842
901
904
Bayer
Nov. 27, 1985
Lotrel
748
1,352
1,075
Novartis
June 16, 1999
Altace
646
653
554
Jan. 28, 1991
Amlodin
636
592
568
Dainippon Sumitomo
NA
Concor (bisoprolol)
520
497
478
Merck KGaA
July 31, 1992
Cardura
506
538
586
Pfizer
Nov. 2, 1990
Vasotec and Vaseretic
495
547
623
Merck & Co.
Dec. 24, 1985, and

Dec. 24, 1985
Tenormin
308
320
352
AstraZeneca
Aug. 19, 1981
Zestril
295
307
332
AstraZeneca
Dec. 30, 1987
Plendil
271
275
360
AstraZeneca
July 27, 1995
Zanidip/Lercadip/
lercanidipine
256
235
194
Recordati
NA
Coniel
254
263
281
Kyowa Hakko Kogyo
NA
Cardizem LA
198
(estimate)
162
(estimate)
132
Abbott Laboratories and

Biovail
Feb. 6, 2003
Abbott 129
(estimate)
Kos 105 (estimate)
Note: Abbott acquired

December 2006.
Biovail 69
Abbott NA
Kos 70
Biovail 62
Biovail 57
Herbesser
176
180
188
February 1974
Teveten franchise
172
(estimate)
154
(estimate)
153
Solvay and
Abbott Laboratories
Dec. 22, 1997

(U.S. approval)
Solvay 145
Solvay 130
Abbott 27
(estimate)
Kos 24 (estimate)
Tanatril
144
145
147
December 1993
Maintate
103
99
102
NA
Exforge
103
10
Novartis
Jan. 18, 2007

(EU approval date)
Calblock
102
88
64
Daiichi Sankyo
2003
Perdipine and
Perdipine LA
66
75
89
Astellas Pharma
1981 and NA
Notes: Abbott acquired

December 2006.
Biovail transferred
product rights for
Teveten to Kos in
May 2005.
Abbott NA
Solvay 125
Kos 22
Biovail 6
Nisis and Nisisco
74
70
57
Ipsen
NA
Hypogonadism
Androgel
422
377
328
Solvay
June 14, 2000

(U.S. approval)
Hypothyroidism
Synthroid
533
534
554
Abbott Laboratories
1955
Euthyrox products
186
176
156
Merck KGaA
NA
Levoxyl
100
112
140
May 25, 2001
Imaging, contrast
enhancement and/or
scintigraphy
Magnevist
413
443
450
(Schering AG)
Bayer
June 2, 1988
scintigraphy
Adenoscan
376
371
353
Astellas Pharma
May 19, 1999
Ultravist
322
304
340
(Schering AG)
Bayer
May 11, 1999

acquisition as of
June 23, 2006.

acquisition as of
June 23, 2006.
62

Primary disease/
medical use
scintigraphy
(continued)
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Omnipaque
312
315
347
Daiichi Sankyo
Dec. 26, 1985

(U.S. approval)
Iopamiron
289
303
332
(Schering AG)
Bayer
NA

acquisition as of
June 23, 2006.
First approval date

(or launch date)
Venoglobulin-IH
129
132
141
January 1992
Infectious diseases (severe)
Venilon
89
94
93
Teijin
February 1980
(Japan launch)
Infertility
Gonal-f
595
533
(Serono)
547
(Serono)
Merck KGaA
Oct. 20, 1995
570
(estimate)
527
(Akzo Nobel)
487
(Akzo Nobel)
Akzo Nobel and

Schering-Plough
Sept. 29, 1997/May 3, 1996
Note: Merck KGaA

with Gonal-f
Jan. 5, 2007.
Follistim/Puregon
Notes: Schering-Plough
Organon BioSciences
along with Follistim/
Puregon Nov. 19, 2007.
Akzo Nobel 513

(estimate)
Schering-Plough 57

are estimated from
remainder of 2007.
Inflammation
Influenza
Insomnia
Intraocular pressure and

glaucoma
Loxonin
336
309
290
Daiichi Sankyo
Feb. 17, 1978
Dasen
77
81
85
November 1968
(Japan launch)
Tamiflu
1,738
2,189
1,298
Oct. 27, 1999

also recorded by parent
company Roche.
Roche 1,738
(includes
Chugai 331)
Roche 2,189
(includes
Chugai 325)
Roche 1,298
(includes
Chugai 301)
Roche and
GlaxoSmithKline influenza
vaccines (primarily
Fluarix and
FluLaval/Fluviral)
640
340
NA
GlaxoSmithKline
Aug. 31, 2005, and

Oct. 5, 2006/Sept. 10, 2004
Relenza
524
182
NA
GlaxoSmithKline
June 1999
Influvac
174
162
137
Solvay
2003 (launch)
Ambien/Stilnox
1,714
2,778
2,083
Sanofi-Aventis
Dec. 16, 1992/June 9, 1987
Lunesta
601
565
327
Sepracor
Dec. 15, 2004
Myslee
215
194
171
Astellas Pharma
Dec. 13, 2000
Rozerem
126
103
30
Sept. 26, 2005 (U.S. launch)
Sonata
79
86
83
Aug. 13, 1999
Xalatan and Xalacom
1,604
1,453
1,372
Pfizer
June 5, 1996, and

second-quarter 2001
Trusopt and Cosopt
787
697
617
Merck & Co.
Dec. 9, 1994, and

April 7, 1998
Lumigan franchise
392
328
268
Allergan
March 16, 2001
Alphagan P, Alphagan,
Combigan
341
296
277
Allergan
March 16, 2001,

Sept. 6, 1996,
fourth-quarter 2003
Timoptic/Timoptol and
Timoptic-XE/Timoptol XE
190
198
211
Merck & Co. 120

(Timoptic and
Timoptic XE)
Merck & Co. 127

(Timoptic and
Timoptic XE)
Merck & Co. 138

(Timoptic and
Timoptic XE)
Merck & Co. and

Santen 70
(Timoptol and
Timoptol XE)
Santen 71
(Timoptol and
Timoptol XE)
Santen 73
(Timoptol and
Timoptol XE)
Timoptic: Aug. 17, 1978

(U.S. approval)
Timoptic-XE: Nov. 4, 1993
(U.S. approval)
Timoptol: September 1981
(Japan launch)
Timoptol XE: November
1999 (Japan launch)
63

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
First approval date

(or launch date)
Venofer
311
309
226
Daiichi Sankyo
Nov. 7, 2000
Iron overload
Exjade
357
143
Novartis
Nov. 2, 2005
(U.S. approval)
Zelnorm/Zelmac
88
561
417
Novartis
March 19, 2002/

Oct. 30, 2001
Bredinin
62
60
61
Asahi Kasei
NA
Leukemia
Gleevec/Glivec
3,050
2,554
2,170
Novartis
May 10, 2001/

June 26, 2001
Sprycel
158
25
June 28, 2006
Leukopenia
Gran
130
134
138
Kirin Brewery
1991 (Japan launch)
ProQuad
264
235
NA
Merck & Co.
Sept. 6, 2005
M-M-R II
228
NA
NA
Merck & Co.
NA
Mearubik
76
59
Menieres Syndrome
Serc
206
200
167
Solvay
NA
Menopausal symptoms
Premarin, Prempro,
Premphase
1,055
1,051
909
Wyeth
1942, Nov. 17, 1995,

Nov. 17, 1995
Livial
201
(estimate)
207
(Akzo Nobel)
211
(Akzo Nobel)
Akzo Nobel and

Schering-Plough
March 1997
Notes:
Schering-Plough
Organon BioSciences
along with Livial
Nov. 19, 2007.
Akzo Nobel 177

(estimate)
Schering-Plough
24

are estimated from
remainder of 2007.
Estrace Cream
73
66
54
Warner Chilcott
Jan. 31, 1984

(U.S. approval)
Femhrt
64
59
61
Warner Chilcott
Oct. 15, 1999

(U.S. approval)
Actovegin
126
108
88
Nycomed
NA
Migraine
Imitrex/Imigran
1,370
1,422
1,394
GlaxoSmithKline
Dec. 28, 1992/1990
Maxalt
467
406
348
Merck & Co.
June 30, 2002
Zomig
434
398
352
AstraZeneca
July 8, 1997
Relpax
315
286
233
Pfizer
June 14, 2001
Frova/Migard
74
58
38+
Endo 52
(Frova)
Endo 41
(Frova)
Endo 38
(Frova)
Holdings and Menarini
Migard: January 2002

(EU approval)
Menarini 22
(Migard)
Menarini 17
(Migard)
Menarini NA
(Migard)
Aldurazyme
124
96
76
BioMarin/Genzyme
(joint venture)
April 30, 2003
Naglazyme
86
47
BioMarin Pharmaceutical
May 31, 2005
Revlimid
774
321
Celgene
Dec. 27, 2005
Velcade
265
221
192
Note: Millennium
figures are net
product sales and
exclude strategic
alliance revenue and
royalties associated
with non-U.S. marketer,
J&Js Ortho Biotech.
Millennium 265
Millennium 221
Millennium 192
Millennium Pharmaceuticals
and Johnson & Johnson
May 13, 2003

(U.S. approval)
J&J NA
J&J NA
J&J NA
Alkeran
74
50
50
Celgene
May 27, 1974
Multiple myeloma
Frova: June 2002

(U.S. launch)
64

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Multiple sclerosis
Copaxone
3,327
2,880
2,413
Teva 1,713
Teva 1,414
Teva 1,176
Sanofi-Aventis
1,614
Sanofi-Aventis
1,466
Sanofi-Aventis
1,237
Avonex
1,868
1,707
Rebif
1,670
1,452
(Serono)
Betaseron/Betaferon
1,409
Notes: Bayer 2006

figure is pro forma after
acquisition as of
June 23, 2006.
2007 company
First approval date

(or launch date)
Teva Pharmaceutical
Industries and Sanofi-Aventis
Dec. 20, 1996
1,543
Biogen Idec
May 17, 1996
1,270
(Serono)
Merck KGaA
February 1998
1,402
1,214
July 23, 1993/Nov. 30, 1995
Bayer 1,409
Bayer 1,359
Novartis NA
Chiron 43
(estimate thru
April 2006)
1,072
(Schering AG)
Bayer and
Novartis
462
64
16
Nov. 23, 2004
Biogen Idec 230
Biogen Idec 36
Biogen Idec 5
Biogen Idec and

Elan
Note: Merck KGaA

with Rebif Jan. 5, 2007.
Chiron 142
Chiron was acquired by

Novartis in April 2006.
Tysabri
Elan 232
Elan 28
Elan 11
Skelaxin
440
415
345
NA
Dacogen
117
(estimate)
36
MGI Pharma
Activase, TNKase,
Cathflo Activase
318
302
258
Roche 318
(includes
Genentech 268)
Roche 302
(includes
Genentech 243)
Roche 258
(includes
Genentech 218)
Roche and
Genentech
Feb. 17, 1996, June 2, 2000,

and Sept. 4, 2001
Zofran
392
1,694
1,674
GlaxoSmithKline
Dec. 31, 1992
Kytril
354
415
417
January 1992
Roche 354
(includes
Chugai 116)
Roche 415
(includes
Chugai 110)
Roche 417
(includes
Chugai 104)
Roche and
Aloxi
216
(estimate)
251
249
MGI Pharma
July 25, 2003
Emend
204
131
87
Merck & Co.
March 26, 2003
Note: Genentech
company Roche.
Nausea and vomiting
Marinol
144
145
115
Solvay
1987 (U.S. launch)

disorders
Tanakan
164
178
166
Ipsen
Neuropathic pain
Lyrica
1,829
1,156
291
Pfizer
July 6, 2004
Neutropenia
Neulasta
3,000
2,710
2,288
Amgen
Jan. 31, 2002
Neupogen
1,277
1,213
1,216
Amgen
Feb. 20, 1991
Neutrogin
338
316
303
Oct. 4, 1991

recorded by parent
company Roche.
Roche 338
(includes
Chugai 335)
Roche 316
(includes
Chugai 309)
Roche 303
(includes
Chugai 276)
Roche and
Rituxan/MabThera
5,214
4,589
3,976
Nov. 26, 1997/June 2, 1998
Notes: Genentech
by parent company
Roche.
Roche 4,597
(includes
Genentech 2,285
and Chugai 159)
Roche 4,033
(includes
Genentech 2,071
and Chugai 154)
Roche 3,462
(includes
Genentech 1,832
and Chugai 152)
Roche,
Genentech,
Biogen Idec,
Zenyaku Kogyo
Biogen Idec 617
Biogen Idec 556
Biogen Idec 514
Biogen Idec records U.S.

joint-promotion profit.
Zenyaku Kogyo NA
Zenyaku Kogyo NA
Zenyaku Kogyo NA
Obesity
Xenical
527
578
529
Roche
July 29, 1998
Rinderon
100
101
102
Shionogi
NA
65

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Opiate addiction
Subutex/Subuxone
220
203
197
Schering-Plough
Oct. 8, 2002
(U.S. approvals)
Osteoarthritic pain
Prexige
91
47
Novartis

New Zealand,
U.K. launches)
Osteoporosis
Fosamax
3,049
3,134
3,191
Merck & Co.
Sept. 29, 1995
Actonel
1,750
(actual)
1,663
(estimate)
1,582
(estimate)
March 27, 1998
P&G 1,229
(estimate)
P&G 1,106
(estimate)
P&G 1,043
(estimate)
Procter & Gamble,

Sanofi-Aventis,
Eisai
Sanofi-Aventis 439
Sanofi-Aventis 481
Sanofi-Aventis 499
Eisai 82
Eisai 75
Eisai 40
1,265
1,178
1,115
Dec. 9, 1997
Eli Lilly 1,091
Eli Lilly 1,045
Eli Lilly 1,036
Eli Lilly,
Daiichi Sankyo
Chugai 137
Chugal 115
Chugai 79
Daiichi 37
Daiichi 18
1,061
597
108
Roche and GlaxoSmithKline
Roche 739
Roche 407
Roche 72
March 24, 2005/

February 2004
Notes: 2007 total is

actual worldwide
figure; P&G figures are
estimates.
Eisai markets Actonel
in Japan.
Evista
Boniva/Bonviva
Overactive bladder
Pain
First approval date

(or launch date)
GSK 322
GSK 190
GSK 36
Forteo
709
594
389
Eli Lilly
Nov. 26, 2002
Miacalcin/Miacalcic
281
339
365
Novartis
July 3,1986/NA
Bonalon
182
138
119
Teijin
August 2001
(Japan launch)
Calcichew
176
174
145
NA
Nycomed 122
Nycomed 128
Nycomed 106
Nycomed and
Group
Shire 54
Shire 46
Shire 39
Benet
165
162
157
May 2002
(Japan launch)
Elcitonin
139
138
152
Asahi Kasei
NA
Onealfa
125
118
120
Teijin
NA
Alfarol
123
125
135
1981
1,190
1,100
988
Pfizer
March 25, 1998, and

Dec. 22, 2000
Vesicare
701
426
174
July 9, 2004
Astellas 601
Astellas 362
Astellas 148
Astellas Pharma and

GlaxoSmithKline
GSK 100
GSK 64
GSK 26
Enablex/Emselex
179
114
46
Novartis

(U.S. appoval)
(EU approval)
Duragesic/Fentanyl
Transdermal
1,164
1,295
1,585
Johnson & Johnson
Aug. 7, 1990
Voltaren group
747
690
689
Novartis
July 28, 1998
Lidoderm
706
567
419
Holdings
March 19, 1999
Kadian
168
138
102
Alpharma
July 3, 1996
Avinza
127
King 109
113
(Ligand)
King Pharmaceuticals and

Ligand Pharmaceuticals
March 20, 2002
Note: King acquired

all rights to Avinza
in the United States,
its territories and
Canada from Ligand
Pharmaceuticals
Feb. 26, 2007.
137
(Ligand)
Seltouch
123
127
137
September 1993
(Japan launch)
Ligand 18
66

Primary disease/
medical use
Pain
(continued)
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
Percocet
122
103
111
Holdings
June 25, 1999
Opana and Opana ER
107
Holdings
July 24, 2006

(U.S. launches)
Ultram ER
87
54
Biovail 87
Biovail 54
Biovail and
Johnson & Johnson
2007 company
First approval date

(or launch date)
J&J NA
J&J NA
Pancreatic exocrine
insufficiency
Creon
271
262
222
Solvay
NA
Parkinsons disease
Mirapex/Sifrol
883
735
595
July 1, 1997/Oct. 14, 1997
Comtan/Comtress and
Stalevo
695
585
477
Novartis and Orion
Comtan: Oct. 19, 1999
Novartis 420
(Comtan/Stalevo
group)
Novartis 330
(Comtan/Stalevo
group)
Novartis 278
(Comtan/Stalevo
group)
Orion 275 (Stalevo

174 and Comtan/
Comtess 101)
Orion 255 (Stalevo

153 and Comtan/
Comtess 102)
Orion 199 (Stalevo

102 and Comtan/
Comtess 97)
Requip
692
536
312
GlaxoSmithKline
Sept. 19, 1997
Azilect
151
57
1+
Teva 120
Teva 44
Teva NA
Teva Pharmaceutical
Industries and H. Lundbeck
March 2005
(Israel launch)
Comtress: Sept. 16, 1998

Stalevo: June 11, 2003
Lundbeck 31
Lundbeck 13
Lundbeck 1
Neupro
71
14
UCB
Feb. 20, 2006

(Europe approval)
Cabaser
59
99
103
September1999
hemoglobinuria
Soliris
66
Alexion Pharmaceuticals
interventions
Angiomax
255
201
150
The Medicines Co.
January 2001
(U.S. launch)
Trasylol
150
210
315
Bayer
Dec. 29, 1993

disease
Novastan
62
54
38
NA
Prorenal
145
138
126
Dainippon Sumitomo
1988
Kinedak
174
173
212
Ono Pharmaceutical
NA
Fosrenol
102
45
54
Group
Oct. 26, 2004
Prevnar
2,439
1,961
1,508
Wyeth
Feb. 17, 2000
Pompe disease
Myozyme
201
59
Genzyme
NA
Urso franchise
248
221
223
Note: Mitsubishi Pharma

and Tanabe Seiyaku
merged Oct. 1, 2007, to
form Mitsubishi Tanabe
Pharma.
Mitsubishi Tanabe
Pharma 171
Mitsubishi
Pharma 159
Mitsubishi
Pharma 176

and Axcan Pharma
July 1962 (Japan)

Axcan 77
Axcan Pharma 62
Axcan Pharma 47
Raptiva
213
160
113
Notes: Total 2007,

2006 and 2005 figures
were reported by
Raptiva developer
Xoma.
Roche 107 (via

Genentech 107)
Roche 90 (via
Genentech 90)
Roche 79 (via
Genentech 79)
Genentech and
Merck KGaA
November 2003
(U.S. launch)
Merck KGaA 106
Serono 70
Serono 34
Taclonex
127
60
Warner Chilcott
Tracleer
983
749
528
Actelion
Nov. 20, 2001
Remodulin
201
153
110
United Therapeutics
Psoriasis
Genentech reports U.S.

by parent company
Roche.
Merck KGaA acquired
Serono Jan. 5, 2007.
Pulmonary arterial
hypertension
67

Primary disease/
medical use
Pulmonary arterial
hypertension
(continued)
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
Ventavis
65+
24+
Actelion
Notes: 2006 figure is

an estimate based on
nine-month 2006 sales
of CoTherix, which
was acquired by
Actelion in
March 2007.
Actelion 65
65+
(estimate)
Sept. 22, 2003

(EU approval)
CoTherix NA
CoTherix 65
(estimate)
Bayer NA
Bayer NA
CoTherix 24
First approval date

(or launch date)
Schering NA
Bayer acquired
Schering AG
June 23, 2006.
Renal failure
Kremezin
124
122
130
Daiichi Sankyo
December 1991
Ethyol
95
(estimate)
87
(MedImmune)
95
(MedImmune)
AstraZeneca and
MedImmune
Dec. 8, 1995
Note: MedImmune
2007 figure is a
first-half estimate;
MedImmune was
acquired along with
Ethyol by AstraZeneca
in June 2007.
MedImmune 52
(estimate)
AstraZeneca 43
Rapamune
365
337
300
Wyeth
Sept. 15, 1999
Thymoglobulin/
Lymphoglobuline
175
150
128
Genzyme
Dec. 30, 1998/NA
Synagis
1,161
(estimate)
1,438
1,414
AstraZeneca
June 19, 1998
MedImmune
1,065
MedImmune
1,063
Abbott 373
(U.S. joint
promotion
revenue)
Abbott 231
(U.S. joint
promotion
revenue)
Notes: MedImmune
was acquired by
AstraZeneca in
June 2007.
Abbott completed the
U.S. joint promotion of
Synagis in December
2006; Abbott recorded
revenue.
AstraZeneca 618
MedImmune 543
(estimate)
Dainippon
Sumitomo 120
RotaTeq
525
163
Merck & Co.
Feb. 3, 2006
Rotavirus infection
Rotarix
182
88
NA
GlaxoSmithKline
Feb. 27, 2006
Schizophrenia
Zyprexa
4,761
4,364
4,202
Eli Lilly
Sept. 27, 1996
Risperdal,
Risperdal Consta,
Invega
4,697
4,183
3,552
Johnson & Johnson
Dec. 29, 1993,

Oct. 29, 2003,
Dec. 19, 2006
Seroquel
4,219
3,584
2,913
Sept. 26, 1997
AstraZeneca
4,027
AstraZeneca
3,416
AstraZeneca
2,761
AstraZeneca and
Astellas Pharma
Astellas 192
Astellas 168
Astellas 152
2,490
(estimate)
1,923
(estimate)
1,368
(estimate)

Nov. 15, 2002
Bristol-Myers
Squibb 1,660
Bristol-Myers
Squibb 1,282
Bristol-Myers
Squibb 912
Otsuka 830
(estimate)
Otsuka 641
(estimate)
Otsuka 456
(estimate)
*2007 U.S. sales for

BMS and Otsuka
total 2,160.

BMS and Otsuka
total 1,623.

BMS and Otsuka
total 1,159.
Geodon/Zeldox
854
758
589
Pfizer
Feb. 5, 2001/May 2002
Topamax
2,453
2,027
1,680
Johnson & Johnson
Dec. 24, 1996
Lamictal
2,194
1,992
1,698
GlaxoSmithKline
Dec. 27, 1994
Depakote
1,575
1,308
1,096
Abbott Laboratories
March 10, 1983
Keppra
1,407
1,043
768
UCB
Nov. 30, 1999
Trileptal
692
721
615
Novartis
November 1999
Depakine
433
413
436
Sanofi-Aventis
NA
Neurontin
431
496
639
Pfizer
Dec. 29, 1993
Abilify
Note: 2007-2005 total
figures are estimates;
2007-2005 U.S. sales
are actual numbers.
Seizures
68

Primary disease/
medical use
Medicine
2007 sales
($ in millions)
2006 sales
($ in millions)
2005 sales
($ in millions)
2007 company
First approval date

(or launch date)
Tegretol
413
391
393
Novartis
March 12, 1972
Depakene
105
102
102
Kyowa Hakko Kogyo
NA
Carbatrol
72
68
72
Group
Sept. 30, 1997
Shingles
Zostavax
236
39
Merck & Co.
May 25, 2006
Sleepiness
Provigil
852
735
513
Cephalon
Dec. 24, 1998
Smoking cessation
Chantix/Champix
883
101
Pfizer
May 10, 2006/

Sept. 29, 2006
Spinal cerebellar
degeneration
Ceredist
152
145
137
September 2000
(Japan launch)
Stroke
Aggrenox
381
308
236
Nov. 22, 1999
Opalmon
373
338
326
Ono Pharmaceutical
1988
Thrombocythemia
Xagrid
69
53
47
Group
November 2004
(EU approval)
Tibia fractures
rhBMP-2
359
308
236
Wyeth
Sept. 17, 2002
Tissue management
TachoSil
88
84
64
Nycomed
NA
Prograf
2,030
1,754
1,459
Astellas Pharma
April 2, 1993
CellCept
1,677
1,535
1,421
May 3, 1995

also recorded by parent
company Roche.
Roche 1,677
Roche 1,421
Chugai NA
Roche 1,535
(includes
Chugai 30)
Roche and Chugai

Pharmaceutical
Neoral and Sandimmun
944
918
953
Novartis
July 14, 1995, and

Nov. 14, 1983
Travelers diarrhea
Xifaxan
64
52
30
May 25, 2004
Tumors
Isovorin
125
140
128
October 1999
(Japan launch)
Ulcerative colitis
Pentasa
176
138
136
Group
May 11, 1997
Colazal
92
103
110
July 18, 2000
Seizures
(continued)
Chugai 0
NOTES/LEGEND:
*This list presents the 500 medicines from the sales-order chart by primary disease/medical use. Many of these products treat various conditions, but each medicine is grouped
under one main heading along with any fellow 500 competitors in that disease area. Certain products are represented by more than one company due to joint-marketing or jointpromotion accords. The combined product sales from such company alliances are presented in this chart at the top of each medicine sales entry, followed by the breakdown in
company-reported sales.
*Estimate = sales were not provided by company or found by Med Ad News editors, who made an estimate based on previous-year figures and/or other information provided.
This report does exclude certain products that probably would have been ranked in the top 500 list for 2007, but were omitted since no 2007 information could be found to make an
estimate. In most of these istances, there are products with declining annual sales figures due to patent expirations.
*All Japanese-company 2007 product sales are for the fiscal year ended March 31, 2008 (2006 = year ended March 31, 2007; 2005 = year ended March 31, 2006), except for Chugai
Pharmaceutical and Kirin Brewery, which report annual sales on a Dec. 31 calendar-year basis.
69

Top 500 Medicines Pharma

Hochgeladen von

Dokumentinformationen

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Top 500 Medicines Pharma

Hochgeladen von

Copyright:

Verfügbare Formate

SPECIAL REPORT JULY 2008

What you will find in this special report (continued)

TOP 500 PRESCRIPTION MEDICINES BY SALES

First approval date

Dec. 17, 1996

Nov. 17, 1997/1998

Aug. 24, 2000/

Aug. 24, 1998

Johnson & Johnson,

March 2000 (Sweden)

Nov. 26, 1997/

Biogen Idec 617

Biogen Idec 556

Biogen Idec 514

Biogen Idec records

Diovan and Diovan

Dec. 23, 1996 and

Sept. 27, 1996

Johnson & Johnson

Dec. 29, 1993,

July 15, 1999

Eli Lilly 371

Eli Lilly 449

Eli Lilly 493

Merck & Co.

Feb. 20, 1998

Sept. 26, 1997

TOP 500 PRESCRIPTION MEDICINES BY SALES

First approval date

Sept. 25, 1998

Dec. 28, 1993

June 11, 2001

March 29, 1993/

Feb. 26, 2004

Cozaar and Hyzaar

Merck & Co.

April 14, 1995, and

Dec. 20, 1996

Eisai and Pfizer

Nov. 25, 1996

Aug. 19, 1999/1997

Dec. 31, 2002

May 10, 2001/

Merck & Co.

Sept. 29, 1995

Major depressive disorder

Aug. 14, 2002/2002

July 31, 1992

Jan. 31, 2002

TOP 500 PRESCRIPTION MEDICINES BY SALES

First approval date

Johnson & Johnson

Dec. 31, 1990/

Johnson & Johnson,

Levaquin: Dec. 20, 1996

Floxin: Dec. 28, 1990

Floxin Otic: Dec. 16, 1997

Type 2 diabetes and

April 20, 2000

July 23, 2004

Avapro: Sept. 30, 1997

Aprovel: Aug. 27, 1997

Oct. 27, 1995

Nov. 15, 2002